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ABSTRACT 
 
Silicon Membranes for Extracorporeal Membrane Oxygenation (ECMO) 
by 
Emily Abada 
 
 In cases of severe lung or heart failure, extracorporeal membrane oxygenation (ECMO) is a life-
saving therapy in which a patient’s blood is passed into a circuit outside of their body to provide 
respiratory support. The circuit’s main component is the membrane oxygenator that drives oxygen into 
the blood from a sweep gas source and removes excess carbon dioxide from the blood. At present, clinical 
use of ECMO is limited by its high risk profile, owing to two intertwined risks: thrombosis from the large 
circuit, and bleeding from the anticoagulation needed to prevent thrombosis. Improvements to the gas 
exchange efficiency and hemocompatibility of the oxygenator could enable the development of a longer-
term supportive ECMO therapy, intended as a bridge-to-transplant or destination therapy for chronic lung 
failure. Here we describe a novel blood oxygenator concept based on parallel plate silicon membranes 
developed for high precision geometry, mechanical rigidity, and high efficiency membrane transport. 
Using these membranes, we create blood oxygenator prototypes consisting of arrays of silicon 
membranes, and endeavor to improve the efficiency and hemocompatibility of this concept. 
 First, multiple types of silicon membranes were evaluated systematically for mechanical rigidity 
and oxygen exchange efficiency, indicators of suitability for a future oxygenator. The combination of a 
silicon micropore membrane (SµM) and a 5 µm-thick polydimethylsiloxane (PDMS) layer maximized 
both qualities, withstanding over 260 cmHg of applied pressure and producing 0.03 mL/min of O2 flux. 
These membranes were then assembled into prototype flow cells, and tested for in vitro and in vivo 
oxygenation, successfully yielding an oxygen permeability of 1.92 ± 1.04 ml O2 STP/min/m2/cmHg. 
From this benchmark, we then attempted to optimize the surface hemocompatibility of the Si-PDMS 
vii 
 
 
composite through application of multiple polyethylene glycol (PEG)-based coatings. Although 
successful application of PEG to the surfaces was demonstrated, none of the coatings appeared to reduce 
protein adhesion to the SµM -PDMS membranes. Finally, we inserted turbulence-inducing spacer meshes 
into the channels of the SµM-PDMS prototypes to disrupt the transport boundary layer adjacent to the 
membranes, with the goal of substantially improving oxygenation. Though a threefold increase in oxygen 
flux was observed in vitro with the spacer meshes, the disruptive turbulence resulted in thrombosis and 
channel occlusion within the channels despite heavy anticoagulation of the blood. In summary, the work 
in this dissertation demonstrates the successful construction and testing of SµM-PDMS oxygenator 
prototypes, laying the foundation for future work to optimize this concept and create a large-scale blood 
oxygenator that can expand the clinical use of this life-saving therapy. 
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ECMO OXYGENATOR DEVELOPMENT – LOOKING TOWARDS THE FUTURE OF 
RESPIRATORY SUPPORT 
 
 
 
 
 
 INTRODUCTION 
For patients with life-threatening lung or heart failure, common clinical approaches to respiratory 
support, such as mechanical ventilation, may not sufficiently meet patient requirements. As a last option, 
extracorporeal membrane oxygenation (ECMO) is a method of providing sustained respiratory support by 
exchanging oxygen and carbon dioxide directly with blood, giving the patient’s lungs time to recover. In 
ECMO, a patient’s venous blood is taken outside of their body and pumped through a mechanical 
oxygenation device containing an array of gas-permeable membranes (Fig. 1.1) 1,2. These membranes 
separate two compartments: one for the patient’s blood, and one for a sweep gas, typically oxygen mixed 
with room air. Gases are exchanged through the membrane via diffusion, powered by concentration 
gradients between the oxygen in the sweep gas and the deoxygenated, carbon dioxide-rich blood. The 
oxygenated blood can then be returned to the patient’s circulation. ECMO can therefore deliver complete 
respiratory support by simultaneously oxygenating and removing carbon dioxide from a patient. 
While ECMO can be a life-saving treatment for critically ill patients, its clinical use is severely 
limited due to the high risk of complications, primarily either thrombosis events or hemorrhage due to 
excessive anticoagulation3,4. Blood in an ECMO circuit travels through complex flow paths outside the 
body, and comes into contact with several square meters of foreign materials. Beyond the oxygenator 
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itself, a complete ECMO system includes many other circuit components including at least one catheter, 
many meters of tubing, and a pump. To mitigate the high risk of thrombosis, clinicians need to supply 
high doses of anticoagulation to patients, typically short-acting unfractionated heparin to block thrombin 
activity. However, though heparin administration is needed to prevent thrombosis, excessive 
anticoagulation can result in hemorrhage/bleeding events, which are the most common complications of 
ECMO in every patient demographic. Given these risks to patients, ECMO is typically only used as a 
salvage therapy to treat patients who have not been successfully recovered by any other method. 
 
Fig. 1.1: Diagram of ECMO operation in veno-arterial (VA) configuration. Deoxygenated blood is 
removed from the right atrium of the patient via a catheter and passed through the extracorporeal circuit. 
The blood first passes through a pump and is supplied with heparin and fluids as needed. Afterwards, the 
blood enters the membrane oxygenator and receives oxygen coming from the sweep gas. Once the blood 
is oxygenated, it is reheated before being returned to the patient’s aortic arch through another catheter. In 
this VA configuration, the patient’s lungs and heart are supplanted by the ECMO circuit. Adapted from 
Frenckner and Radell 2.  
 
Fluids Heparin
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As of the 2019 ELSO registry, over 12,000 patients per year were supported by ECMO 
worldwide 4. While ECMO use in general has been steadily rising since the year 2000, the adult ECMO 
population in particular has dramatically increased in the last 10 years, now making up the largest group 
of ECMO patients. Historically, ECMO has been primarily a therapy for neonates rather than adults, as 
neonates are less likely to suffer from unrecoverable chronic lung conditions that would contraindicate 
ECMO 5,6. However, the success of the CESAR trial and the advent of the H1N1 pandemic in 2006 and 
2009, respectively, led to the surge in ECMO for adult patients 3,7,8. Adult candidates for ECMO are more 
likely to suffer from chronic, progressive lung disease without long-term treatment endpoints such as 
chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, or end-stage lung failure 9–11. For 
these patients, ECMO can be used as a bridge-to-transplant, often with favorable outcomes compared to 
mechanical ventilation 6,12,13. Bridge-to-transplant patients have consistently shown better treatment 
outcomes with active rehabilitation programs using a semi-ambulatory ECMO circuit, though these 
patients still require constant monitoring by care teams within the intensive care unit.  
These bridge-to-transplant programs have spurred considerable clinical interest in increasingly 
portable ECMO systems that deliver sufficient respiratory support while minimizing circuit complexity 
and thrombogenicity 13,14. In an ideal case, an ambulatory ECMO system would effectively exchange O2 
and CO2 with minimal anticoagulation and clinician intervention, enabling use outside of the intensive 
care unit (ICU), and possibly outside of the hospital. Beyond improving bridge-to-transplant outcomes, a 
portable ECMO circuit with reduced thrombosis risk could make ECMO a more viable treatment option 
for other patient groups who may benefit from more frequent or prolonged oxygenation. With technology 
advances, an ambulatory, hemocompatible ECMO could be envisioned as a destination therapy for 
chronic lung failure patients. 
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 NEEDS FOR DESIGNING AN OXYGENATOR 
The design of an ECMO circuit, particularly the oxygenator, requires consideration of many 
design elements, as well as human factors for the clinician or patient. An ideal ECMO circuit would 
effectively exchange O2 and CO2 through its membranes, while minimizing thrombosis and hemorrhage 
risk to the patients. For an ambulatory ECMO circuit, the overall size and complexity of the circuit are 
also paramount, as well as durability over an extended treatment duration. 
 
Fig. 1.2: Schematic of oxygen and carbon dioxide exchange through an ECMO oxygenator. Oxygen in 
the flowing sweep gas diffuses through the oxygenator membrane pores. Once in the blood compartment, 
the oxygen enters a diffusion boundary layer that sequesters much of it due to the dominant effects of 
viscosity over convection. Eventually the oxygen diffuses into the bulk of the plasma, where it can be 
taken up by hemoglobin in red blood cells. Meanwhile, carbonic anhydrase enzyme maintains an 
equilibrium between dissolved carbon dioxide and bicarbonate ion as part of the blood’s pH buffering 
system. Excess dissolved carbon dioxide in venous blood can diffuse through the membrane and into the 
sweep gas, where it is carried away by the flowing oxygen. 
 Hemocompatibility/Anticoagulation 
In order to provide sufficient respiration, ECMO requires a patient’s entire cardiac output to 
travel through a complex and potentially turbulent extracorporeal circuit, and come into contact with a 
large area of foreign materials. Given the obvious likelihood of thrombosis under these circumstances, 
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clinicians must continuously dose of patients with anticoagulants throughout ECMO treatment, and 
frequently adjust their anticoagulation regimens as complications arise. On the whole, patient 
complications on ECMO are overwhelmingly centered around either clotting or bleeding events, 
indicating either inadequate or excessive anticoagulation, respectively. From multiple retrospective 
surveys of ECMO patients, several of the most common complications include mechanical failure of the 
ECMO system, circuit clotting, and surgical site hemorrhage 3,11. Furthermore, long-term ECMO circuit 
performance is known to deteriorate as a result of fibrin and cellular deposition on the membrane 
surfaces, reducing gas exchange efficiency over time and increasing pressure resistance from the 
oxygenator 15. These complications indicate a lack of hemocompatibility of the circuit itself, necessitating 
substantial blood anticoagulation that – in turn – raises the risk of bleeding. Therefore, improving 
hemocompatibility to the greatest extent possible could improve patient outcomes on long-term ECMO. 
Blood responsiveness to various disturbances in medical devices is a combination of three factors, 
comprising Virchow’s triad: the overall blood coagulatory status, mechanical forces on blood movement, 
and any blood-materials interactions with foreign surfaces 16,17. The first of these factors – the blood’s 
overall coagulatory status – is typically addressed through clinical administration of continuous systemic 
heparin in an ECMO circuit, rather than through device design 18,19. In the context of ECMO circuitry, the 
latter two factors can be addressed through engineering of the blood flow path throughout the circuit, and 
modifying the material surfaces to improve blood interactions.  
Flowing blood is subjected to a number of mechanical stimuli, typically a combination of 
velocity, pressure, and shear stress. Alterations to any of these mechanical forces individually or in 
combination can lead to a disruption of hemostasis, leading to thrombus formation. Shear stress on blood 
cells outside of typical physiologic ranges can lead to thrombosis through a number of different 
mechanisms including platelet activation, red blood cell hemolysis, and collection of pro-coagulatory 
factors in regions of uneven shear stress. Hemolysis can also contribute to the development of acute 
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kidney injury in ECMO patients, and therefore presents a significant clinical concern beyond thrombosis 
20. Interestingly, both low (< 50 s-1) and high (> 1500 s-1) shear rates have been shown to produce 
hemolysis and thrombosis in ECMO circuits, indicating that thrombosis is best prevented when shear 
rates are kept as consistent as possible 21,22. Higher shear rates are particularly associated with 
significantly increased platelet activation and red blood cell hemolysis, while lower shear rates also lead 
to increased red blood cell hemolysis and higher fibrin deposition. Low flow velocities – particularly 
regions of near stagnancy – are also highly associated with thrombus deposition in ECMO circuits. Given 
the complexity of most ECMO circuitry, especially the oxygenator, many stagnant zones can develop and 
have been shown to consistently lead to clot formation in the same regions. Some of these zones include 
the connectors throughout the circuit; the oxygenator inlet, in which flow is distributed throughout the 
membranes; and around the impellers of centrifugal blood pumps 23–25. Low flow regions are likely 
regions of low shear stress as well, and likely lead to thrombus formation through increasing local density 
of coagulatory proteins. In addition to shear stress, hydrostatic pressure on red blood cells can lead to 
hemolysis and subsequent thrombosis. High hydrostatic pressure is typically accompanied by higher flow 
velocities and shear rates, creating a potent combination for thrombus formation. Historically in ECMO, 
most of the resistance in the circuit originated from the oxygenator, since blood must pass through a dense 
array of membranes packed into a small volume. As such, most modern ECMO designs endeavor to 
minimize the pressure drop across the oxygenator unit, preventing one of the possible sources of 
hemolysis in the oxygenator 20,26,27. Still, regardless of hydrostatic pressure, shear rate alone is a 
significant contributor to hemolysis. Ultimately, from a flow mechanics perspective, ideal ECMO 
operation would maintain consistent physiologic shear stress throughout the entire circuit flow path, with 
as few regions of stagnancy as possible. Blood flow velocity should be kept at a relatively high rate for 
the device size to prevent stagnancy, but pressure drop in the oxygenator circuit should also be minimized 
to prevent the use of high hydrostatic pressure at high blood flow rates. 
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The third arm of Virchow’s triad – blood-materials interactions – arises from the absence of 
native vascular endothelium throughout the artificial ECMO circuitry. Healthy vascular endothelial cells 
secrete many different molecules to prevent both platelet activation and thrombin generation via the 
coagulation cascade. Since ECMO circuits contain no endothelium, blood proteins, platelets, and cells 
immediately react to the foreign materials in the circuit. Although systemic heparin administration can 
deter thrombin formation by increased antithrombin activity, circulating blood proteins quickly adsorb to 
the circuit materials and encourage clot formation by recruiting other proteins, cells, and platelets to the 
surfaces. Beyond increasing thrombosis risk, protein deposition on oxygenator membranes limits O2 and 
CO2 exchange through the membranes, gradually reducing ECMO effectiveness over time 15. Foremost 
among these proteins is fibrinogen which converts into fibrin when enzymatically cleaved by thrombin, 
making it a crucial step in thrombogenesis 28,29. When adsorbed to a surface, fibrinogen undergoes 
significant conformational changes that also trigger platelet adhesion and activation, acting as a trap for 
the platelets to form a “white” fibrin clot 29,30. Fibrinogen and other proteins show differential binding 
when adsorbing to surfaces with different chemistries, with fibrinogen binding preferentially to 
hydrophobic surfaces compared to other blood proteins like albumin 31,32. In addition, protein binding to 
material surfaces cycles through a dynamic process known as the Vroman Effect: proteins that are more 
adsorbent to a specific surface displace less adsorbent proteins over time 31,33,34. Essentially, fibrinogen 
may displace other proteins that initially adsorbed onto a surface – such as albumin – if fibrinogen is more 
adsorptive to that surface. This means that some common methods of reducing fibrinogen adsorption, 
such as albumin passivation of a surface, will rapidly become ineffective once fibrinogen is available to 
adsorb. Aside from surface chemistry, the topography of a biomaterial surface can influence 
thrombogenicity via protein binding and platelet interactions, depending on the length scale of the surface 
features. Blood cells and proteins may perceive rough surface features as similar to exposed endothelial 
basement membrane fibers (10-300 nm), leading to thrombotic reactions in an attempt to repair the 
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damaged endothelium 35. Most studies generally indicate that surface topography starts to influence 
protein binding when roughness is as low as 30-50 nm, although fibrinogen also shows significant 
adsorption onto surfaces with < 30 nm scale topography that allow further denaturing of its rod-shaped 
structure 36,37. In contrast, platelets are more responsive to topographies with roughnesses greater than 50 
nm, definitively in the hundreds of nanometers range, since any lower surface roughness is essentially 
smooth to platelets 38,39. However, some studies have shown that platelet adhesion in particular can be 
reduced using intentionally structured nanomaterial surfaces. Organized structures on the order of 
hundreds of nanometers, such as pillars or nanotubes, reduce the amount of available surface for platelets 
to contact, and can lower platelet adhesion compared to a completely smooth surface 39. Still, a smooth 
biomaterial surface would be the ideal topography to reduce thrombogenicity when considering both 
platelet and protein adhesion to surfaces. Between surface chemistry and topography, a smooth and 
hydrophilic surface would be the most likely to reduce materials-related thrombogenicity on oxygenator 
membranes. 
 Gas Exchange Efficiency/Portability 
Beyond hemocompatibility and anticoagulation, another significant consideration for oxygenators 
is the efficiency of the membranes at blood-gas exchange of O2 and CO2. To act as a total lung 
replacement, a blood oxygenator must be able to: 1. Supply a patient’s entire oxygen requirements, 2. 
Ventilate carbon dioxide adequately, and 3. Maintain rates of O2 and CO2 exchange at a blood flow rate 
equivalent to the patient’s cardiac output. All three parameters are dependent on a patient’s size and age, 
and clinicians should continuously evaluate and adjust ECMO support based on individual patient needs. 
As such, the values in Table 1.1 are generalized for each demographic 40.  
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Table 1.1: ECMO operation requirements for patients by age in units of mL/kg/min. 
Age Demographic O2 Exchange CO2 Exchange Blood Flow Rate 
Units mL/kg/min mL/kg/min mL/kg/min 
Neonate 6 3-6 100 
Pediatric 4-5 3-6 80 
Adult 3 3-6 60 
 
 For example, an adult patient with a mass of ~70 kg would require 210 mL/min of oxygenation 
and 315 mL/min of CO2 ventilation, while at a blood flow rate of 4.2 L/min through the ECMO circuit. 
The current market-leading oxygenator – the Maquet Quadrox-i series – has been independently 
evaluated to supply 125 mL/min/m2 of area-normalized oxygen flux at 4 L/min blood flow 27,41. With a 
membrane surface area of 1.8 m2, its total oxygen output would be around 225 mL/min, successfully 
meeting the needs of a 70 kg adult ECMO patient.  
ECMO circuits perform both O2 and CO2 exchange with blood, as in healthy lungs, although the 
exchange mechanism of each gas is distinct. Providing adequate oxygenation through the ECMO circuit 
is crucial for most hypoxic lung failure patients (arterial pO2 < 60 mmHg) . Once O2 enters the 
bloodstream, it can only be stored as a dissolved gas until it is taken up by hemoglobin in red blood cells. 
Also, given that hemoglobin has a finite capacity for oxygen storage, the amount of blood oxygenation 
that can be achieved is limited by the oxygen dissociation curve of hemoglobin 42,43. As such, O2 transport 
in ECMO is driven by the pressure gradient between the oxygen in the sweep gas compartment, and the 
dissolved oxygen gas in the bloodstream. In contrast, CO2 levels in the blood are primarily modulated by 
the bicarbonate buffering system, which involves enzymatic conversion of dissolved CO2 into bicarbonate 
ion: [HCO3]-. The vast majority of the body’s CO2 is stored as bicarbonate ion (90% in arterial blood, 
60% venous), with some amounts of dissolved CO2 gas (5% arterial, 10% venous) and some CO2 bound 
to hemoglobin as carboxyhemoglobin (5% arterial, 30% venous) 44,45. With most of the body’s CO2 stored 
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as acidic bicarbonate ion, the main complication of hypercapnic respiratory failure is reduced blood pH 
and respiratory acidosis (pH < 7.32). CO2 ventilation in ECMO is controlled by the flow rate of the 
oxygen sweep gas: as dissolved CO2 exits the bloodstream and transits the ECMO membranes, the 
gaseous CO2 is rapidly swept away by the flowing O2 to continuously eliminate the CO2 in the sweep gas. 
Between the two gases, O2 is poorly soluble in blood, whereas CO2 is over 20 times more soluble due to 
the bicarbonate buffering system 45. The Henry’s Law solubility coefficients of the gases in mL gas (100 
mL plasma)-1 mmHg-1 are 0.003 for O2 and 0.069 for CO2 45,46. Therefore, oxygenation is significantly 
more difficult in ECMO than CO2 ventilation. Due to the poor solubility of O2 in blood, oxygenators are 
typically designed to have large surface areas (1-2 m2 for adults) and operate at high blood flow rates (2-7 
L/min for adults) to maximize O2 flux through the membranes. These conditions are usually conducive to 
CO2 ventilation as well, since sufficient CO2 removal can still be achieved with lower blood flow rates 
(~500 mL/min for adults) and reduced surface area. 
Given the difficulty of oxygenation through ECMO, it is important to optimize oxygen delivery 
in ECMO at each stage of transport from the sweep gas to the hemoglobin. Improvements to oxygenator 
efficiency would also translate to improvements in hemocompatibility by minimizing blood-contacting 
surface area, overall device size, and hydrostatic pressure drop across the device. As O2 enters the 
oxygenator from the sweep gas, the O2 must travel by diffusion through the oxygenator membranes, after 
which the O2 enters the bloodstream. At this point, the O2 enters a fluidic boundary layer near the surface 
of the membrane. Diffusion boundary layers form at the interface of a solid and a flowing liquid, and it is 
in these regions where viscous forces are dominant over convective forces. In the case of O2, the 
boundary layer essentially sequesters most of the oxygen near the membrane surface, reducing the 
pressure gradient of oxygen across the ECMO membranes and thereby lowering transmembrane O2 flux. 
Eventually, the O2 diffuses out of the boundary layer and into the bulk of the flowing plasma, where it is 
finally be taken up by the hemoglobin in red blood cells. While the membranes themselves present some 
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resistance to oxygen transfer, by far the most significant resistance to O2 transport in conventional ECMO 
is this blood boundary layer, possibly comprising ~80-100% of the total resistance to transport 47–49.  
Overcoming the resistance of the blood-side boundary layer is a significant challenge in 
oxygenator development. Most oxygenators are designed to operate in laminar flow regimes in order to 
avoid fluidic turbulence and thrombosis, yet this laminar flow prevents convective forces from interfering 
with the boundary layer. Designing fluid flows that minimize the effect of the boundary layer may be one 
strategy to create a more efficient oxygenator that maximizes transport with minimal membrane area and 
blood volume. Based on Blasius solutions to laminar boundary layer equations, the thickness of the 
boundary layer ( ) grows along the membrane surface at position x  in inverse proportion to the square 
root of the Reynolds number 50:  
 
4.9
Rex
x
                                                               Eq. 1.1.1 
This means that boundary layer thickness is related to the inverse of the blood velocity: higher 
blood flow rates reduce the boundary layer thickness. Essentially, operating ECMO at higher blood flow 
rates should allow for more efficient gas exchange across the membranes, which is confirmed by 
manufacturer data. Also, generating secondary fluid flows – as in turbulent boundary layers – could 
disrupt the formation of the boundary layer and encourage more transport 51,52. However, these concepts 
must be balanced with pro-thrombotic concerns of generating high pressure resistance and uneven shear 
stresses. Overall, boundary layer disruption is likely a powerful method to create a more efficient ECMO 
oxygenator, yet should be considered holistically alongside hemocompatibility strategies. 
Designing a more efficient oxygenator can be a critical factor in creating a truly ambulatory 
ECMO circuit. With a small and efficient oxygenator, other components of the ECMO circuit could 
possibly be reduced or eliminated. For example, an oxygenator with a low priming volume and a low 
pressure drop could allow the circuit to be operated without a pump, which is a major potential source of 
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ECMO thrombosis. In this configuration, the patient’s own heart flow would be able to pump blood 
through the oxygenator without additional assistance. 
 CURRENT ECMO OXYGENATOR DESIGNS 
Considering the development of a future ambulatory ECMO circuit, examining various 
oxygenator modalities may elucidate what design concepts make for superior oxygenator performance. 
Specifically, this section will briefly evaluate oxygenators in the commercial and research landscapes 
through the lenses of hemocompatibility and portability potential. 
 Standard of Care: Hollow Fiber Oxygenators 
From 1971 onwards, clinical ECMO units have used hollow fiber technology to create membrane 
oxygenators 53,54. In these devices, blood from the pump enters a manifold containing a bundle of tightly-
packed fibers, around which the blood must navigate towards the exit (Fig. 1.3). These fibers are hollow 
and contain the oxygen-rich sweep gas. As the blood navigates around the hollow fibers, gas exchange of 
O2 and CO2 is facilitated through the fiber membranes. Since their introduction, they have been the 
standard of care, and currently the only type of oxygenators clinically available.  
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Fig. 1.3: Current generation of hollow fiber oxygenators. (a)-(c) shows the Maquet Quadrox oxygenator 
unit going from (a) the packaged device, to (b) a general diagram of blood and sweep gas flow, then to (c) 
SEM imaging of hollow fibers in cross section 41,55. (d) shows a functioning circuit with the Quadrox 
device, with visibly increased O2 saturation after blood exits the oxygenator 56. In contrast, (e) shows the 
pumpless Novalung ECCO2R device in a femoral arteriovenous configuration 57. 
 
The complexity of the blood flow paths around the hollow fiber membranes creates unique 
hemocompatibility challenges, but offers some benefits to gas exchange efficiency. Blood flowing around 
the hollow fibers can be subjected to many zones of stagnant flow and uneven shear stresses, leading to a 
pro-thrombotic state. Furthermore, in studying the locations of clots within hollow fiber devices, 
researchers have pointed to certain locations that tend to nucleate clots, some of which are inherent to the 
design of hollow fiber devices. Notably, these areas include the flow distributor region at the device inlet, 
in which the blood first contacts the hollow fibers, and any corners of the manifold such as in the market-
leading Maquet Quadrox series 25,58. Systemic heparinization is required to likelihood of clotting due to 
Images from Maquet and Muller 2009
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these uneven flow paths. However, the complex flow paths around the hollow fibers are capable of 
generating secondary flows, which can disrupt the diffusion boundary layer and increase gas exchange 
through the device 22,51,52. Also, as hollow fiber technology has advanced, the devices currently on the 
market are able to operate at high blood flow rates while maintaining a low pressure drop reducing 
hemolysis resulting from high hydrostatic pressure. For example, the adult Maquet Quadrox oxygenator 
yields only 8.4 mmHg of pressure drop per liter per minute of blood flow rate 27. 
From a materials perspective, hollow fibers have largely converged on a few material choices and 
coating combinations. Though some hollow fiber oxygenators are still made of polypropylene (PP), 
polymethylpentene (PMP) has become the optimal polymer choice for hollow fiber membranes because it 
features a microporous structure with an extremely thin (~0.1 µm) liquid-tight outer skin 59,60. This allows 
the transit of O2 and CO2 with minimal resistance through the micropores, while also preventing leakage 
of blood plasma into the sweep gas. As a hemocompatible coating, most manufacturers have conjugated 
heparin to the fiber surfaces, in addition to systemic heparin administration for anticoagulation. However, 
heparin has a relatively short bioactivity period of only a few hours, and some researchers have linked 
heparin coatings with heparin-induced thrombocytopenia 61–65. Therefore, heparin coatings may only 
benefit hollow fiber membranes over a short span within the ECMO support timeline. Some makers have 
instead employed polymeric coatings, often with a negative surface charge, although these are currently 
less common and their composition is typically proprietary 66–68. 
The dimensions of current hollow fiber oxygenators can provide a benchmark upon which to 
evaluate other technologies. Using 3M Membrana OXYPLUS PMP membranes as a contemporary 
example, hollow fibers are generally around 300-400 µm in diameter with a wall thickness of ~90 µm 
59,69. They are packaged in sheets at a density of 44 fibers per inch as specified by the manufacturer. The 
market-leading adult model Maquet Quadrox-i oxygenator contains 1.8 m2 of membrane surface area with 
215 mL of priming volume, and recommended blood flow can range from 0.5-7 L/min 41. 
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 Hollow Fiber Derivatives 
Using hollow fiber membranes as a foundation, a few notable oxygenator derivatives have been 
developed to fill specific application niches. Examining these devices can elucidate what design priorities 
are valuable in each setting, and may be relevant for the development of similar gas exchange devices. 
1.3.2.1 ECCO2R 
Although adequate O2 and CO2 exchange is critical for ECMO patients, oxygenation is typically a 
clinical priority over CO2 ventilation, partially due to poor solubility of O2 in blood. However, there are 
some clinical indications where specifically CO2 removal is critical. In hypercapnic cases of respiratory 
failure, body’s inability to ventilate CO2 leads to high concentrations of bicarbonate ion in blood, which 
reduces blood pH and results in respiratory acidosis (pH < 7.32). Patients who suffer from acute 
hypercarbia as in an asthma attack or COPD exacerbation may see a significant benefit from ECMO for 
CO2 removal compared to mechanical ventilation 70,71. One further consideration is that prioritizing CO2 
removal is mostly pertinent in cases of acute hypercapnia. Many adult patients have chronic conditions 
that have altered their respiratory physiology over time, such as COPD; these patients often develop 
compensated respiratory acidosis, with elevated pCO2 values (pCO2 > 50 mmHg) but normal physiologic 
blood pH (pH > 7.35). For these patients, CO2 removal may not be as critical, since their blood pH is not 
acidotic. 
A newer therapy of extracorporeal carbon dioxide removal (ECCO2R) has been specifically 
developed to address this population of acute hypercapnic patients. Given that CO2 is significantly more 
soluble in blood than O2, blood CO2 ventilation can be achieved with far less surface area, smaller 
catheters, and at lower blood flow rates than ECMO for oxygenation 42,72. Blood flow rates for ECCO2R 
range between 0.3-1 L/min (generally around 0.5 L/min), and surface area of 0.3-0.7 m2 70,71,73. Most 
studies on ECCO2R have shown positive patient outcomes compared to mechanical ventilation treatment 
alone, although the available clinical data is insufficient for conclusive evidence of ECCO2R’s benefits 70. 
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Compared to conventional ECMO, ECCO2R therapy may result in an increased risk of thrombosis to 
patients. Many studies have speculated that the lower flow rates of ECCO2R lengthen the time that blood 
is in contact with foreign materials in the circuit, contributing to an increased likelihood of thrombosis 
70,71,74. The lower flow rates may also yield lower shear stresses on blood cells, leading to the same 
outcome 75. As of 2019, the leading ECCO2R system – the Hemolung RAS, manufactured by ALung 
Technologies – has received the CE mark in 2013, and is undergoing two prospective clinical trials in the 
United States and the United Kingdom, primarily to evaluate the safety and efficacy of the ECCO2R 
device for acute COPD exacerbations 76,77.  
1.3.2.2 Pumpless ECMO (Novalung) 
One of the most prominent contributors to thrombosis in ECMO is the pump needed to drive flow 
throughout the circuit, at flow rates equivalent to the patient’s cardiac output (2-7 L/min for adults). 
Elimination of the pump alone could reduce the overall likelihood of thrombotic events in the circuit, and 
improve portability through size and weight reduction 55,78,79. To achieve pumpless operation, blood flow 
through the circuit would be entirely driven by the natural pressure gradients of the patient’s heart, 
meaning a low-resistance oxygenator is paramount to pumpless operation. For adults, pulmonary artery to 
left atrium pressure differential is ~15 mmHg for veno-venous operation 79, while the mean arterial 
pressure of 60-80 mmHg could be used to drive flow in an arterio-venous configuration 80,81. Furthermore, 
without a pump to drive flow, a pumpless device would likely operate with only a fraction of the patient’s 
entire cardiac output, meaning flow through the device – and therefore oxygenation support – would be 
limited 80,82. Still, a pumpless, low-flow gas exchange device could be used for ECCO2R therapy, or as a 
device intended for respiratory assistance rather than complete support. 
The Novalung iLA device, now produced by Xenios, is intended as a respiratory assistance 
therapy for bridge-to-transplant cases. Similar to other ECMO and ECCO2R devices, the Novalung is 
constructed of PMP hollow fibers with a heparin coating, and designed with a low pressure resistance of 
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only ~15 mmHg at a flow rate of 2.5 L/min 80,83. Generally, a fraction of the body’s cardiac output is 
shunted through the Novalung device for respiratory assistance, which is connected in an arterio-venous 
configuration between femoral arteries and veins (Fig. 1.3e) 81,83. The device has a surface area of 1.3 m2 
and is rated between 0.5-4.5 L/min of blood flow, although typical blood flows are mostly kept to ~1.5 
L/min 54,55,80. Using the device, supportive carbon dioxide removal – but only minimal oxygenation – has 
been demonstrated in patients, essentially making the Novalung another type of ECCO2R device 80. As 
the system is completely pumpless, the Novalung circuit uses less priming volume compared to 
conventional ECMO (~250 mL), and greatly simplifies the clinical monitoring of the device 82. However, 
the pumpless Novalung operates at a relatively low blood flow rate similar to other ECCO2R devices, and 
so has shown somewhat increased platelet activation in some tests 82. 
 CURRENT RESEARCH DIRECTIONS 
Research groups worldwide are endeavoring to build novel gas exchange devices that improve 
upon the hemocompatibility and efficiency of current hollow fiber ECMO oxygenators. Some researchers 
have been attempting to optimize versions of hollow fiber oxygenators, while others have been studying 
alternative membranes and gas exchange paradigms altogether. 
 Improvements to Hollow Fiber Devices 
One prominent research objective involves the optimization of hollow fiber membrane assembly 
with the goal of constructing a portable lung assistance device. Multiple groups have used hollow fiber 
membranes to construct new devices that improve upon the efficiency and hemodynamics of existing 
ECMO units. Efforts at the University of Michigan and University of Pittsburgh have separately 
developed portable paracorporeal lung assistance devices through optimization of hollow fiber packaging 
52,79,84,85. The Pittsburgh approach centers around the integration of a centrifugal pump in the same unit as 
the oxygenator (Fig. 1.4a) 84,86, while the Michigan device aims for pumpless flow through the circuit. 
Both devices improve overall circuit portability through the consolidation of circuit components. Other 
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efforts have attempted to improve gas exchange efficiency through unconventional boundary layer 
disruption techniques such as oscillation of the hollow fiber bundles, rotation of the hollow fiber bundle, 
or introducing pulsatility to the blood flow into the fiber bundles 87–89. None of these techniques has been 
integrated into a larger-scale oxygenator, but all address the desire for improved gas exchange via 
boundary layer disruption and increased mixing. 
 
Fig. 1.4: Examples of improvements to hollow fiber membrane gas exchange devices. (a) shows the 
University of Pittsburgh pediatric ambulatory lung with integrated blood pump – an advancement in 
compactness and portability 86. (b) shows endothelialization of perfused PMP hollow fibers with human 
cord blood derived cells at Hannover Medical School 90. 
 
Improvements to hemocompatible coatings on hollow fibers are also a notable area of research 
and development. Generally, these alternative coatings tend to emphasize high hydrophilicity, or add a 
new functionality to the membranes beyond their original capabilities. Zwitterionic coatings have gained 
considerable traction as biomaterial coatings, including on oxygenator membranes. The combination of 
positive and negative ionic residues on the same molecule imbues surfaces with unparalleled 
hydrophilicity, drawing a hydration layer to the surface that prevents protein adhesion and thrombosis 
91,92. On oxygenator membranes specifically, zwitterionic coatings that have been tested have include 
phosphorylcholine derivatives 93–95, carboxybetaine bonded to dopamine 65, and sulfobetaine 93. The 
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majority of these studies have shown favorable reductions in protein fouling on surfaces and platelet 
activation, often with little to no significant reduction in gas exchange with coating application.  
More advanced coatings on hollow fibers have attempted to imbue an additional functional 
benefit to the coatings beyond reducing protein fouling. Work by Arazawa, et al. at the University of 
Pittsburgh combined an enzymatic coating (carbonic anhydrase) with an acidic sweep gas to enhance 
carbon dioxide removal through hollow fibers 73. This combination leveraged the equilibrium between 
bicarbonate ion and dissolved CO2 in the blood to drive increased carbon dioxide ventilation compared to 
either the sweep gas or the coating alone. Other coatings attempt to mimic the native vascular 
endothelium by continuously eluting the natural anticoagulant – nitric oxide – into the bloodstream 96,97. 
Nitric oxide (NO) is naturally secreted by healthy endothelial cells to quell platelet activation, and 
therefore could be highly beneficial to a potent anticoagulation strategy for ECMO. Some examples of 
NO-releasing coatings include the NORel polymer coatings developed at the University of Michigan for 
over a decade 96,98,99, and the copper-embedded elastomer coatings from Carnegie Mellon University 
100,101. 
Another intriguing approach to enhancing ECMO hemocompatibility is the endothelialization of 
the hollow fibers themselves to create a “biohybrid” artificial lung (Fig. 1.4b). Theoretically, 
endothelialization of the oxygenator membranes would achieve the ultimate hemocompatible surface by 
becoming a functional vascular endothelium, similar to alveolar capillaries in the native lung 102. Multiple 
research groups have studied the establishment of a confluent endothelial cell layer onto surface-modified 
hollow fiber membranes. Cell types have included bovine aortic endothelial cells 89, and human umbilical 
cord blood endothelial cells 90,103,104. Generally, research has demonstrated that, under physiologic levels 
of shear stress in vitro, the endothelial cells can be successfully seeded and maintained on oxygenator 
fibers for up to 28 days of culture. However, the in vivo feasibility and longevity of this endothelial layer 
has yet to be thoroughly demonstrated. When exposed to blood, bovine endothelialized hollow fibers have 
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shown reduced thrombosis compared to uncoated membranes with over an hour of exposure, but also 
significantly reduced oxygen permeability 55,89. More recent studies on human cord blood cells have not 
yet explored the gas exchange consequences of endothelialization or hemocompatibility. The viability of 
the endothelial layer over long-term exposure to blood and highly oxygenated sweep gas has not been 
studied, since the few experiments that expose endothelium to blood have only studied cell viability over 
a few hours. Any defects in the conformity of the endothelium could expose the hollow fiber membrane 
surfaces to blood, possibly triggering thrombus formation despite the endothelial coating. Also, the 
immunologic consequences of patient blood to this endothelium have not yet been explored, especially if 
the cell source is autologous or xenogenic to the patient. Significantly more research will need to be 
conducted on the feasibility of endothelialized oxygenator membranes, but – if long-term gas transfer and 
biocompatibility is demonstrated with these units – they could be a significant benefit to overall ECMO 
hemocompatibility. 
 Microfluidic Artificial Lungs 
Moving away from hollow fibers altogether, many research groups have developed prototype 
artificial lungs based on synthetic microfluidic capillary beds, which attempt to create a synthetic lung 
structure by mimicking native alveolar vasculature. These microfluidic devices use advanced 
microelectromechanical systems (MEMS) production techniques, including soft lithography of silicone 
elastomers, to emboss highly organized microchannel structures into flat sheets of materials such as 
polydimethylsiloxane (PDMS). With unparalleled precision and reproducibility, many of these flat 
silicone sheets can be stacked in parallel plate layers that alternate between sweep gas and blood flow 
channels, forming the oxygenator membrane structures. By routing blood through highly organized 
microchannels, researchers hope to mimic the hemodynamic and gas transfer qualities of the native lung, 
which hollow fiber membranes are inherently incapable of recreating. While no large-scale microfluidic 
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prototypes currently exist, research in this field presents unique solutions to concerns with hollow fiber 
ECMO, and provides an intriguing direction for a potential future artificial lung. 
 
Fig. 1.5: Microfluidic blood oxygenator schematics and actualizations. (a) shows a schematic of a stacked 
array of microfluidic channels in parallel plate configurations 55. (b) shows an SEM cross section of such 
a device separating the sweep gas in the alveolar chamber from the blood in the vascular network 105. (c) 
shows the blood-perfused capillary bed of a branched microfluidic oxygenator 106, while (d) shows the 
current largest microfluidic oxygenator consisting of four microfluidic units in parallel 107. 
 
Dimensions of microfluidic oxygenators vary widely between each research group’s devices 55. 
One of the earliest iterations of a microfluidic oxygenator by Lee, et al. (2008) used a relatively thick 130 
µm PDMS membrane, and comparatively thin 15 µm blood flow channels 108. Subsequent early devices 
by the Draper Lab 105,109–111, McMaster University 112, and the University of Michigan 113,114 substantially 
reduced the PDMS membrane thickness into the tens of microns, ranging from 10-63 µm. Blood capillary 
heights of these early devices either attempted to mimic ultrathin alveolar vasculature (10-20 µm) 55,113, or 
design significantly wider channels to ensure low-resistance flow (80-200 µm) 105,112. Although ECMO 
membranes are not generally significant contributors to O2 and CO2 transfer resistance, microfluidic 
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oxygenators can create extremely thin gas exchange membranes that effectively make membrane 
resistance negligible. PDMS has a naturally high permeability to both O2 and CO2 115–118, and  does not 
lead to gas emboli formation or plasma leakage. Still, because PDMS is a flexible material, the thin 
PDMS membranes need to be sufficiently structurally supported so as not to collapse into the blood flow 
channels. Most researchers have settled on blood channel widths of 50-60 µm to ensure adequate channel 
support without collapse 106. The most recent generation of microfluidic oxygenators has converged on 
PDMS membrane thicknesses of 30-60 µm – thinner than PMP hollow fiber wall thickness – and blood 
channel capillary heights of 30-100 µm 106,107,119. The McMaster University research group has also 
explored the reinforcement of their PDMS membranes with stainless steel wire meshes, which provide 
significant structural rigidity and robustness under pressure 107,120. Ongoing efforts within these groups 
have endeavored to increase device scale to oxygenate large scale animals, with the goal of reaching 
human scale. The largest microfluidic oxygenators so far have used priming volumes of 7-8 mL to handle 
12-17 mL/min of blood flow, using 14-32 cm2 of effective gas exchange surface area  – maximally ~63 
cm2 when multiple units are arrayed 106,107. In terms of overall portability, some researchers have designed 
novel packaging techniques to keep the microfluidic oxygenators as compact as possible. Researchers at 
McMaster University and the University of Michigan have explored rolling their oxygenator beds into 
cylindrical structures, or in a cup-shaped bundle 79,107,121. At this prototype stage of development, though, 
it is difficult to determine the extent to which microfluidic oxygenators can improve overall ECMO 
portability by achieving pumpless operation, or using room air as a sweep gas instead of O2 55. 
The most significant advantages to microfluidic oxygenators are the highly controlled flow paths 
that can be constructed with MEMS precision, and the high oxygen transfer that can be achieved using 
micromachined gas exchange channels. Blood flow paths can be divided throughout the artificial capillary 
bed using natural scaling and branching patterns similar to native lung structure, altering hydraulic 
diameter between larger and smaller channels to retain consistent flow dynamics. Among microfluidic 
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ECMO research groups, the University of Michigan group has extensively utilized Murray’s Laws of 
parent-daughter vessel construction to guide branching angles and microchannel heights 106,114. The 
Draper Lab group has used biomimetic branching angles as well, but generally single-height blood flow 
channels that do not vary with parent-daughter branching 111. By contrast, the McMaster University group 
has opted for simple 90° capillary branching angles and no variance in capillary height, demonstrating 
that biomimetic branching angles are not a requirement for microfluidic design 112,121,122. In theory, 
distributing blood flow in a biomimetic branching manner should improve the flow path arm of 
Virchow’s triad by keeping flow rates and shear stresses on platelets consistent throughout the entirely 
smooth, laminar flow path. Ordinarily, keeping blood flow paths entirely laminar in a microfluidic device 
would prevent any boundary layer mixing, reducing the oxygenation potential of such a geometry. 
However, microfluidic devices can be designed with channel heights in the tens of microns, nearing 
alveolar capillary channel heights of 8 µm 55,112,113. This means that the boundary layer essentially 
encompasses the entire microchannel, and therefore transfer resistance is negligible. Furthermore, MEMS 
soft lithography techniques could be used to emboss mixing structures onto the PDMS microchannels and 
create gas transfer-enhancing flow paths, though these have yet to be tested for hemocompatibility 123.  
As with hollow fibers, many researchers developing microfluidic oxygenators have applied 
coatings on top of PDMS to improve the hemocompatibility of the surface. Though it is bioinert, PDMS 
alone is a naturally hydrophobic material, and thus attracts considerable protein deposition onto the 
surface that could trigger thrombus formation. For microchannels specifically, improving the 
hydrophilicity of PDMS also ensures that all channels will become properly wetted with fluid. Surface 
modification of PDMS is possible with plasma treatment followed by silane bonding chemistry to 
covalently attach hydrophilic moieties to the surface. Coatings that have been studied on microfluidic 
oxygenators specifically include polyethylene glycol 124, and zwitterionic polymers including sulfobetaine 
125. In addition, research groups have attempted to build an endothelialized microfluidic PDMS 
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oxygenator 111,126. The most significant research on this topic, conducted at RWTH Aachen University, 
has successfully cultured human vascular endothelial cells on RGD-modified PDMS for up to 33 days, 
though O2 and CO2 exchange was significantly reduced compared to unmodified PDMS 126,127. 
While initial work on microfluidic ECMO devices have demonstrated proof-of-concept, the 
biggest hurdle to further development is the scale-up of this technology to a full-scale, human-sized 
device. At the prototype stage, assembly of oxygenators involves laborious PDMS molding and layer-by-
layer stacking, currently done by manually . In the future, automated MEMS tooling could be used to 
greatly simplify and standardize this process 55. Microfluidic ECMO devices are currently operating at a 
prototype scale that is significantly smaller than full-scale hollow fiber membrane devices, but have 
shown promising comparability of gas transfer. Using more recent prototypes as examples, oxygen 
transfer rates range from 88-130 mL/min/m2 106,121. At the higher end of this range, a microfluidic 
oxygenator may be comparable to a hollow fiber device such as the Maquet Quadrox-i series. Still, no 
device has come close to providing enough total oxygen flux for human respiratory support. 
Hemocompatibility results for microfluidic oxygenators are mixed thus far. With the help of 
hemocompatible coatings, short term patency of microfluidic devices over the range of hours has been 
demonstrated in many studies, with a few experiments showing patency of > 18 h 114. However, blood 
flow through the very narrow artificial capillary beds results in high pressure gradients and shear stresses 
across prototype oxygenators. One recent example from Thompson, et al (2018) demonstrated a pressure 
drop of 66 mmHg at a blood flow rate of 17 mL/min, while a Maquet Quadrox-i has a pressure drop of 
only 8.4 mmHg per L/min of blood flow 27,106. Despite efforts to improve hemodynamics through 
controlled branching design, the artificial capillary beds inherently present a significant resistance to 
blood flow, potentially resulting in hemolysis and thrombosis from the uneven shear stresses and high 
hydrostatic pressure. Scale up of the devices may be able to mitigate this issue by routing blood flow 
through more channels, thereby reducing pressure drop. Considering the advantages and drawbacks of 
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microfluidic oxygenators, this research presents unique solutions to the hemodynamic issues with current 
ECMO devices, and scale up of the technology could put this concept on a competitive level with hollow 
fiber membranes. 
 SILICON MEMBRANE OXYGENATOR 
For over a decade, our lab has developed porous silicon membranes with high precision and 
reproducibility, made using scalable MEMS technology from the silicon integrated circuits industry 128–
131. These membranes possess a mechanically rigid – yet thin – structure, and can be readily arrayed in 
parallel plate configurations for controlled exchange of materials between two separated compartments. 
With a range of pore sizes from < 10 nm to 1 µm, silicon membranes can readily reproduce a variety of 
physiologic filtration functions, by way of their unprecedented selectivity and filtration efficiency. As 
such, silicon membranes can serve as individual filtration units for the construction of large-scale 
artificial organ devices, including as an artificial lung device. 
 
Fig. 1.6: Silicon membranes for artificial organ devices, highlighted for use as ECMO membranes. (a)-(c) 
show the hierarchy of highly precise silicon structures from a macroscopic (6.5 cm2 membrane) to 
nanometer scale. (d) shows a cross section of a silicon-PDMS composite membrane, intended for liquid-
tight blood oxygenation. (e) shows a schematic of a blood oxygenator assembly using the composite 
membranes, and (f) shows an early proof-of-concept prototype using a 1 cm2 silicon membrane to 
conduct blood oxygenation 132. 
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By developing and characterizing silicon membranes, our lab has prototyped artificial organ 
replacements for the kidneys, pancreas, and lungs. Significant research in our lab has focused on renal 
filtration using nanoporous (~10 nm pore) silicon membranes (SNM) to controllably filter small solutes. 
Compared to a hollow fiber renal dialyzer, the SNM allow for highly selective filtration of over relatively 
short (200-500 nm) diffusion distances 131,133,134. With highly efficient membrane filtration, the SNM can 
be arrayed into a compact artificial kidney, intended for long-term implantation as a renal replacement 
therapy 135–137. In addition to filtration, the silicon membranes are capable of supporting cell populations 
through protective encapsulation in one of the device compartments 138–140. The silicon membranes can 
permit an encapsulated population of cells to interact with small molecules and nutrients in a patient’s 
bloodstream, while also protecting the cells from larger entities such as the patient’s immune cells. Using 
silicon membranes in the sub-micron (~500 nm) range for immunoisolation has led to the design of a 
bioartificial pancreas device 138,139. Through separation of an islet chamber from the bloodstream, a 
population of autologous or xenogenic pancreatic islets can be viably kept for sustained blood glucose 
regulation.  
Further research has investigated the sustained hemocompatibility of silicon membrane devices, 
including membranes coated with hemocompatible polymers such as polyethylene glycol 131,135 and 
sulfobetaine methacrylate 91,141,142. Given that silicon membranes are rigid, flat sheets, prototype devices 
are assembled with the silicon membranes in parallel plate configurations, similar to microfluidic 
oxygenator devices. Laminar flow throughout the devices is achieved at flow rates up to 60 mL/min in 
vivo, with computationally optimized shear stress throughout the blood flow path 91. Membranes can be 
assembled into devices with blood flow channels ranging from 50 µm to 3 mm in height, allowing a high 
degree of tailoring to meet the needs of a particular application 91,132,139. Since the silicon membranes are 
mechanically rigid, blood flow channels can be kept very wide (1-8 cm range) relative to their height to 
ensure low pressure resistance throughout the entire flow path 135,139,143. Compared to a microfluidic 
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oxygenator, high rates of blood flow with very low pressure drop can be achieved with silicon membrane 
geometries, while keeping the membrane’s mass transfer resistance exceptionally low due to material 
thinness. Devices with zwitterionic coatings on silicon substrates have shown sustained patency and 
hemocompatibility for 26 days of implantation into a flowing blood porcine model, indicating a high 
degree of hemocompatibility of both the coated silicon and the parallel plate assembly 91. 
As with the kidney and pancreas, silicon membranes have been studied as a potential oxygenator 
membrane. Early studies in 2009 with SNM demonstrated that O2 transfer can occur through silicon 
membranes, possibly at an enhanced level due to free molecular flow inside of the silicon nanopores 144. 
Subsequent work by Yeager moved to the use of a microporous silicon membrane surmounted with an 
ultrathin layer of PDMS to construct a rigid, liquid-tight oxygenator membrane 54,145. In this work, a 
proof-of-concept oxygenator was built using a 1 cm2 silicon membrane, through which some O2 and CO2 
exchange was observed with ovine blood. Still, at this small prototype stage, much about the oxygenator 
concept was not yet established. These preliminary gas exchange rates were only measured through a 
small membrane, and systematic characterization the gas permeance of different silicon membranes had 
not been conducted. The design of the device prototype had not been optimized for hemocompatibility, 
and no coatings other than PDMS were used to minimize surface thrombogenicity. Future work from 
these experiments would need to systematically determine gas exchange through membranes, and 
optimize a larger-scale oxygenator prototype to further the silicon membrane oxygenator concept. A 
comparison of a hypothetical silicon membrane oxygenator to current and future gas exchange devices 
can be found in Table 1.2 
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Table 1.2: Comparison of advantages and disadvantages of current and future gas exchange devices. 
Critical size parameters are specified, with notes about overall circuit portability potential. Flow 
hemodynamics, surface materials, and gas exchange properties of each device are characterized. 
Device Dimensions 
 
δm: wall thickness 
hc: channel height 
SA: surface area 
Flow Path and 
Hemodynamics 
Blood-Materials 
Interactions 
Gas Exchange 
Efficiency 
Hollow Fiber 
Oxygenator – 
Maquet Quadrox-i 
Adult 41 
 
 
 
δm: 90 µm 
hc: ?, est. 200 µm 146  
SA: 1.8 m2 
 
Advantages 
- Full-scale device 
Disadvantages 
- Thick membranes 
- Not compact or 
ambulatory 
- Pump required 
 
Advantages 
- Low resistance 
 
Disadvantages 
- Uneven shear → 
hemolysis, platelet 
activation 
- Stagnant regions 
→ thrombosis 
Advantages 
- PMP: liquid 
barrier, permits 
gas diffusion 
 
Disadvantages 
- Heparin coatings 
unstable over time 
- Membrane fouling 
over time 
Advantages 
- Secondary flows 
induce boundary 
layer disruption 
- High flow rates → 
high O2, CO2 flux 
 
Disadvantages 
- Thick membranes, 
long diffusion 
distances 
ECCO2R – 
Hemolung 147 
 
 
δm: 90 µm 
hc: ?, est. 200 µm  
SA: 0.59 m2 
 
Advantages 
- Full-scale device 
- Compact design 
Disadvantages 
- Only CO2 support 
- Not ambulatory, 
still requires pump 
 
Advantages 
- Low resistance 
 
Disadvantages 
- Uneven shear  
- Low flow rates → 
hemolysis 
- Stagnant regions 
Advantages 
- PMP: liquid 
barrier, gas 
diffusion 
 
Disadvantages 
- Heparin coatings 
unstable over time 
- Membrane fouling 
Advantages 
- Secondary flows 
induce boundary 
layer disruption 
 
Disadvantages 
- Low flow rates → 
only CO2 support 
 
Pumpless 
ECCO2R – 
Novalung 57 
 
 
δm: 90 µm 
hc: ?, est. 200 µm 
SA: 1.3 m2 
 
Advantages 
- Full-scale device 
- Pumpless 
Disadvantages 
- Only CO2 support 
- Not ambulatory 
- Requires cardiac 
functionality 
 
Advantages 
- Ultra-low 
resistance 
- Pumpless usage 
 
Disadvantages 
- No control over 
flow rates 
- Uneven shear and 
stagnant zones 
- Low flow rates → 
hemolysis 
 
Advantages 
- PMP: liquid 
barrier, gas 
diffusion 
 
Disadvantages 
- Heparin coatings 
unstable over time 
 
Advantages 
- Secondary flows 
induce boundary 
layer disruption 
 
Disadvantages 
- Low flow rates → 
only CO2 support 
- No control over 
flow rates → 
unknown 
respiratory support 
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Device Dimensions 
 
δm: wall thickness 
hc: channel height 
SA: surface area 
Flow Path and 
Hemodynamics 
Blood-Materials 
Interactions 
Gas Exchange 
Efficiency 
U. Pitt. Pediatric 
Lung Assist 
(Hollow Fiber) 86 
 
 
 
δm: 90 µm 
hc: ?, est. 200 µm 
SA: 0.3 m2 
 
Advantages 
- Full-scale 
pediatric device 
- Ambulatory with 
compact circuit 
Disadvantages 
- Pump required 
Advantages 
- Integrated pump 
→ lower total size 
 
Disadvantages 
- High resistance 
- Complex pump 
flows due to 
integrated design 
- Uneven shear and 
stagnant zones 
- Device failure in 
limited early trials 
 
Advantages 
- PMP: liquid 
barrier, gas 
diffusion 
 
Disadvantages 
- Currently no 
coating, future: 
zwitterionic 
 
Advantages 
- Secondary flows 
induce boundary 
layer disruption 
 
Disadvantages 
- Low flow rates → 
less efficient gas 
exchange 
U. Michigan 
Microfluidic 
Oxygenator 106,125 
 
 
δm: 30 µm 
hc: 30 µm 
SA: 31.5 cm2 (gas 
exchange) 
 
Advantages 
- Compact, efficient 
circuit 
Disadvantages 
- Prototype scale, 
not human size → 
future size TBD 
- Soft lithography 
scale up unknown 
 
Advantages 
- Controlled laminar 
flow paths 
- Biomimetic 
capillary bed 
 
Disadvantages 
- High resistance 
- High shear stresses 
- Long term patency 
unknown 
 
Advantages 
- PDMS: liquid 
barrier, ultrathin 
- Possible zwitterion 
coating 
 
Disadvantages 
- Zwitterionic 
coating longevity 
unknown 
 
Advantages 
- Thin blood 
channels → 
efficient gas 
exchange 
 
Disadvantages 
- No boundary layer 
disruption 
 
Silicon Membrane 
Oxygenator 
 
 
δm: 5 µm (PDMS) 
hc: 50 µm – 3 mm 
SA: ? 
 
Advantages 
- Stackable array 
- Silicon MEMS 
scale up 
Disadvantages 
- Prototype scale, 
not human size → 
future size TBD 
 
Advantages 
- Controlled laminar 
flow paths 
- Even shear  
- Low resistance 
- Long-term flow 
path patency 
 
Disadvantages 
- Scale up flow path 
not optimized yet 
- Not biomimetic 
Advantages 
- PDMS: liquid 
barrier, ultrathin 
 
Disadvantages 
- Hemocompatible 
coatings unknown 
 
Advantages 
- Thin membranes 
→ efficient gas 
exchange 
- Tunable flow path 
height 
 
Disadvantages 
- No boundary layer 
disruption 
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 RESEARCH OBJECTIVE 
Between hollow fiber and microfluidic oxygenators, there exists a need for a blood oxygenator 
with maximal gas exchange efficiency and long-term hemocompatibility. Such a device could be 
conceived as part of a portable, ambulatory ECMO circuit for long-term support of patients in need of a 
bridge-to-transplant or destination lung replacement therapy. To achieve this goal, the technology used to 
make this oxygenator would need to improve upon the existing hemocompatibility issues with blood flow 
paths around hollow fibers (uneven flow paths, areas of stagnancy) or through microfluidic circuits (high 
pressure resistance and shear stress). Furthermore, the oxygenator would need to be optimized for 
efficient gas exchange and long-term blood-materials contact, similar or better than existing oxygenators. 
This work endeavors to develop a prototype device that uses silicon membrane technology to 
build a hemocompatible blood oxygenator, capable of efficient O2 and CO2 exchange with blood. In this 
work, various generations of silicon membranes with pore sizes from 10 nm to 1 µm, with and without an 
additional PDMS layer, were systematically tested for suitability as oxygenator membranes (Chapter 2). 
The membrane selected from this work was then deployed in larger oxygenator prototype flow cells to 
evaluate the membranes’ in vitro and in vivo performance (Chapter 3). These foundational studies were 
the basis for making further improvements to the surface hemocompatibility (Chapter 4) and boundary 
layer mixing (Chapter 5) of silicon membrane devices. Ultimately, we hope to expand upon this work to 
continue the scale-up of a compact and hemocompatible blood oxygenator founded upon silicon 
membrane technology. 
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EVALUATION OF SILICON MEMBRANES FOR EXTRACORPOREAL MEMBRANE 
OXYGENATION (ECMO) 
Substantial portions of this chapter have been published in Biomedical Microdevices (2018);20:86 
 
 
 
 
 INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a clinical alternative to mechanical ventilation 
by which oxygen is delivered to the blood and carbon dioxide is removed. Since its initial development, 
ECMO has become a well-established treatment that is used on nearly 8,000 neonatal, pediatric, and adult 
patients annually worldwide 3,7,54. Despite ECMO’s effectiveness as a treatment, its use remains limited 
due to its high risk profile 148. The large membrane area and tortuous blood flow path around the hollow 
fibers can cause blood clotting within the circuit; in turn, the high systemic anticoagulation prescribed to 
prevent these clots can cause devastating bleeding. Clotting and bleeding are the most common causes of 
complications in patients, pointing to the need for a smaller, more efficient ECMO system with reduced 
dependence on high systemic anticoagulation 149,150. 
Advances in microelectromechanical systems (MEMS) technology may be able to address the 
deficiencies of hollow fiber membranes through innovative approaches to high flux gas exchange 
membranes, and overall device design 55. Past work in our lab has developed silicon nanopore membranes 
(SNM) for use in blood-contacting devices 131,135,139,151. Since then, we have expanded this concept to 
include membranes with larger, micron-scale pores employed for gas transport applications 132,143. One 
potential disadvantage of these silicon micropore membranes (SµM) is that they are far more susceptible 
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to transmembrane leakage of gas bubbles or blood plasma compared to the smaller pore SNM. To address 
this potential limitation of SµM, we have developed a method of applying a solid layer of 
polydimethylsiloxane (PDMS) to the surface of the SµM – an adaptation derived from PDMS 
microfluidic oxygenators 143. PDMS is highly permeable to both oxygen and carbon dioxide, making it 
capable of facilitating respiratory gas exchange. With the combination of the silicon membrane and 
PDMS layer, the composite “SµM-PDMS” is imbued with several possible advantages, whereby the 
silicon membrane mechanically reinforces the PDMS while preventing transmembrane leakage. 
The purpose of this work is to examine the effect of SNM and SµM design on pressure resilience 
and maximum gas flux. An ideal ECMO membrane would be robust enough to withstand high sweep gas 
pressures, which would lead to a greater pressure gradient that would drive oxygen into the blood. SNM 
and SµM may have different advantages when considered as potential ECMO membranes: the SNM can 
withstand higher sweep pressures with a smaller pore size, while the higher pore area of the SµM may 
yield a higher oxygen flux. As such, both types of silicon membranes were evaluated for the effects of 
pore size, pore area, and distribution on maximum gas pressure prior to gas bubble formation. 
Subsequently, the most robust membranes were examined for gas transport efficiency, which would 
determine the final suitability of the silicon membranes for ECMO applications. 
 MATERIALS AND METHODS 
 Membrane Fabrication 
Following prior work in this lab, the SNM and SµM were created with a uniform pore 
distribution and high level of pattern fidelity 131,135,143. Briefly, SNM are created from a silicon wafer 
starting with thermal oxidation growth of SiO2 followed by low pressure chemical vapor deposition 
(LPCVD) of polysilicon, which is then patterned through dry etching (Fig. 2.). Controlled, tunable growth 
of another layer of sacrificial SiO2 on top of this polysilicon defines the width of the future pores in the 
membrane. An anchor layer is then patterned through wet etching. A second layer of polysilicon is 
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deposited with LPCVD flush with the existing layers, followed with a blanket etch of the polysilicon until 
the sacrificial oxide is exposed. The SNM are then protected with deposited low temperature oxide, and 
original silicon wafer is etched away through deep reactive ion etching (DRIE) to expose the sacrificial 
oxide on both sides. Finally, the oxide is etched away in a wet etching process to yield the nanometer-
scale pores. SµM are manufactured with a simpler process, in which the pores are directly patterned into a 
single layer of polysilicon on top of silicon oxide (Fig. 2.2a-d). The initial oxide only is etched away to 
create the pores. Pore sizes for SNM were intended to be 11, 30, and 40 nm as defined by oxide thickness, 
while SμM pores were intended to be 500 and 1000 nm as defined by the lithography step.  
 
Fig. 2.1: Fabrication of SNM membranes. Step (c) shows the deposition of sacrificial oxide to form 
pores, which is removed through wet etching in step (e). 
 
To create SµM-PDMS, a 5µm-thick layer of PDMS is made using a multistep sacrificial layer 
method, and then applied to the surfaces of the SµM via O2 plasma bonding (Fig. 2.2e-g). A ~300 µm 
layer of Sylgard 184 PDMS (Dow Corning: 4019862) is mixed at a 10:1 monomer-to-crosslinker ratio, 
spin coated onto a silicon wafer, and then cured for 2 hours in an 80°C oven. After a brief oxygen plasma 
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treatment to make the surface wettable (Harrick Plasma PDC-001, Harrick Plasma, Ithaca, NY USA), a 
5% w/w solution of polyvinyl alcohol in water is spin coated on top of the first PDMS layer and cured for 
1 hour at 60°C (Sigma Aldrich: P8136-250G). Finally, mixed Sylgard 184 is diluted with hexanes (Sigma 
Aldrich: 227064-1L) at a 1:1 ratio, spin coated on top of the PVA to a thickness of ~5µm, and cured at 
80°C for 2 hours. The cured PDMS is cut from the wafer into strips, and placed into the plasma oven 
along with the SµM. Following plasma treatment, the SµM are briefly dipped into DI water, and the strips 
of PDMS are placed face down on top of the membranes such that the 5 µm PDMS layer is in contact 
with the polysilicon face of the membrane. The plasma bond  is strengthened with 70°C heat and pressure 
to ensure even contact. After 12 hours of bonding, the excess PDMS is cut from the membrane and the 
membranes are allowed to soak in 70°C DI water until the PVA layer completely dissolves creating the 
SµM-PDMS membrane.  
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Fig. 2.2: Fabrication of SµM (a-d), and application of PDMS (e-g) to form SµM-PDMS. Adapted from 
Dharia, et al (2017). 
 
Pore widths were validated through hydraulic permeability testing and SEM imaging of 
membranes. Hydraulic permeability testing was performed on SNM after wet etching of the pores 152. By 
establishing a ~5 cmHg pressure gradient of water across the membrane, the volume flow rate of the 
permeate from the membrane could be measured through timed collection. From the following equation, 
the actual pore width of the membrane could be related to the permeate flow rate, pressure drop, and other 
length dimensions of the pore: 
 
1
312 permh Q
w
L P
  
=  
 
  Eq. 2.1 
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All variables and constants for transport equations can be found in Table 2.1. Hydraulic permeability 
testing showed that the SNM had pore sizes of 10.2 ± 0.6, 22.3 ± 3.4, and 33.0 ± 3.1 nm. The measured 
pore sizes indicated that the SNM were patent, and that the pore sizes were on the same order of 
magnitude as intended. Since the pores of the SµM were large enough to be easily visualized, light 
microscopy was used to measure the size of SµM pores (Leica DM4000M, Leica Microsystems, Buffalo 
Grove, IL USA), and hydraulic permeability testing was unnecessary. SEM imaging was used to confirm 
the pore widths of SNM and SµM, and the thickness of the PDMS layer of the SµM-PDMS was 
determined to be ~5µm (Fig. 2.3). 
Table 2.1: List of variables and constants for membrane transport equations. 
Variable Units 
Pore Width (w) m 
Pore Length (L) m 
Pore Depth (h, δm) m 
Membrane Area (Am) m2 
Pressure (P) cmHg 
Flow Rate (Q) m3s-1 
Bubble Point Shape Factor (κ) --- 
Hydraulic Diameter (DH) m 
Flux (J) mL O2,STPmin-1 
Total Mass Transfer Coefficient (kT) cm O2,STP3 m-2 min-1 cmHg-1 
Permeability (Pm) mol O2 m-1 min-1 cmHg-1 
Constants Units Value 
Surface Tension – Water/Air (σ) mN/m 72.75 
Contact Angle – Water on Si (θ) Degrees 40 
Density of Oxygen (ρSTP) kg m-3 1.429 
Henry’s Law Constant (H) mol H2O ∙ atm O2/mol O2 4.2 ∙ 104 
Molar Concentration of Water (cL) mol/L 55.5 
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Fig. 2.3: SEM images of membranes. (a) and (b) are 1.82k magnification plan view images of 30 nm and 
500 nm pore membranes, respectively. (c) is a 25k magnification plan view image of a 30 nm-pore wide 
membrane with dimensions labeled. (d) is a cross sectional image of a 500 nm pore membrane showing 
pore depth. 
 
Table 2.2: Dimensions of SNM and SµM as measured by SEM. 
Dimensions Nanopore Membranes (SNM) 
Micropore Membranes 
(SµM) 
Pore Width (nm) 10.4 29.0 39.1 600.8 1027.0 
Pore Length (µm) 2.17 1.83 1.92 .46 3.45 
Pore Depth (nm) 400 400 400 1000 1000 
Pore Spacing (nm) 386 368 362 400 468.9 
Pores Per Membrane 1.56E+07 1.56E+07 1.56E+07 3.16E+06 2.10E+06 
Pore Area (m2) 3.60E-07 7.02E-07 9.36E-07 5.53E-06 7.36E-06 
Membrane Area 
(m2) 1.91E-05 1.91E-05 1.91E-05 1.48E-05 1.48E-05 
Porosity (Pore 
Area/Membrane 
Area) 1.89% 3.67% 4.90% 37.33% 49.68% 
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 Failure Point Testing 
The failure point of the membranes was investigated to determine the maximum sweep gas 
pressure that the membranes could support prior to gas bubble formation in liquid. Failure point can be 
further characterized as either bubble point or rupture point, depending on the cause of the bubble 
formation. Bubble point is defined as the gas pressure at which the largest pore of a wetted membrane 
will become completely de-wetted, leading to gas bubbles on the liquid side of the membrane. Rupture 
point is the pressure at which the membrane will break due to the mechanical strain arising from the 
deflections upon application of gas pressure, causing gas bubbles to traverse the membrane. Unlike 
rupture point, which is an irreversible and non-repeatable measurement, bubble point testing is both 
reversible and consistent because the membrane remains intact upon completion of the test. Silicon 
membranes with smaller pores will require higher gas pressure to de-wet and reach bubble point than 
those with larger pores. Ultimately, they may reach their rupture pressure before they reach their bubble 
point.  
For this study, a selection of membranes was used with pore sizes ranging from approximately 10 
nm to 1 µm, and classified as either SNM (pore size < 100 nm) or SµM (pore size > 500 nm). To visually 
measure bubble or rupture point, SNM and SµM were diced into 1x 1 cm square membranes, completely 
wetted with water, and mounted inside of a gasket-sealed transparent acrylic flow cell (Fig. 2.4). One side 
of the membrane was exposed to circulating deionized water at a flow rate of 1 mL/min, allowing 
visualization of gas bubbles in the liquid. The opposite side of the membrane was connected upstream to 
an air-filled syringe pump (kdScientific Gemini 88, Holliston, MA USA) and a pressure gauge (Druck 
DPI 104, General Electric, Billerica, MA USA); air flow was blocked downstream of the flow cell. The 
side of the membrane with the polysilicon pores was oriented to face the water to mimic the configuration 
of membranes when in contact with blood. Measurements of bubble point gas pressure (cmHg) were 
taken by pressurizing the air using the syringe pump until bubbles were observed in the liquid. Each 
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membrane was re-tested upon completion of the first test to determine if the membrane had ruptured or 
had reached a repeatable bubble point. A ruptured membrane would permit bubbles at very low gas 
pressures – significantly lower than during the first test – while a membrane that reached its bubble point 
would become pressurized to the same level as the initial test. 
 
Fig. 2.4: Diagram of bubble/rupture point testing setup. The membrane in the flow cell is shown with 
bubbles traversing the membrane as bubble or rupture point has been reached. 
 
The bubble point of any membrane can be described by the following equation:  
 
( )4 cos
H
P
D
   
 =  Eq. 2.2 
where κ is an empirical, unitless “shape factor” constant that applies to non-cylindrical pore membranes 
and P  has units of Pa 153. Given that hydraulic diameter is inversely proportional to bubble point 
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pressure, membranes with larger pore sizes will reach bubble point with less pressure than membranes 
with smaller pores. 
 Oxygen Flux and Permeability In Vitro 
Following bubble/rupture point testing, SNM and SµM that withstood the highest gas pressure 
without gas emboli were chosen for subsequent experiments. These membranes were assessed for their 
gas permeability at a constant, low pressure below the bubble/rupture point of all membranes (Fig. 2.5). 
The SNM and SµM membranes were diced to a size of 1 cm x 6.5 cm, thoroughly dried, and mounted 
into a gasket-sealed polyether ether ketone (PEEK) flow cell with a channel height of 200 µm. For gas 
permeability testing, the membranes were diced larger than for the bubble point testing in order to ensure 
adequate gross gas transport. For this test, the face of the membrane with polysilicon pores was exposed 
to circulating, nitrogen-sparged water at a rate of 10 mL/min and hydrostatic pressure of under 5.17 
cmHg, and the backside was exposed to pressurized pure oxygen sweep gas. In this experiment, the gas 
flow was not blocked downstream of the flow cell, but instead permitted to flow completely through. An 
optical oxygen probe (NeoFoxGT with FOSPOR probe, Ocean Optics, Dunedin, FL, USA) was placed 
downstream of the flow cell on the liquid side to detect oxygen transport across the membrane. The gas 
pressure of the oxygen sweep gas was raised to 26 cmHg, and oxygen flux into the water was measured 
by the probe. Flux (J, mL O2/min) was determined using the measured oxygen concentration in µmol/L 
before and after adding oxygen to the circuit ( 2 iO and  2 fO , respectively), with a conversion of 22.4 L 
O2/mol at STP: 
    ( ) 62 2 10 22.4f i
mol L
J O O Q
mol mol
−= −     Eq. 2.3 
Q is the flow rate of water in mL/min. From the flux, the coupled mass transfer coefficient (, mL O2 min-1 
m-2 cmHg-1) was determined to represent the total transport efficiency of oxygen through the sweep gas, 
the membrane, and the liquid. To obtain this value, the flux from Eq. 2.3 is normalized by the total 
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pressure driving force between the gas and liquid ( gas liquidP − , cmHg), as well as the membrane area ( mA
, m2): 
 T
gas liquid m
J
k
P A−
=
 
 Eq. 2.4 
For the calculations in this study, the membrane area was taken to be the total area of open pores on the 
membrane. The mass transfer coefficient can be further broken down into its measurable parameters, 
where 
2 ,O gas
P is the gas driving pressure (cmHg) and
2 2,O H O
P is the partial pressure of oxygen in the water 
measured using the oxygen probe (cmHg): 
 
 
2 2 2 2
2
2
, , , ,
,
2
T
O H O f O H O i
O gas m
O Q
k
P P
P A
 
=
− 
−  
 
 Eq. 2.5 
Both the oxygen flux and mass transfer coefficient can be used to aid our understanding of the influence 
of membrane design on gas transfer, and thereby, help determine if silicon membranes are suitable for 
ECMO. 
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Fig. 2.5: Schematic of in vitro oxygen permeability testing setup. Water is shown as blue when 
deoxygenated, and red when oxygenated after contact with the silicon membrane. 
 
 RESULTS AND DISCUSSION 
 Failure Point Testing 
 Failure point data for the SNM, SµM, and SµM-PDMS are shown in Table 2.3 and Fig. 2.6. The 
SµM without PDMS showed bubble points at approximately 84.1cmHg for 500 nm pores, and 43.9cmHg 
for 1000 nm. These bubble points were found to be repeatable, indicating that the micropore membranes 
had not ruptured. The smaller pore SµM had a higher bubble point than the larger pore membrane, which 
is consistent wsith Eq. 2.2. While the SNM without PDMS produced identifiable bubble points, the SµM-
PDMS showed no membrane rupture or bubbles during the course of the test. Instead, the membranes did 
not rupture prior to the maximum gas pressure permitted by the syringe pump testing system – 
approximately 260 cmHg. 
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Table 2.3 Failure points of nanopore and micropore membranes. The 11 nm pore SNM and 1000 nm pore 
SµM with PDMS both exceeded the maximum pressure of the syringe pump without bubbling or 
rupturing. Maximum pressure of the syringe pump was somewhat variable due to inconsistent syringe 
pump performance, leading to differences between the membrane maximum pressures.  
Pore Size (nm) 11 30 40 500 1000 1000+PDMS 
Failure Point 
(cmHg) 
310 ± 67.4 
(MAX) 
220 ± 59.5 
(rupture) 
170 ± 26.7 
(rupture) 
84.1± 4.95 
(bubble) 
43.9 ± 2.99 
(bubble) 
276 ± 65.6 
(MAX) 
 
 
Fig. 2.6: Bubble or rupture points of silicon membranes related to pore size. Significant difference (p < 
0.05) is indicated above chart bars: difference from from 11 nm SNM shown by (a), 30 nm shown by (b), 
40 nm shown by (c), and 1000 nm-PDMS membrane. Maximum pressure indicated by dashed line. 
The two SNM with relatively larger pore sizes ruptured at pressures of 220 cmHg and 170cmHg 
for membranes with 30 and 40 nm pores, respectively. This rupture point was the result of the membranes 
breaking while under pressure, which was verified through light microscopy. The 40 nm pore SNM 
ruptured at a lower pressure than the 30 nm pore SNM likely due to the fact that the larger pore 
membrane was reinforced with less additional silicon than the smaller-pore counterpart. The SNM with 
the smallest pores (~11 nm) did not rupture or reach bubble point before the syringe pump system reached 
its maximum pressure. Ultimately, the two types of membranes with the highest bubble/rupture points 
were the SµM-PDMS, and the 11 nm pore size SNM. These membranes were able to resist rupture before 
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the conclusion of the test, indicating that they would be able to withstand greater than ~260 cmHg of 
pressure prior to the formation of gas emboli in blood. This pressure is comparable to that of existing 
hollow fiber oxygenators, which can be used at pressures up to 260 cmHg (50 psi) clinically 154,155. 
Microfluidic, PDMS-based oxygenators are comparatively used at sweep gas pressures of 16 cmHg or 
lower to prevent rupture 156. For example, Potkay (2011) used a sweep gas pressure of 16.0 cmHg, while 
Hoganson (2010) and Lee (2008) used lower pressures of 0.475 cmHg and 1-2 cmH2O, respectively 
105,108,113.  
 Oxygen Flux and Permeability In Vitro 
From the initial set of membrane types, the SµM-PDMS and 11 nm pore SNM were selected for 
further testing to determine oxygen flux through each membrane, since they were able to resist failure 
prior to the end of the test. Since one of the membrane types selected was the SµM-PDMS, an additional 
group of 500 nm pore SµM without PDMS was also tested for gas permeability. It was essential to 
compare the transport of the SµM with and without PDMS to determine if the PDMS layer had a 
significant impact on gas transport. Gas permeability testing was conducted for all chips at a sweep gas 
pressure below the failure point of all membranes (26 cmHg) to achieve comparative tests of gas flux. 
The oxygen flux from each membrane (using Eq. 2.3) is shown in Fig. 2.7a. Based on Eq. 2.5, the 
coupled mass transfer coefficient was also determined for each membrane, taking the area to be the area 
of open pores on the membranes (Fig. 2.7b). The PDMS coated membranes produced the most oxygen 
flux at 0.03 mL/min. As can be seen in Fig. 2.7a, the oxygen flux from the SµM with and without PDMS 
are indistinguishable and values for both membranes were also insignificantly different. The PDMS layer, 
therefore, provides little resistance to oxygen transport. Compared to the SµM, the SNM showed 
significantly lower oxygen flux – only 40% of the SµM flux. Higher transport through the SµM is likely 
due to the significantly greater open pore area of SµM compared to the SNM. However, the mass transfer 
coefficient of the SNM when normalized by actual pore area is significantly higher by an order of 
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magnitude. This result would indicate that, per pore, more transport is exhibited by the smaller pore 
membranes – pointing to a nonlinear relationship between pore area and gas flux 144. Despite the higher 
transport per pore of the SNM, compared to the SµM, overall more gas transport was generated when 
using membranes of higher porosity. 
 
Fig. 2.7: Plots of (a) oxygen flux and (b) pore area-normalized mass transfer coefficient from silicon 
membranes downselected from bubble point experiments. Bars above chart indicate significant difference 
by one way ANOVA (p < 0.05). 
 
A few hypotheses may help explain this nonlinear behavior. One possibility is that the small 
pores of the SNM are capable of inducing free molecular (Knudsen) flow of the oxygen gas. In a Knudsen 
flow regime, the frequency of gas molecule collisions with solid walls increases relative to the frequency 
of intermolecular collisions. This effect leads to higher gas flux through nanochannels that would 
otherwise be expected with Navier-Stokes continuum flow 144. To determine if Knudsen flow occurs 
through a nanochannel, the Knudsen number can be calculated as the ratio between the mean free path of 
the gas (λ) and the width of the channel (w): 
 Kn
w

=   Eq. 2.6 
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The mean free path of oxygen is known to be 63 nm, making the Knudsen number equal to 6.19 through 
an 11 nm pore SNM. This Knudsen number falls short of the threshold for free molecular flow (Kn ≥ 10), 
but is higher than the Knudsen number for continuum flow (Kn ≤ 0.01). A Knudsen number between 0.01 
and 10 implies that the SNM are in a “transitional” flow regime between free molecular flow and 
continuum flow.  
To determine which flow regime most accurately describes the flux data, the experimental flux data 
through the SNM can be compared to predictions of Knudsen flow and continuum flow. In a continuum 
flow regime, the volume flow rate in mL/min can be calculated using: 
 
( )3
12 2
in out
continuum
out
w L P
Q
h
 
 
+ 
=   Eq. 2.7 
The corresponding volume flow rate in a Knudsen regime can be calculated through: 
 
4
m
Knudsen
out
v wL
Q C P
P
=    Eq. 2.8 
where C is a geometry-dependent shape factor and vm is the mean molecular speed. Formulas for 
calculating both C and vm can be found in Fissell et al. 2011144. Using Eq. 2.7 and Eq. 2.8, the volume 
flow rates for continuum and Knudsen flow were predicted for theoretical SNM pore sizes from 1-100 nm 
using the same experimental conditions as in the oxygen permeability test. The predictions are plotted 
against the measurements of SNM oxygen flux in Fig. 2.8. Ultimately, the average of the SNM 
measurements (9.57E-10 mL/min/pore) was an order of magnitude beneath the continuum prediction 
(6.91E-08 mL/min/pore), and several orders of magnitude below the Knudsen prediction (9.18E-06 
mL/min/pore). This result differs from data in Fissell (2011), in which transport through SNM pores 
matched Knudsen predictions better than continuum models. However, the experiments of the Fissell 
study were conducted using an SNM between two gas compartments, whereas the experiments in this 
study involved membranes between a gas and liquid compartments. Considering the different study 
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conditions, even if the SNM induce Knudsen flow, the benefits of free molecular flow may be outweighed 
by transport behavior in the liquid compartment. 
 
Fig. 2.8: SNM flux measurements plotted against continuum flow and Knudsen flow predictions. 
 
Following the Knudsen calculations, the transport between the membrane and the liquid was 
examined to determine if transport within the liquid compartment was responsible for the nonlinearity 
between pore size and flux. From the analytical modeling described for this testing system in Dharia, et al 
(2017), the total coupled mass transfer coefficient can be related to mass transfer through the membrane 
and the liquid: 
 
2 2,
1 m
T m STP L O H O
H
k P c k

 
= +  Eq. 2.9 
The first entity in this equation represents transport through the membrane itself: δm is membrane 
thickness (m),  represents membrane permeability (cmSTP3cm cm-1min-1 cmHg-1), and ρSTP is the density of 
oxygen at standard temperature and pressure (mol/m3). The second part represents transport through of 
gas through the liquid phase of the system: H is the Henry’s Law Constant, cL is the molar concentration 
of water. When using silicon membranes for gas-into-liquid transport, it can be assumed that transport 
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within the gas regime is instantaneous, and contributes little to transport resistance. By extension, 
transport through the silicon membrane can also be assumed instantaneous since the pores are filled with 
gas, reducing the mass transfer coefficient to: 
 
2 2,
1
T L O H O
H
k c k
=  Eq. 2.10 
Essentially, this reduction leaves liquid phase as the largest determinant of transport in this regime, 
although the amount of open membrane area dictates how much of the membrane contributes to transport. 
Considering the importance of the liquid phase to overall gas transport, we speculate that the high area-
normalized transport in SNM is due to phenomena within the liquid phase boundary layer. As oxygen gas 
exits the membrane, it enters a microns thick boundary layer that collects oxygen near the surface before 
it can diffuse into the liquid bulk. Within the boundary layer, the pores of both SNM and SµM behave as 
point/area sources for oxygen, which can diffuse outwards laterally into the spaces between pores. The 
effect of this lateral diffusion implies the membranes yield a higher oxygen flux than the pore area alone 
would suggest, creating a nonlinear relationship between open pore area and oxygen flux. In SµM, pore 
size and pore spacing are of similar magnitude, and the additive effect of the boundary layer lateral 
diffusion is likely minimal when flux is normalized by pore area. Comparatively, the pores of SNM are 
far smaller than the spacing between pores, and contribution of this accumulated oxygen to overall flux is 
far more evident than for the SµM. The effect of this nonlinear relationship drives the transport of SNM 
to appear higher when normalized by open pore area, since the pores comprise such a small fraction of the 
overall membrane surface area. However, the accumulated oxygen in the boundary layer of the SNM is 
not sufficient to outdo the advantage of the overall open pore area of the current SµM.  
From the SµM-PDMS flux data, the oxygen transport rates of the membranes were found to be 
0.03 mL O2/min, with a membrane area of 6.5e-4 m2 at a 10 mL/min liquid flow rate. Although the device 
conditions of this study were not optimized for scale up, it is possible to use this transport data to 
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determine the operating conditions of a theoretical full-scale oxygenator. To oxygenate a 3.5 kg neonate 
with an oxygen requirement of 6 mL/kg/min, a total of 700 membranes would be needed with a 
membrane area of 0.455 m2. This surface area is similar to that of the Maquet QUADROX-i Neonatal 
(0.38 m2), and could be reduced with fabrication of more porous membranes. However, at the flow rate 
used in this study, a scaled up device with 700 membranes and 0.455 m2 of area would be capable of 7 
L/min of blood flow, which far exceeds the 0.35 L/min cardiac output of a neonate. Ultimately, a future 
SµM ECMO device will require optimization of the device design to fully scale the flow rate and oxygen 
transport to match patient requirements. 
One drawback of this study is the limited range of pore sizes of membranes available. Between the 
SNM and SµM, there is an unaddressed transitional range of 50-500 nm pores. It is possible that a 
membrane with pores in the transitional range would be better suited to meet bubble point and gas flux 
metrics than either the SNM or SµM. A membrane with pores between 100-500 nm may have a higher 
bubble point than the current SµM for more pressure resistance, while also retaining the higher pore area 
of the SµM for more gas flux. 
 CONCLUSION 
This study demonstrates that silicon membranes can be used with high sweep gas pressures and 
yield high-efficiency oxygenation in vitro, opening up possibilities for use as ECMO membranes. The 
highest gas transfer and rupture resistance was seen with the SµM coated with PDMS, making this type of 
membrane the most suitable silicon membrane for ECMO. Subsequent research on device design would 
be required to scale the membranes to meet clinical oxygenation needs. Further optimization of the device 
design would be needed to establish the effects of channel height, liquid flow rate, and membrane pore 
distribution on oxygen flux. With optimization of the device design, silicon membranes could be 
employed for robust, high efficiency oxygenation.   
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SILICON MICROPORE-BASED PARALLEL PLATE MEMBRANE OXYGENATOR 
Substantial portions of this chapter have been published in Artificial Organs (2018); 42:2 166-173 
 
 
 
 
 INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a life support system that circulates the blood through 
an oxygenating system to temporarily (days to months) support heart or lung function during 
cardiopulmonary failure until organ recovery or replacement. Over the past two decades, ECMO has 
become more common, and is now used to treat nearly 8000 patients annually worldwide, including a 
fivefold increase over the past decade in the adult population3,157,158. Still, commercially available ECMO 
systems have considerable drawbacks and limitations, including the most common complication of 
bleeding159. There have been several approaches to improve on ECMO technology including further 
refinement of hollow fiber membrane technology, or use of microfluidic soft lithography to approximate 
human lung architecture55. However, these approaches have inherent limitations that lead to membrane 
fouling and risk of thrombosis, necessitating the use of high levels of anticoagulation. As an alternative to 
these systems, our lab has adopted an alternative strategy utilizing MEMS (microelectromechanical 
systems) fabrication techniques to create novel gas exchange membranes consisting of a rigid silicon 
micropore membrane (SμM) support structure bonded to a thin film of gas-permeable 
polydimethylsiloxane (PDMS).The silicon membrane support structure provides structural integrity, 
which allows for the PDMS layer to be an order of magnitude thinner than commercially available 
polymer membranes160. We anticipate that the composite SμM-PDMS membranes will yield efficient 
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oxygen transport, and can be arranged in a parallel plate design that can be readily modified to finely tune 
the blood flow path to allow for optimized hemocompatibility. The goal is to house the SμM-PDMS 
membranes in a compact design with an improved hemocompatibility profile compared to the current 
standard of care. In this paper, we develop a proof-of-concept parallel plate membrane oxygenator and 
demonstrate in vivo feasibility in a porcine model. 
 MATERIALS AND METHODS 
 Fabrication of the Silicon-PDMS Membrane and Flow Cell 
The fabrication of the SμM-PDMS membrane is based on prior work in this lab on silicon 
nanopore membranes, with adaptations specific to this project128,131,138,160.  Briefly, the prior work 
describes a process by which controlled growth of silicon dioxide produces arrays of sub-100 nm 
rectangular pores within silicon wafers (Fig. 3.a). For this study, the process was modified to utilize 
lithographic patterning to define pore dimensions at the 500 nm-1000 nm range. To create the PDMS 
layer of the composite membrane, a multilayered sacrificial substrate was used to transfer the thin layer 
(3-5 μm) of polydimethylsiloxane (PDMS) to the SμM (Fig. 3.b). A thick layer of Sylgard 184 PDMS 
(Dow Corning, Midland, MI) was mixed at a monomer-to-crosslinker ratio of 10:1, spin coated (500 
RPM for 10s) onto a 4 inch silicon wafer, and cured for 2 hours at 80°C. Then, the surface was treated 
with O2 plasma (100W, 20s, 200SCCM) to make the surface wettable. Subsequently, a second sacrificial 
layer of polyvinyl alcohol (PVA) 5% w/w in water was spin coated (1000 RPM, 30s) onto the PDMS 
layer, cured at 60°Cfor 1 hour, and slowly cooled to room temperature. As the final thin layer of PDMS, 
mixed Sylgard 184 was diluted with hexanes (Sigma Aldrich) at a 1:1 ratio, and spin coated directly on 
top of the layer of PVA (6000 RPM, 300s). The thick PDMS-PVA-thin PDMS construct was peeled off 
the silicon wafer and bonded to the SμM membrane using oxygen plasma to activate both surfaces 
(100W, 20s, 200 SCCM). After at least 12 hours of bonding time, the membranes were submerged 
 
 
52 
 
 
 
in70°C water for 3-4 hours to fully dissolve the PVA layer and release the thick PDMS layer, leaving the 
thin PDMS layer (3-5 microns) bonded to the SμM. 
 
Fig. 3.1: Schematic of the fabrication of the silicon micropore membranes (1a) and of the PDMS transfer 
process (1b) to achieve 3-5 micron thick PDMS layer bonded to the silicon micropore membranes. 
 
 Oxygen Diffusion Through Membranes 
Oxygen diffusion through the SμM-PDMS membranes was determined by measuring the oxygen 
concentration change in degassed water after passing over the membrane, similar to previous work and 
shown in Fig. 3.2 161,162. A 6.5 cm x 1 cm PDMS-SμM membrane was mounted into a machined polyether 
ether ketone (PEEK) flow cell with a water channel height of 200 microns, such that the PDMS would be 
in contact with the water while the silicon support structure was exposed to sweep gas.  Oxygen was then 
removed from water by bubbling in nitrogen gas to establish a low starting concentration of oxygen in the 
water. This degassed water was pumped across the membrane at a rate of 10 mL/min (Cole Palmer pump) 
with an optical oxygen sensor (NeoFox inline optical oxygen sensor - Ocean Optics, Dunedin, FL) at the 
distal end of the device (Fig. 3.2). For each measurement, pure oxygen was used to pressurize the sweep 
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gas and the resulting oxygen flux into the water from the membrane was determined by the oxygen 
sensor. The pressurized sweep gas of pure oxygen was held between 2 and 10 PSI to establish a trans-
membrane partial pressure gradient of between 800 and 1200 mmHg. The upper range of these pressures 
was chosen to be less than half the pressure at which mechanical failure occurred of the SμM-PDMS 
membrane.  
At the end of each test, the oxygen supply was removed and the sweep gas was vented. The 
coupled oxygen permeability coefficient 
2O
k  was determined using the following formula (mL O2 min-1 
m-2 cmHg-1), where is  2O  the concentration of oxygen before and after the device (ml O2 ml water-1), 
2H O
Q  is the flow rate of fluid (ml water min-1), mA  is the membrane area (m
2), and 
2O
P  is the partial 
pressure of oxygen in the sweep gas and in the water at the start and end of the membrane (cm Hg). 
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Fig. 3.2: Diagram (a) and picture (b) of experimental setup to measure oxygen diffusion into water. 
 
 Blood Oxygenation in an In Vivo Porcine Model 
Oxygen permeability for the SμM-PDMS membranes arranged in a parallel plate geometry was 
determined in an in vivo porcine model. Four membranes were secured into each half of a titanium flow 
cell using epoxy (Epoxy Technology OD2002) for eight total membranes per device (Figure 4). The two 
halves were then assembled using 125 μm silicone gaskets to guide the sweep gas path, as well as seal the 
blood path.  The channel height of the blood flow path was estimated to be approximately 100-125 μm for 
each of the devices, with some uncertainly related to gasket compression. The channel flow path was 
roughly 4 cm wide and 6.5 cm long. Each flow cell was tested for leaks with deionized water prior to each 
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experiment. Over a series of three separate experiments, ~55 kilogram Yorkshire pigs were sedated, 
anesthetized, anticoagulated with heparin to goal ACT > 400 seconds, and their trachea were intubated. 
Two 16 French venous sheaths were placed into the right internal jugular and the left femoral vein of each 
pig. Using a mixture of nitrogen and oxygen as the inhaled gas, the pig’s peripheral oxygen saturation 
was lowered to 80% for the entirety of the study. After the pigs reached a steady oxygen saturation state, 
a sweep gas of pure oxygen was applied to the backside of the silicon membranes. Blood was pulled from 
the femoral vein and pumped through the blood channel of the flow cell and returned to the animal via the 
internal jugular vein. In these experiments, blood flow rate was mostly kept at 25 mL/min, with some 
samples taken at 15 and 50 mL/min to examine the effect of flow rate on oxygen flux into blood. Samples 
of blood were taken proximal and distal of each the device simultaneously every 15 minutes for 3 hours. 
Blood samples were run on an iStat ABG - G8 cartridge to determine O2 content  in ml O2 per ml of blood 
(Eq. 3.2)43, where Hg  is the hemoglobin of the blood (mg ml-1), 2SaO   is the percent of hemoglobin that 
are bound to oxygen, and 2PaO  is the partial pressure of oxygen in the blood (mm Hg). 
  2 2 21.36 0.0031O Hg SaO PaO=   +    Eq. 3.2 
The difference in oxygen content pre- and post-device was used to determine the gas permeability of the 
membranes in this device. This analysis was based on a modified Eq. 3.1, where 
2H O
Q  is broken into 
bloodV  (volume of blood within the device in ml) and t  (residence time within the device in minutes) 
(Eq. 3.3). 
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At the conclusion of the study, the animal was sacrificed as per protocol that was approved by the 
Institutional Animal Care and Use Committee (IACUC) at SurpassInc CRO (Mountain View, CA) and 
the assembly was dismantled and inspected for gross clots and membrane defects.  
 Model Formulation 
A model to predict and describe oxygen transport in the PDMS-SµM oxygenator was developed 
to provide insight into variables to focus on for future refinement.  Similar to prior gas transport models, 
this model also accounts for non-porous regions of the membranes which create a heterogeneous gas 
exchange surface.  For details on model derivations please see supplementary information, where the 
result is the equation: 
 ( ), , ,
L bL L
o L C b L b
dpq c
k w p p
H dx
= −   Eq. 3.4 
where Lq  is the volumetric flowrate in the liquid, Lc  is the liquid molar concentration, H  is the Henry’s 
law coefficient for oxygen in water, Lw  is the channel width, x  is the distance along the membrane 
length, p  is partial pressure of oxygen in the sweep gas and at the liquid boundary layer, and ok  
represents the overall mass transfer coefficient through: 
 1 m
o L L m STP
H
k c k P


= +   Eq. 3.5 
In blood, hemoglobin acts as a sink for oxygen, dramatically decreasing the change in blood plasma 
oxygen concentration compared to that of pure water. The rate of change of occupied oxygen sites in 
blood hemoglobin ( )bounddC  relative to the rate of change of free plasma oxygen ( )dC   can be related 
through a rearrangement of the Hill equation 163: 
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  Eq. 3.6 
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which depends on the saturated oxyhemoglobin concentration 
sat
HC  , the serum oxygen partial pressure at 
which fifty percent of oxygen sites on hemoglobin are saturated 50
np  , and the cooperative binding factor 
n  . The m  parameter can be then incorporated into the differential equations for the change in blood 
side oxygen concentration 163: 
 
( )
( ), ,
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L o L G b L b
d C C
q k w p p
dx
+
= −   Eq. 3.7 
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+
= −   Eq. 3.8 
For the case of no hemoglobin, 0m =  and Eq. 3.8 simplifies to Eq. 3.4.  
The external mass transfer coefficients for the liquid channel can be taken as hk ShD d=  
where Sh  is the Sherwood number and hd  is the hydraulic diameter of the flow channel. For a long, thin 
rectangular channel, the Sherwood number can be approximated by 164:   
 
0.33
1.65 Re h
d
Sh Sc
L
 
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 
  Eq. 3.9 
where Re b hu d =  and is the ratio of momentum forces to viscous forces, and Sc D  = , and is 
the ratio of momentum diffusivity and mass diffusivity. In both cases,   is the solvent density and   is 
the solvent viscosity.  
 RESULTS 
 Membrane Fabrication 
Silicon micropore membranes were fabricated using a MEMS-based approach. The resulting 
wafers were diced into ~1cm x 6.5 cm rectangular membranes with a total porous region of 2.16 cm2, 
comprising 9000 windows of pores with a pore density of 8.67E6 pores/cm2. The pores were either 4 μm 
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long, 1 μm thick with a width of either 500 nm or 1 μm, depending on the specific device. The 
membranes had consistent pore distribution with a high level of pattern fidelity (Fig. 3.3). A thin layer of 
PDMS was plasma-bonded to the surface of the silicone micropore membrane to create a membrane to 
function as a membrane oxygenator that is resistant to mechanical deformation, while minimizing the 
membrane thickness. These composite membranes consisted of a thin gas permeable membrane coupled 
with a highly porous rigid support structure which were then secured into a flow cell. 
 
Fig. 3.3: The SμM membrane was fabricated with the windows of pores as seen under bright field and 
individual pores as seen by SEM imaging (a and b). A thin layer of PDMS was bonded to the surface of 
the membrane and imaging was accomplished with SEM (c).  This shows both the rigid silicon support 
structure and a gas permeable membrane consisting of PDMS. 
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 Oxygen Diffusion of the Membranes 
Oxygen permeability of the SμM-PDMS membranes was determined using a water-based testing system 
to obtain reproducible, non-destructive data. From Eq. 3.1, oxygen permeability for SμM-PDMS 
membranes was found to be 3.03 ± 0.42 mL O2 min-1 m-2 cmHg-1.  
Testing in a simplified system was critical to develop the model of oxygen transport in our membrane 
oxygenator. We needed to determine the oxygen permeability of PDMS treated with plasma, which is 
known to be lower than that of untreated PDMS but is not defined in the literature115. To do this, we used 
the experimentally-derived pure water data to implicitly determine the membrane permeability by fitting 
experimental water data to the theoretical model (Eq. 3.8). Minimization of the square of the difference 
between model output (with changing mP ) and experimental data resulted in an optimized value of mP  = 
309.5 *10-10 cm3STP cm cm-2 s-1 cmHg-1 (Barrer). Fig. 3.6a depicts experimental water results and model 
output using this membrane permeability under three operating conditions. As per model predictions, the 
results confirm that higher flow rates lead to smaller changes in water oxygen partial pressure due to 
shorter system residence time. Furthermore, at a given flow rate, higher driving pressure leads to greater 
overall oxygen diffusion into the working fluid. Finally, by determining of the oxygen permeability of the 
PDMS, we were able to apply the model to the subsequent blood testing and validate the model.  
 Blood Oxygenation in an In Vivo Porcine Model 
Oxygen transport into whole blood was accomplished using an in vivo porcine model to determine the 
oxygen transport of the SμM-PDMS membrane. Using Eq. 3.3, the oxygen permeability of the SμM-
PDMS membranes into whole blood was found to be 1.92 ± 1.04 mL O2 min-1 m-2 cmHg-1 (Fig. 3.4). No 
occlusive clots were noted over the SμM-PDMS membranes after disassembly, although small non-
occlusive clots were noted at the exits of the devices (Fig. 3.5). 
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Fig. 3.4: O2 permeability for three separate flow cells ± SD. Combining all flow cells, average gas 
permeability was found to be 1.92 ± 1.04 ml O2 STP/min/m2/cm Hg (n=7 for each of the three flow cells). 
 
 
Fig. 3.5: Picture of flow cell with top and bottom half of the blood flow path exposed after in vivo test. 
Fig. 3.6b compares the model output with experimental blood data. Most of the experimental blood data 
was collected at a flow rate of 25 mL/min, with the model prediction well within the standard deviation of 
the experimental results.  At blood flow rates of 15 mL/min and 50 mL/min, where only one to two data 
points were collected, there still appears to be relatively close agreement with the model. 
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Fig. 3.6 Comparison of model output with experimental water data (a) and experimental blood data (b) 
showing the partial pressure of oxygen at a particular water or blood flow rate at a certain sweep gas 
pressure before and after (both experimentally and model-predicted) the device. 
 
 DISCUSSION 
In this study, we designed and built a parallel plate silicon membrane oxygenator, and developed 
an accompanying analytic model to predict gas transport. Initial testing and model development was 
performed in a simplified water setup with subsequent validation in vivo. Consistent with the model, the 
porcine in vivo testing showed a silicon membrane oxygenator able to achieve effective oxygen flux. 
There are several advantages of the SµM-PDMS membrane when compared to hollow fiber 
membrane technology. By using the porous rigid support structure of the silicon membrane, the layer of 
highly gas permeable PDMS can be an order of magnitude thinner than hollow fiber membranes. This 
thinness prevents the membrane itself from hindering gas exchange through the oxygenator, as has been 
shown in Abada et al (2018) 160. Additionally, the ability to resist mechanical deformation with the 
underlying rigid support structure allows this device to be operated at sweep gas pressure over 258 mm 
Hg (5 psig), thus creating a high driving pressure of oxygen into the blood. These advantages of thinness 
and mechanical resistance are unique to this design since other technologies, such as hollow fiber 
membranes and microfluidic devices, would be at risk for mechanical failure and air embolism if using 
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such high sweep gas pressures with thin membranes. Although additional work is needed to further 
improve the efficiency of the membranes, this can necessitate less surface area required to achieve 
adequate gas exchange and will improve hemocompatibility by decreasing foreign material to blood 
contact. In regards to improving hemocompatibility, perhaps more important is the ability to precisely 
control the blood flow path, including the shear stress and pressure drop, within the device. In this device, 
since the membranes are flat sheets, a laminar flow pattern is established and engineered to prevent areas 
of high shear and turbulence while avoiding areas of stagnation. This can be seen as an advantage when 
being compared to the relatively disorganized blood flow path of hollow-fiber membranes. The clear 
tradeoff in establishing a laminar, more organized blood flow pattern is that the liquid-side boundary layer 
becomes more significant to gas flux resistance, and has the potential to strongly limit gas transport161,165. 
Since this was a proof-of-concept experiment, there remain several limitations to the data. First, we used 
relatively low blood flow rates to generate the gas transport data. The flow rate was limited in part to size 
of the overall device as well as the narrow channel height. Given the small channel height, the flow rates 
were kept such that the pressure drop across the device was not excessive. Additionally, considerable 
variability of oxygen transport measurements was observed both between devices, and during a single 
experiment using the same device. This variability could be related to the use of different blood flow 
rates, error in the measurement tools, variable blood flow from transient clots, or air bubbles initially in 
the device. The difference between the mass transfer coefficient between the water studies and the blood 
can be explained by different channel heights, flow paths, flow rates, and membrane fouling after 
exposure to blood, but the exact reason for the difference will need further study.  
This work can be used to guide the design and fabrication of future generations of devices. The 
first modification will be focused on optimizing the balance between smaller channels with superior gas 
transport with taller channels that have acceptable pressure drop and shear stress to avoid hemolysis and 
activation of the coagulation cascade 19. In this version of the device, there was a large pressure drop 
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across the device of just over 100 mmHg, compared to current membrane oxygenators that have an 
overall pressure drop of less than 40 mmHg. Future devices will likely require larger channel heights to 
decrease pressure drop, which will need to be assessed effects on mass transfer. The modeling that was 
developed in this work aims to predict how system changes, such as changes in membrane geometry and 
blood flow properties, would affect the rates of oxygen transport. The data from the water tests were used 
to define the oxygen permeability of our plasma-treated membranes, which was then used in the 
subsequent blood studies. This model built on prior work in the literature to describe oxygen transport by 
incorporating membrane geometry to better predict gas flux. Still, since the model has only been validated 
for a small number of flow rates with a single channel height, we will need additional data to ensure the 
model continues to perform well under a variety of flow rates and channel heights. 
Future iterations of the next generation SμM-PDMS membrane oxygenator will build upon the 
flow path and mass transfer data collected in this study. As a focus of this future work, gas transfer 
efficiency may be improved through studying disruption of the liquid-side boundary layer, overcoming 
the liquid mass transport resistance. This disruption can include the use of surface mixers or the use of 
sound waves to increase the rates of gas transport166,123,167. While these techniques have the potential to 
increase gas transport efficiency, they will need to be closely examined for negative effects on device 
hemocompatibility. Once the flow cell and membrane are fully optimized, additional studies will need to 
be conducted to specifically answer if this approach does indeed improve hemocompatibility of 
membrane oxygenators, and how this ultimately affects the whole ECMO system. While the SμM-PDMS 
membrane oxygenator is still early in development, this initial work provides the rationale and the tools to 
proceed with investigating the use of silicon micropore membranes for the use of ECMO systems. 
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PEG-SILANE COATING VARIATIONS ON SILICON AND PDMS FOR IMPROVED 
HYDROPHILICITY 
 
 
 
 
 
 INTRODUCTION 
Polydimethylsiloxane (PDMS) elastomers have long been used in the development of biomedical 
microfluidic devices owing to their machinability, mechanical strength, and biological inertness 168,169. An 
additional property of PDMS – high gas permeability to oxygen and carbon dioxide – has led researchers 
to design extracorporeal membrane oxygenation (ECMO) devices consisting of stacked layers of PDMS 
forming capillary-like blood channels 55,106,112,170. These PDMS oxygenators optimize blood flow 
dynamics through precisely engineered parallel plate channels, while utilizing the high gas permeability 
and mechanical strength of PDMS to effectively exchange gas with the blood. Similarly, we have 
developed a parallel plate oxygenator consisting of composite silicon-PDMS membranes that are capable 
of robust, efficient gas transfer 143,160. Compared to the PDMS microfluidic devices, the use of a PDMS 
film surface reinforced by silicon micropore membranes (SµM) allows us to build composite membranes 
that leverage the nonreactivity of PDMS, as well as the mechanical robustness of the SµM-PDMS 
combination 160. Crucial to any PDMS-based blood oxygenation devices is the ability of PDMS to 
withstand continuous blood contact without thrombosis within the blood channels 55. In order to meet 
clinical needs of ECMO patients, the PDMS-based oxygenators must be able to remain patent for a 
minimum of 6 hours, and not trigger formation of thrombi that occlude the channel or travel downstream 
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to the patient . As such, ensuring the hemocompatibility of PDMS is highly important to PDMS 
oxygenator development. 
While PDMS is not a bioactive material, it is naturally very hydrophobic, demonstrating water 
contact angles around 100-120° 168,171. Hydrophobic materials in contact with blood are known to attract 
proteins and cells to their surfaces, causing rapid biofouling and clot formation 15,172. Furthermore, 
hydrophobic microfluidic devices are subject to poor wettability and consequently poor flow performance 
124,173. To address the hydrophobicity and biocompatibility of PDMS, many researchers working on 
PDMS microfluidic devices have devised treatments that attempt to engineer a stable, hydrophilic surface 
173,174. Physical surface modifications, commonly oxygen plasma treatment, can create a suitably 
hydrophilic surface on PDMS through the creation of surface hydroxyl groups 174–176. However, PDMS 
undergoes continuous rearrangement as uncrosslinked polymers migrate throughout the bulk structure, 
leading to “hydrophobic recovery” as the surface hydroxyl groups migrate into the bulk 177,178. Due to the 
hydrophobic recovery of PDMS, developing a surface coating that maintains hydrophilicity over time is 
critical. Another approach to attaining PDMS hydrophilicity is to chemically modify the surface by 
attaching hydrophilic surface coatings. Considerable research has been conducted on a variety of 
hydrophilic surface coatings to PDMS, which can be covalently modified with silane groups after 
activating the PDMS surface through plasma treatment 124,174,179–181. An ideal coating for a blood-
contacting PDMS surface would be hydrophilic, omniphobic to both cell and protein adhesion, and would 
remain stable on the surface for extended periods of time. 
One common surface coating that is frequently used in biomaterials research is polyethylene 
glycol (PEG), which has historically been an effective coating to improve hemocompatibility 124,174,182,183. 
The hydrophilic PEG chains on a surface sterically hinder the adhesion of cells and proteins, combining 
physical deterrence and hydrophilicity. A silane derivative of PEG can be used to modify silicon or 
PDMS – both constituents of our SµM-PDMS membranes. In our past work with silicon membranes, we 
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have developed protocols to attach PEG as an alkoxysilane to silicon surfaces, and shown that PEG 
attachment reduces protein fouling and cell/platelet adhesion 131,135,184. Although these studies showed 
clear benefits to PEG application, another recent study from our lab using the same protocol showed no 
improvement in omniphobicity with PEG-modified silicon, calling into question if this protocol would be 
successful over time 141. Other research groups have also shown substantial hemocompatibility benefits 
with PEG on PDMS, including near-negligible fouling and sustained stability 124,178,181. One such protocol, 
described in Kovach, et al (2014), was specifically developed improve the hemocompatibility of a PDMS-
based blood oxygenator, and uses the same PEG-silane derivative as our previous work 124. If we employ 
PEG-silane to modify our oxygenator membranes, we would need to determine the optimal protocol 
conditions that result in a stable, hydrophilic chemical modification to our silicon-PDMS composite. 
In this study, we examine multiple protocols for the application of PEG-silane to silicon and 
PDMS substrates to determine which, if any, improves hydrophilicity and in vitro protein fouling 
resistance. After applying PEG-silane films to the surfaces, we also perform additional characterization 
using ellipsometry and atomic force microscopy (AFM) to determine what attributes of the films result in 
superior fouling resistance. Using this information, we speculate if any modification of PEG may be able 
to protect the SµM-PDMS membranes from sustained blood contact. 
 MATERIALS AND METHODS 
 Silane Application 
4.2.1.1 Substrates  
Three substrates were prepared for testing the coating protocols, as seen in Fig. 4.. The first 
substrate – abbreviated as Si – consisted of 1 cm2 pieces of silicon cut from 400 µm-thick double side 
polished, p-type wafers. This substrate was similar to past work from our lab 131,141,142, and was used to 
compare results between this work and prior studies. As a surrogate for silicon membranes, pieces of Si 
substrate were bonded on one face with a 5 µm-thick layer of PDMS, creating the Si-PDMS substrate. 
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Briefly, this PDMS layer was formed from spin-coated Sylgard 184 PDMS (Dow Corning, Midland, MI, 
USA) mixed at a 10:1 elastomer-to-crosslinker ratio, and then diluted 1:1 with hexanes (Millipore Sigma, 
Burlington, MA, USA). Further processing methods can be found in Dharia, et al (2017) 143. The final 
substrate consisted of undiluted Sylgard 184 PDMS mixed at a 10:1 elastomer-to-crosslinker ratio, which 
was cast into a 3 mm-thick sheet and cut into 1 cm2 discs. These discs – abbreviated as PDMS – were 
intended to mimic the PDMS microchannels from Kovach, et al. (2014) 124 and also act as a material 
control for the Si-PDMS group. 
 
Fig. 4.1: Substrates for functionalization with PEG-silane. 
 
4.2.1.2 PEG-Silane Application 
Three different protocols were used to attach the PEG silane to the surfaces of the substrates. A 
comparison of the silanization methods can be found in Table 4.1. The first protocol (1A, Table 4.1) was 
adapted from previously described methods used in our lab 131,139. First, Si-PDMS and PDMS samples 
were treated with oxygen plasma (Harrick Plasma PDC-001, Harrick Plasma, Ithaca, NY) for 30 seconds 
at high power (~30 watts) to produce reactive hydroxyl groups on the surfaces. Si samples were activated 
with a 20-minute exposure to “piranha” solution, consisting of a 3:1 mixture of sulfuric acid (96%) and 
hydrogen peroxide (30%). After activation, all samples were then submerged in a 1% solution of PEG-
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silane (6-9 monomer chain length, Gelest SIM6492.7, Morrisville, PA, USA) in pure ethanol within a 
glass petri dish. This mixture was heated to 70°C for 2 hours and mixed with a magnetic stir bar. Finally, 
after functionalization, the samples were washed three times each in ethanol and deionized water for 3 
minutes per wash, totaling 6 washes.  
Based on the methods described in Kovach et al (2014), a second protocol (2, Table 4.1) was 
employed to attach the PEG-silane with a higher silane density 124. After plasma or piranha treatment of 
the surfaces, the substrates were submerged in a 1:1 mixture of PEG-silane and anhydrous acetone 
(SeccoSolv C992H04, Millipore Sigma, Burlington, MA) in a glass petri dish. This solution was kept at 
room temperature for 1 hour with no stirring. These samples were then washed twice each with acetone, 
ethanol, and water for 3 minutes per wash.  
As a bridge between both PEG silanization protocols, a third method was adapted from both 
methods (1B, Table 4.1). After surface activation, the substrates were immersed in a 1% solution of PEG-
silane in anhydrous acetone for 2 hours at 70°C under agitation by a magnetic stir bar. Due to the elevated 
temperature, the acetone in this protocol largely evaporated during functionalization, and was replenished 
as needed throughout the experiment. This solvent evaporation allowed a much higher concentration of 
the PEG silane to collect on the surfaces of the substrates. Washes were conducted in a manner similar to 
the first protocol.  
Table 4.1: Reaction conditions for PEG protocols. 
Reaction Condition  Protocol 
 
 1A 1B 2 
Solvent Ethanol Acetone Acetone 
PEG Concentration 1% 1%  50% 
Activation O2 Plasma  O2 Plasma O2 Plasma 
Reaction Time  2h 2h  1h 
Temperature 70°C 70°C 21°C 
Stirring Applied  Stirring  Stirring Static  
Storage Time  7 days  7 days 7 days  
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 Analysis of Silane Layers 
4.2.2.1 Contact Angle 
Contact angle, which measures hydrophilicity of a surface, was used to assess successful 
application of the silane coatings. Changes to the contact angle after applying a coating would indicate if 
surface modification had occurred, though wettability changes alone do not definitively confirm the 
presence of a coating. Sessile drop measurements using deionized water were recorded for each sample 
using a Biolin Scientific Theta Lite optical tensiometer (Stockholm, Sweden) with OneAttension software 
141. Samples were measured for contact angle on the day of coating (Day 0), stored in ambient air, and 
analyzed again 6 days later (Day 6) to mimic sample processing conditions in Kovach, et al 124. In waiting 
6 days for further study, the hydroxyl surface groups created by plasma treatment could dissipate through 
hydrophobic recovery, allowing restoration of the underlying native surface 177,178,185–187. 
4.2.2.2 ELISA 
After 7 days of storage, the coatings were evaluated for in vitro protein fouling using a surface 
enzyme-linked immunosorbent assay (ELISA) of human serum albumin (HSA, A3782, Millipore Sigma, 
Burlington, MA, USA) 141,142. Briefly, each sample is incubated in a 1 mg/mL solution of HSA in PBS for 
1.5 h at 37°C. The HSA is rinsed off with 0.5 mL PBS five times, and any unbound sites on the samples 
are then blocked with a 1 mg/mL solution of bovine serum albumin (BSA, ≥98%, Millipore Sigma, 
Burlington, MA) in PBS for 1.5 h at 37°C. Subsequently, the samples are rinsed again, transferred to new 
containers, and incubated for 1.5 h with a 10 μg/mL solution of anti-HSA antibody conjugated with 
horseradish peroxidase (ab19183, Abcam, Cambridge, MA). Samples are rinsed again, transferred to new 
containers, and treated with 0.5 mL of an aqueous solution of 0.5 mg/mL o-phenylenediamine (oPD, 
VWR Inc., Visalia, CA), 0.03% H2O2, and 0.05M citrate phosphate buffer (pH 5.0, Millipore Sigma, 
Burlington, MA). The reaction was protected from light for 7-10 minutes at room temperature to allow for 
color development, and then stopped with a 1M solution of H2SO4. Light absorbance of the solutions was 
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measured at 490 nm in triplicate. Protein adsorption data was normalized to two controls: a positive 
control of tissue culture polystyrene (TCPS), and a negative control of the uncoated substrate without 
HSA added. Since three different substrates were functionalized, the data for each substrate was 
normalized separately to a negative control of the same material. 
 
Fig. 4.2: Characterization methods of PEG-silane surfaces: (a) contact angle of hydrophilic and 
hydrophobic surfaces, (b) AFM scan showing topography of unmodified PDMS, (c) schematic of protein 
fouling ELISA showing the steps to yield oPD color change, and (d) example of high and low albumin 
adsorptivity in the protein ELISA 
 
4.2.2.3 Ellipsometry 
The thickness of the PEG coatings on the Si substrates was measured using a LSE Stokes 
ellipsometer (Gaertner Scientific, Skokie, IL). Methods are described in Iqbal, et al 141. Only the Si 
substrates could be assessed using ellipsometry because the ellipsometer used requires a reflective surface 
within 1 µm of the top of the sample, and both the Si-PDMS and PDMS substrates do not meet this 
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requirement. One Si sample of each coating group was characterized by measuring thickness in three 
locations on the surface, which were then averaged. The thickness measurements from the unmodified 
substrate were taken to be the thickness of the native oxide on Si, and the average thickness of the 
unmodified group was subtracted from all groups as a baseline. 
4.2.2.4 AFM 
The coated substrates were examined through atomic force microscopy (AFM) to visualize the 
morphology of the coatings. 3 μm by 3 μm surface scans of one sample of each group were taken in air 
using a MultiMode III (Digital Instruments, Santa Barbara, CA, USA) and Scanasyst-Fluid+ AFM probes 
(Bruker AFM probes, Santa Barbara, CA, USA) in PeakForce QNM tapping mode. The scans were 
processed using NanoScope Analysis software to obtain root mean square (RMS) roughness values for 
the substrates. 
4.2.2.5 Statistical Analysis 
A minimum of three measurements was taken for all samples in the contact angle and ELISA 
experiments. Statistical significance was determined using Graphpad Prism 8.2.0 (San Diego, CA, USA). 
Contact angle measurements were analyzed through two-way ANOVA. Tukey post-hoc tests were used to 
determine statistical difference (p < 0.05) between the same coating conditions on Day 0 and Day 6 of the 
experiment, and between different coating conditions at the same time point. ELISA measurements were 
analyzed for each substrate independently through one-way ANOVA, with Tukey post-hoc tests to 
determine significant difference between different coating conditions on the same substrate. Ellipsometry 
measurements on silicon were averaged for each substrate. The average thickness value of the unmodified 
Si substrate was considered native oxide, and this value was subtracted from all groups to normalize the 
data to the unmodified group. Significant difference in thickness was determined by one-way ANOVA 
with Tukey post-hoc tests. 
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 RESULTS 
 Contact Angle 
Measurements of contact angle (average ± SD) taken on days 0 and 6 after coating application are 
shown in Fig. 4.3. Data from Si substrates (Fig. 4.3a) shows the hydrophobic recovery of the unmodified 
substrate after piranha activation, reaching 25° on Day 6. The contact angles of all PEG-modified groups 
are significantly higher than the unmodified group, and remain stable from Day 0 to Day 6. The contact 
angles of PEG 1A and 1B on Si were similar at ~41°, while the contact angle of PEG 2 was significantly 
lower than the other PEG groups on both days – around 30°. The measurements of unmodified Si and 
PEG 1A on Si are similar to those published in Iqbal, et al., and also close to the manufacturer-specified 
contact angle of 36° 141. The steady contact angle over time indicates that a stable film of PEG may be 
present on all the Si modified surfaces. Both the Si-PDMS (Fig. 4.3b) and PDMS (Fig. 4.3c) substrates 
show that the unmodified PDMS surfaces are strongly hydrophobic – around 102° – and that plasma 
activation temporarily renders the PDMS hydrophilic 124,185. With the Si-PDMS substrates, all PEG-
modified groups have similar contact angles at Day 0, generally ~45°, which is similar to the Si 
substrates. However, by Day 6, all of the PEG groups exhibited statistically significant hydrophobic 
recovery, possibly indicating that any PEG coating may have degraded over time. Compared to the other 
two substrates, the PEG-modified PDMS pieces showed much lower contact angles on Day 0; all were 
insignificantly different at ~24°. On Day 6, only the PEG 1A group showed hydrophobic recovery, and 
the PEG 1B and 2 groups remained stable. 
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Fig. 4.3: Contact angle of PEG-silane on (a) Si, (b) Si-PDMS, and (c) PDMS. Statistical comparisons 
were drawn between the same coating conditions on Day 0 and Day 6, noted by * if p < 0.05, and 
between different coating conditions on the same day, noted by the bars above the columns if p < 0.05. 
 
Based on the known contact angle of PEG-silane, it is likely that the Si and Si-PDMS surfaces 
were successfully PEG-modified in all groups on Day 0, though this result cannot be confirmed without 
additional characterization. Results on Day 6 indicate that the PEG was stable on the Si substrates, but the 
substantial hydrophobic recovery on Si-PDMS surfaces may indicate that the PEG on the surfaces was 
inconsistent, or degraded over time. Day 0 contact angles of PEG-modified PDMS groups were 
significantly lower than the manufacturer’s published values for contact angle. However, this data is 
consistent with values published by Kovach, et al, which showed a maximum contact angle of 27.2° with 
the PEG 2 protocol on cast PDMS 124. Two of the PEG groups – 1B and 2 – showed a steady contact 
angle over time, indicating that stable PEG modification had likely occurred. The PEG 1A group also 
showed less hydrophobic recovery than the plasma group, which may also point to some modification.  
 ELISA 
Protein fouling results from the albumin ELISA are in Fig. 4.4. Within the Si group (Fig. 4.4a), 
unmodified Si showed a relative fouling of 33.8% of TCPS, which is less than the ~45% fouling in Iqbal, 
et al 141. Relative to the unmodified control, only PEG 1B showed significantly less albumin fouling, at 
23.7% of TCPS – 30.1% less than the unmodified control. While older data from our lab has shown a 
strong fouling reduction with the PEG 1A protocol on Si 142, more recent data has shown that PEG-silane 
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makes little difference to protein fouling 141. The Si-PDMS substrates (Fig. 4.4b) showed no significant 
difference between the unmodified and any of the PEG groups. Plasma treatment of Si-PDMS slightly 
increased albumin fouling compared to the unmodified group from 28.7% to 37.8% of TCPS. Within the 
PDMS group (Fig. 4.4c), the unmodified, plasma-treated, and PEG 1A groups showed the same level of 
fouling. Interestingly, the PEG 1B and PEG 2 groups showed a strong reduction in protein fouling, with 
both reaching the same low level as the PDMS experimental negative control – 0% on the graph.  
 
Fig. 4.4: Albumin fouling ELISA results for (a) Si, (b) Si-PDMS, and (c) PDMS. Significant difference 
within each substrate group (p < 0.05) is shown by the bars above the graphs. 
 
Ultimately, PEG modification only strongly reduced protein fouling on the PDMS substrates, with some 
reduction seen with PEG 1B on silicon as well. Therefore, the PEG 1B protocol overall was the most 
effective at reducing albumin fouling of the surface. By contrast, the PEG 1A did not reduce fouling on 
any substrate, and the PEG 2 protocol was only effective on PDMS.  
 Ellipsometry 
Ellipsometry measurements of coating thickness on Si substrates can be found in Fig. 4.5. PEG 
1A had a thickness of 2.38 nm, which was not different from the unmodified group. The PEG 1B and 
PEG 2 groups had significantly thicker coatings at 12.4 and 17.5 nm, respectively. These coatings were 
significantly thicker than the unmodified and PEG 1A groups, though not different from each other. 
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Fig. 4.5: Ellipsometry results on Si substrates, taking the thickness of the native oxide on the unmodified 
substrate to be a baseline. Significant difference is shown by the bars above the graph. 
 
 AFM 
Topographic surface scans of the Si, Si-PDMS, and PDMS substrates can be seen in Fig. 4.6, 
with the corresponding roughness values below the scans. From the Si scans (Fig. 4.6a), most of the 
surfaces are smooth and featureless, except for the “islands” on the PEG 2 surface. Within both the Si-
PDMS and PDMS samples, the unmodified PDMS surfaces start with a natural texture, with similar RMS 
values of 2.42 and 2.28 respectively. Plasma treatment then smoothens the texture, although the PDMS 
sample acquired several surface cracks 187. While the PEG-modified Si-PDMS were all nearly as smooth 
as the plasma sample, the PEG-modified PDMS pieces show a variety of wrinkled textures on the 
surfaces. Specifically, the PEG 1B sample shows a pronounced wrinkling of the entire surface, spanning 
~60 nm in height. The PEG 1A substrate shows a similar texture, though less pronounced, while the PEG 
2 substrate shows overall fewer, faint wrinkles. Compared to the plasma-treated PDMS, the presence of 
this wrinkled texture on all three PEG groups suggests that films may be present on the surfaces. Given 
the depth of the wrinkled patterns, these films are likely on the order of tens of nanometers thick. 
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Fig. 4.6: AFM topographic scans of 3 µm x 3µm spots on (a) Si, (b) Si-PDMS, and (c) PDMS substrates. 
Each scan is shown in top view and at an angle. The Si and Si-PDMS scans are scaled to heights of -10 to 
10 nm. The PDMS scans are scaled from -30 to 30 nm due to the increased feature roughness.  Roughness 
values (Rq) are shown below the corresponding scans. 
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 DISCUSSION 
In this study, we examined multiple application protocols of PEG-silane to determine which 
protocol, if any, would improve the future biocompatibility of a PDMS surface for blood oxygenation. 
Since our membrane material was akin to the Si-PDMS substrate in this work, we sought a coating that 
would be stable on that substrate surface, possibly increase hydrophilicity, and reduce protein fouling. 
Ultimately, none of the coating protocols was able to meet all criteria. Comparing the results between all 
substrates may explain why the PEG-silane was ineffective on Si-PDMS specifically, and broadly how 
the PEG modification is altered by each protocol. 
From the contact angle measurements, the wettability of the PEG-modified Si and PDMS 
substrates indicates that successful PEG modification may have taken place, particularly with the PEG 1B 
and PEG 2 groups. However, all of the PEG-modified groups on Si-PDMS showed a substantial degree of 
hydrophobic recovery, indicating that any surface modification present may be unstable. Both the Si-
PDMS and PDMS substrates involved application of the PEG-silane to PDMS surfaces, so the 
discrepancy in hydrophobic recovery between the substrates was surprising. One reason behind this 
difference may be related to the ways in which the Si-PDMS film and the PDMS discs were formed. The 
PDMS discs were cast from an undiluted mixture of the elastomer and curing agent, while the PDMS film 
on Si-PDMS was created from hexane-diluted elastomer that was spin coated to achieve the thin film. It is 
possible that the hexane dilution altered the plasma reactivity of the Si-PDMS film compared to the 
undiluted PDMS discs. However, hexane dilution of PDMS has often been used as a solvent extraction 
method to remove uncrosslinked PDMS from the bulk, which should improve the overall stability of the 
PDMS film 188. Indeed, the thinness of the Si-PDMS film should also increase stability compared to the 
undiluted PDMS pieces, since thin layers of spin-coated PDMS have been shown to form stronger 
crosslinks than thicker, bulk PDMS 189. Another explanation may be that the height difference between 
the two substrates – 3 mm thick for PDMS, 400 µm for Si-PDMS – may have influenced the PEG 
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modification efficacy. Without additional analysis techniques to examine coating thickness or graft 
density, it is difficult to determine if the film composition on PDMS and Si-PDMS was the cause of the 
less stable Si-PDMS modifications. Nonetheless, it is at least probable to conclude that PEG films were 
present on Si and PDMS, and may have initially been present on Si-PDMS. 
Based on the ELISA results, the PEG 1B protocol was the most effective at reducing protein 
fouling on any substrate, although none of the PEG protocols reduced fouling on Si-PDMS. While the 
PEG 1B protocol was effective on both Si and PDMS, only the PDMS substrates showed a substantial 
reduction in albumin fouling. Similarly, the PEG 2 protocol only showed a strong reduction in fouling on 
the PDMS substrate, akin to results from Kovach, et al. The PEG 1B protocol was the only group on Si 
that showed any reduction in fouling, and the Si-PDMS substrates showed no difference with any 
protocol of PEG-silane. It is possible that the increased hydrophilicity of those two PEG modifications, as 
seen in Fig. 4.3c on PDMS, may have led to lower HSA fouling in the ELISA, since proteins are apt to 
adsorb to more hydrophobic surfaces. However, there does not appear to be a relationship between lower 
contact angle and decreased protein fouling for either the Si or Si-PDMS substrates. For instance, the Si 
PEG 1B group showed significantly less fouling than any other Si group, yet the contact angle of the PEG 
1B group was around the same as the unmodified and PEG 1A groups. Similarly, despite the significant 
differences in contact angle between the Si-PDMS PEG groups, all PEG-modified groups showed the 
same protein adsorption. Considering only the contact angle and HSA ELISA of the substrates, there does 
not appear to be a concrete relationship between hydrophilicity and reduced protein fouling. 
Ellipsometry and AFM data provide additional information about how the different protocols of 
PEG-silane affected the resulting layers of PEG modification. The ellipsometry data on Si shows that 
PEG film thickness varied strongly with the different protocols, with the PEG 1A protocol resulting in an 
extremely thin film and the PEG 1B and PEG 2 protocols resulting in substantially thicker films. Given 
that the PEG-silane is a small molecule with a molecular weight of 459-591 Da, we would expect a 
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monolayer to have a film thickness of less than 1 nm 190. In this case, the PEG 1A protocol is closest to a 
monolayer, and the PEG 1B and PEG 2 protocols are clearly beyond a monolayer in thickness. Instead, it 
is likely that the PEG-silane has formed multilayers on these surfaces. This formation may have occurred 
through either covalent bonding of the reactive silane terminuses to each other, or through hydrogen 
bonding interactions throughout the films 191–193. Additional characterization would be needed to 
determine the structure of these multilayers. 
The AFM topography scans may point to a similar film thickness trend on the PDMS pieces. 
Though the scans revealed little on Si and Si-PDMS, the PDMS pieces show particularly prominent 
surface textures. It is known that plasma oxidation leads to the formation of a glassy SiO2 layer on PDMS 
surfaces, which can form microscopic cracks under physical stress 187,194,195. Evidence of stress-induced 
cracking can indeed be seen on the plasma-treated PDMS, but additional wrinkled texturing is obvious on 
all of the PEG-modified samples. The surfaces indicate that the PEG-silane films have experienced 
“buckling”, which occurs when a rigid film deforms due to thermal or mechanical stresses on a more 
elastic, underlying substrate 196,197. PDMS is certainly an elastic substrate, as it is often used for testing 
film buckling. The flexibility of the cut PDMS discs in this study likely caused any films on the surface, 
particularly the glassy SiO2 layer, to become mechanically stressed due to extensive handling during 
processing 178. Additionally, the PEG 1A and PEG 1B samples were heated during functionalization, 
likely causing additional thermal stresses on those films 198. As can be seen in Fig. 4.6c, the PEG 1A and 
1B samples do show a denser pattern of buckling compared to the PEG 2 sample, which was not heated. 
Comparatively, the Si and Si-PDMS substrates were backed by rigid silicon pieces, and so would not be 
affected by those handling stresses. Given the amplitude of the buckling observed on the PDMS samples, 
the thickness of the PEG-silane films on PDMS can be speculated. The depth of the wrinkles on the PEG 
1A sample appears to be ± 5 nm, likely indicating a sub-5 nm film, while the depth of the PEG 1B 
wrinkles was ± 30 nm, indicating a film in the tens of nanometers. While these estimates do not 
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definitively calculate the PEG-silane film thicknesses, they do point to a substantial difference between 
PEG 1A and PEG 1B on PDMS. Since the PEG 2 film is less buckled than the others, its thickness is 
difficult to determine from buckling depth. Still, it appears that the film thicknesses on PDMS follow a 
similar trend to the ellipsometry measurements on Si.  
Ultimately, while it is likely that PEG-silane modification occurred in all cases, the protein 
fouling resistance of the resulting films appears the most related to the films’ thickness and structure, 
rather than any innate fouling resistance conveyed by PEG-silane as a monolayer. The PEG 1A protocol, 
which likely yielded monolayer films, did not reduce fouling on any substrate. Many studies have 
indicated that PEG monolayer films should reduce protein fouling of a substrate 124,128,174,178, although 
others have shown no reduction in fouling with PEG application 141. In this study, it is possible that the 
protocol resulted in a low grafting density of PEG, or that the short chain length of the PEG-silane 
produced a film too thin to be protective 199. The latter seems likely, given the apparent relationship 
between protein fouling and film thickness. Indeed, the most fouling resistance was seen with multilayer 
films of agglomerated PEG-silane, particularly the PEG 1B groups. 
Still, the fouling reduction with thick PEG-silane films was not universal for all groups, 
indicating that other factors in addition to thickness may influence omniphobicity. One possibility is that 
the multilayers may be structurally unstable, especially if the PEG-silane molecules are noncovalently 
attached to each other 193. If the multilayer films are weakly bound, the ELISA processing steps may be 
sloughing off the PEG-silane during the test. This would lead to lower apparent HSA binding, as the 
bound HSA would be removed with the PEG-silane. However, not all PEG multilayer films showed 
lower protein fouling, and – lacking additional characterization techniques – it is difficult to determine 
what types of bonds exist within the PEG multilayers. Since the PDMS PEG 1B and PEG 2 samples were 
the only groups that showed substantial protein fouling resistance, those samples may provide the clearest 
indicators of omniphobicity. Notably, buckling is associated with film delamination from the underlying 
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substrate, meaning that the thin films may detach from the surface when they become buckled 200. It is 
possible that the buckled films on the PDMS samples specifically may have become delaminated, 
particularly during the ELISA handling processes, and that this delamination led to seemingly lower 
protein fouling as any bound HSA would be removed during the test. Further experiments on film 
stability, similar to the shear rate experiments found in Iqbal, et al., would be valuable towards 
determining if the PEG-silane multilayers are stable, and if buckling leads to destructive delamination 
91,201. 
Much of the work in this study was limited by a lack of additional characterization of the PEG-
silane films, and so the hypotheses in this discussion are not substantially supported by the data. First, 
XPS data is essential to identifying the composition of the films on the surface, and high-resolution XPS 
scans could even provide some insights to the film structure. This information could indicate the presence 
of covalent bonds within the PEG-silane multilayers, possibly supporting some of the speculation about 
the multilayer stability. Contact angle alone can indicate that a substrate surface has been modified, but 
cannot prove that the modification is as intended by the protocol. Also, the film thicknesses were 
ultimately only measured on Si substrates, and so the film thicknesses on Si-PDMS and PDMS are 
unknown. A spectroscopic ellipsometer with multiple angles, rather than a single wavelength ellipsometer 
with a fixed angle, would be able to provide a more complete picture of film thickness on PDMS. In 
addition, the stability of the PEG-silane films in aqueous flow conditions was not assessed, possibly using 
methods described in Iqbal, et al 91. This testing would provide insight into how stable the PEG-silane 
layers are, particularly if delamination of the buckled layers had occurred. Finally, no hemocompatibility 
testing was conducted in this study, so the blood response to the PEG-silane layers is unknown. Based on 
the protein fouling data, we can speculate that there would be little difference in thrombogenicity between 
PEG-functionalized substrates and their unmodified controls, but this cannot be proven without blood 
contact with the surfaces. 
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 CONCLUSION 
In this study, multiple application protocols of PEG-silane were compared on three substrates, 
with a goal towards determining future suitability in a blood-contacting device made of silicon 
membranes. The resulting films yielded inconsistent contact angle and protein fouling between substrates, 
and none of the films significantly improved the hydrophilicity or omniphobicity of the desired Si-PDMS 
substrate. Additional thickness and topography data revealed that two of the protocols formed thick 
multilayers of PEG-silane on the surfaces rather than monolayers, and that the thicker coatings tended to 
correlate with improved resistance to protein fouling. However, this fouling reduction may have been due 
to unstable bonds within the multilayers, or delamination of the PEG-silane layer entirely. Ultimately, 
while additional characterization is necessary, this study indicates that PEG-silane does not effectively 
reduce protein fouling or improve hydrophilicity, and that certain application protocols may result in 
unstable films.  
Future work will focus on determining an alternative coating on Si-PDMS that increases the 
hydrophilicity of the surface, lowers protein fouling, and remains stable on the surface over time. As an 
alternative to PEG, recent research has explored the use of zwitterionic coatings such as sulfobetaine, 
carboxybetaine, and phosphorylcholine, which are strongly polar molecules with both positively and 
negatively charged functional groups 91,93,125,141,174,180. These coatings have been shown to increase 
hydrophilicity and omniphobicity beyond PEG, and successful application of zwitterionic coatings to 
PDMS has been achieved with multiple protocols. Another option may be heparin coatings, similar to 
those currently used in ECMO hollow fiber oxygenators 202. Although the bioactivity of heparin is short-
lived, heparin-derived coatings on PDMS could substantially improve the hemocompatibility of the 
PDMS surfaces at least acutely. Lastly, since the silicon membranes are intended for use in an 
oxygenator, it may be possible to leverage a functional coating that improves gas transfer, possibly in 
addition to improving hemocompatibility. Arazawa, et al, designed a coating consisting of immobilized 
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carbonic anhydrase enzyme, which – in conjunction with an acidic sweep gas – was highly effective at 
CO2 removal from blood by creating a locally acidified environment 73. An acidic biomolecule 
immobilized on PDMS may be able to facilitate higher CO2 removal as well. Continuing work on the 
SµM-PDMS oxygenator will focus on determining if one of these alternative coatings is best able to 
improve the oxygenator’s hemocompatibility and functionality.  
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IMPROVED OXYGENATION VIA TURBULENT BOUNDARY LAYER DISRUPTION 
 
 
 
 
 
 INTRODUCTION 
Over the last several decades, extracorporeal membrane oxygenation (ECMO) has been a life-
saving supportive treatment for critically ill patients with severe lung or heart failure. In recent years, 
increasing use of ECMO has led to more interest in a compact ECMO device for patient transportation or 
ambulation. Current hollow fiber ECMO systems are large and most often require patients to be 
bedbound, resulting in muscle deconditioning and poorer patient outcomes. Clinical advances in 
cannulation and patient management have led many ECMO centers to introduce awake and ambulatory 
physical therapy programs for patients 14,203,204. These programs’ successes have directed ECMO research 
towards the development of smaller ECMO devices that are designed to be wearable and ambulatory, 
often as a bridge to transplant or destination therapy. Some research groups have constructed miniaturized 
hollow fiber ECMO units consisting of an oxygenator with integrated pump 205–207, a few of which have 
been tested in preclinical trials. As a promising alternative to hollow fiber membranes, other researchers 
have been leveraging the miniaturization advantages of microelectromechanical systems (MEMS) 
technology to develop microfluidic artificial lungs. These devices consist of multiple layers of stacked 
polydimethylsiloxane (PDMS) forming parallel plate, capillary-like blood channels, which are optimized 
for minimal surface area, low priming volume, and low pressure drop 106,110,121. At present, manufacturing 
difficulties have prevented most of these devices from scaling up to support a full-size patient, although 
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they present a compelling solution to compaction by maximizing the amount of gas-diffusing surface area 
55. In our lab, we have developed an alternative parallel plate microfluidic oxygenator based on silicon 
micropore membranes (SµM) coated with a sub-5 µm thin layer of PDMS 143. The rigidity imparted by 
the SµM allows the composite SµM-PDMS membranes to withstand very high (> 250 cmHg) oxygen 
sweep gas pressures to maximize the driving force of oxygen into the blood 160. In the future, these 
membranes can be arrayed in stacked parallel plate flow paths to create a larger oxygenator. 
Ultimately, the most significant obstacle to designing a compact ECMO device is the high 
membrane area required for sufficient gas exchange. Typically, blood flow within oxygenators is kept in 
an entirely laminar flow regime to minimize the possibility of blood clotting in response to turbulent flow. 
Consequently, oxygen and carbon dioxide transport in ECMO are limited by a diffusional boundary layer 
within the blood, adjacent to the membrane surface. Due to this diffusion-limited process, hollow fiber 
ECMO oxygenators must be designed with large blood-contacting surface areas. As a reference point, the 
market-leading Maquet Quadrox-i adult model has a surface area of 1.8 m2, translating to an area-
normalized oxygenation efficiency of roughly 250 mL/min/m2 if used at its average blood flow rate of 3.5 
L/min 41. One wearable ECMO device in prototype stage – the PAAL – provides a slightly higher 
oxygenation efficiency of 278 mL/min/m2 in a device with 0.65 m2 of surface area at the same 3.5 L/min 
blood flow rate 85. Microfluidic artificial lungs are similarly limited by boundary layer formation, since 
they maintain exceptionally laminar flow paths. Most of these devices have shown oxygenation exchange 
efficiency of below 250 mL/min/m2 55, with recent devices demonstrating 88 mL/min/m2 and 130 
mL/min/m2 106,121. Scale up to a larger device may alter the oxygen flux from these prototype 
measurements. Past results with our SµM-PDMS oxygenator have shown a similar oxygenation 
efficiency in blood of 174 mL/min/m2 143. Despite design optimization efforts, most devices are unable to 
significantly surpass the gas exchange efficiency of the current hollow fiber technology, leading 
researchers to search for additional processes that enhance gas exchange. 
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Dating back to the inception of ECMO oxygenators, many researchers have sought solutions to 
overcoming the diffusion-limited transport in oxygenators, typically by introducing convective elements 
to the flow paths. Additional localized turbulence in the blood compartment can disrupt the diffusion 
boundary layer and strongly increase mass transfer, though possibly at the cost of considerable hemolysis 
and/or thrombosis 208. For hollow fiber oxygenators, attempts have been made to introduce convection 
through oscillating hollow fibers 88, causing markedly increased hemolysis, or combining sinusoidal-
shaped hollow fibers in conjunction with fluctuating liquid flows 209, the effects of which have not been 
tested in blood. Researchers working with microfluidic oxygenators have used the machinability of 
PDMS to create various turbulence-promoting textures on their membranes. Some examples include 
furrowed membranes similar to those developed by Bellhouse, et al, in 1973, and embossed staggered 
herringbone trenches taken from the broader PDMS microfluidics fields 123,210,211. Although some of these 
methods have been promising in vitro with water, no results with blood have been published.  
Another approach to improve transport is the use of fluidic spacer meshes inside parallel plate 
ECMO channels, as used in pre-hollow fiber ECMO devices 54,212,213. Fluidic spacers are known to 
promote increased transport through membranes by creating localized turbulence and disturbing the 
transport boundary layer near the membrane surface, even in flow conditions with low Reynolds numbers 
214. Some materials used for the spacer meshes included nylon, vinyl-coated fiberglass, and 
polyvinylidene chloride. The landmark Kolobow oxygenator used reinforced silicone membranes wound 
in a spiral coil with a plastic spacer mesh in between the membrane layers 215. Similarly, the Travenol 
oxygenator used nylon screens to separate silicone parallel plate membranes 216. Using spacers helped 
overcome the diffusive difficulties (~50 µm thick membranes and large plate separations) imposed by 
manufacturing capabilities at the time 54. In addition to keeping the silicone layers apart for patency, the 
spacers improved gas transfer throughout the oxygenators and led to a twofold reduction in device size. 
However, hollow fiber oxygenators succeeded these early oxygenators in the late 1970s due to their lower 
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overall pressure drops, though they required a significantly higher membrane surface area. Given the 
recent interest in compact ECMO devices, spacers may be a concept to revisit for miniaturized parallel 
plate oxygenators such as our SµM-PDMS oxygenator. Scale up of microfluidic oxygenators has proven 
difficult due to laborious manufacturing processes, and routing blood flow to many parallel channels. 
Using spacers – or turbulent mixing in general – should make scale-up much simpler by significantly 
decreasing the number of channels needed for sufficient respiratory support. A full-size oxygenator could 
be constructed with a fraction of the surface area and size of a hollow fiber device, making ambulatory 
use feasible. 
The purpose of this work is to evaluate fluidic spacers as a method of improving mass transfer in 
the SµM-PDMS oxygenator, with additional focus on any hemocompatibility consequences of the 
spacers. In this study, we constructed a prototype SµM-PDMS oxygenator flow cell, and measured the 
spacers’ impacts on O2 transfer and pressure drop in vitro. Then, we exposed the flow cells to flowing 
porcine blood to simultaneously examine O2 and CO2 transfer in vivo, and hemocompatibility of the 
spacers. From this information, we speculated the size reduction of a hypothetical ECMO device using 
spacers, and if the spacers are a viable strategy for improving gas transfer in a parallel plate microfluidic 
oxygenator. 
 MATERIALS AND METHODS 
 Silicon Membrane Design 
Planar silicon membranes can be used with spacers to determine the effects of spacers on blood 
oxygenation. Following prior work 138,143,160, silicon micropore membranes (SμM) were fabricated 
through photopatterning 1000 nm-wide pores on one face of a silicon wafer. The wafer was diced into 
1x6.5 cm2 membrane pieces. For placement of the membrane inside the oxygenator flow cell, a soft 
silicone rubber gasket (BIHT6135, Marian Chicago, West Chicago, IL USA) was oxygen plasma-bonded 
to the nonporous face of the membrane (Harrick Plasma PDC-001, Harrick Plasma, Ithaca, NY USA). 
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After applying these “backside” gaskets, the porous face of the membranes was plasma bonded to a 5 μm 
thick layer of polydimethylsiloxane (PDMS), as in Dharia et al. 2017 and Abada et al. 2018. The 
combined SμM-PDMS were then used as the gas exchange membranes in the oxygenator flow cell. 
 Spacers 
Two mesh sheets made from FDA-compliant polypropylene were obtained to use as spacers in 
the oxygenator (Industrial Netting, Minneapolis, MN USA). Polypropylene is considered an inert 
biomaterial, and has been used as a membrane material for hollow fiber ECMO (Federspiel and Henchir 
2004; Shimono et al. 1997). The meshes were considered as “coarse” or “fine” based on larger or smaller 
hole size, respectively (Fig. 5.1, Table 5.1). Each sheet was cut into pieces measuring 0.8x6.5 cm, which 
would fit over the entire membrane area inside of the oxygenator device.  
For theoretical calculations of spacer performance, one cut spacer mesh of each type was massed 
and measured for volume using the volume displacement method 164,218. Measurements of mass and 
calculated volume can be found in Table 5.1. 
 
Fig. 5.1: Coarse and fine spacer meshes cut to fit in flow cell channels 
 
500 μm 
Coarse Spacers 
Fine Spacers 
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Table 5.1: Dimensions of meshes used as spacers. Product Number, open area, hole size, and thickness 
are as stated by the manufacturer. Mass and calculated volume of a single cut mesh were measured for 
this study. 
 Fine Spacers Coarse Spacers 
Product Number XN6070 XN5170 
Open Area (%) 35 50 
Hole Size (mm) 0.635 x 0.762 1.016 x 1.346 
Thickness (mm) 0.356 0.483 
Measured Mass (g) 0.0504 0.0654 
Calculated Volume (m3) 1.06e-07 1.14e-07 
 
 Oxygenator Device Design and Assembly 
A custom prototype flow cell was constructed from two stainless steel plates to house the SμM 
and spacers (Hayes Manufacturing, Sunnyvale, CA USA). Each of the identical steel plates had a port for 
the liquid inlet or outlet and two slots for placing the SμM (Fig. 5.2). With two steel plates forming a 
complete device, a total of four SμM were used in each device. Underneath the membrane slots were the 
sweep gas channels, which were each accessible by two ports. The SμM with backside gaskets were 
secured in their slots by applying a slight vacuum to the sweep gas channels to compress the backside 
gaskets. The liquid flow path was defined by a set of silicone gaskets to divide the liquid flow from the 
inlet into two channels over the membranes (R750009P, McMaster-Carr, Santa Fe Springs, CA USA). 
The liquid channel gasket was chosen to be 0.5 mm-thick and medium in stiffness to accommodate the 
thicknesses of both spacers within the liquid channel, and provide a fluidic seal around the device. Once 
the SμM, gaskets, and spacers were placed, the steel plates were assembled together to yield a continuous 
flow path. 
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Fig. 5.2: Design views of oxygenator flow cell with spacers. (a) shows an exploded view of the 
oxygenator with a spacer and membranes in place, (b) shows a cross section with the sweep gas channels, 
and (c) shows computational modeling of the flow path at 50 mL/min with an arrow highlighting a region 
of low wall shear. 
 
 Oxygen Flux and Pressure Drop In Vitro 
Three stainless steel flow cells were tested in vitro to determine the effects of the spacers on gas 
permeability and hydraulic pressure drop across the device (Fig. 5.3). Each device was tested with coarse 
spacers, with fine spacers, and without spacers. The flow cells were exposed to circulating, nitrogen-
sparged water at flow rates of 10, 20, and 40 mL/min. A pressure gauge was placed upstream of the flow 
cell to detect hydrostatic pressure resulting from the spacers. Each membrane was supplied with flowing, 
pressurized oxygen sweep gas. An optical oxygen probe (NeoFox GT with FOSPOR probe, Ocean 
Optics, Dunedin, FL, USA) was placed downstream of the flow cell on the liquid side to detect oxygen 
transport across the membrane. The gas pressure of the oxygen sweep gas was raised to 10 cmHg, and 
oxygen flux into the water was measured by the probe. Area-normalized flux (J, mL O2/min/m2) was 
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determined using the measured oxygen concentration in µmol/L before and after adding oxygen to the 
circuit ( 2 iO and 2 fO , respectively), with a conversion of 22.4 L O2/mol at STP: 
 
   ( ) 62 2 10 22.4f i
m
mol L
O O Q
mol mol
J
A

−−   
=  
Eq. 5.1 
Where Q is the flow rate of water in mL/min, and Am is membrane area in m2.  
Based on the calculated oxygen flux, the impact of spacers can be compared to determine if spacers 
benefit gas transport. 
 
Fig. 5.3: Schematic of gas permeability testing setup, showing a spacer insert in one half of the flow cell. 
 
 Hemocompatibility In Vivo  
The devices with and without spacers were tested for blood compatibility extracorporeally in a 
40kg Yucatan minipig. Under general endotracheal anesthesia, a 15-French dialysis catheter (Arrow 
Cannon II, Teleflex, Wayne, PA USA) was inserted into the left external jugular vein using Seldinger 
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technique, with the tip positioned at the cavoatrial junction. Heparin (100u/kg) was administered 
intravenously and serially re-dosed to achieve ACT>300. The venous and arterial ports of the catheter 
were then attached to a closed flow circuit consisting of Tygon tubing (Masterflex L/S 16 Tygon E-LFL, 
Cole-Parmer, Vernon Hills, IL USA), with flow dividers to create three parallel blood channels, each 
containing one oxygenator device: one each with fine spacers, coarse spacers, and no spacers (Fig. 5.4). 
The circuit was primed with isotonic crystalloid solution prior to establishing blood flow by activation of 
a peristaltic pump. Three-way stopcocks were inserted in the Tygon tubing at the inlet and outlet of each 
oxygenator device to allow blood sample collection before and after exposure to the oxygenator’s 
membranes. 
After one hour of extracorporeal blood circulation at 20 mL/min without oxygenation, flowing 
oxygen sweep gas was supplied to any patent device at a flow rate of 3 L/min, and minimal pressure. 
Three blood samples were taken from the inlet and outlet of each patent device at 20 mL/min blood flow 
rate, for blood gas analysis to assess pO2, pCO2, pH, and HCO3- using an iSTAT handheld blood analyzer 
(Abbott Point of Care Inc., Princeton, NJ, USA). The blood flow rate was then decreased to 10 mL/min, 
and three inlet and outlet samples were collected from each patent device for blood gas analysis. After a 
total of three hours of blood exposure, the devices were flushed with saline and disassembled. Should any 
of the devices clot prior to the end of the experiment, they were removed from the circuit early. The 
devices were grossly inspected for clots, and the membranes were removed and broken into pieces. The 
experiment was conducted at a contract resource organization (PMI Preclinical, San Carlos, CA). 
The area-normalized flux of O2 and CO2 through the membranes was calculated from the ABG or 
iSTAT readings at the inlet and outlet of each device. Inlet and outlet O2 content ( 2O , mL O2/mL 
blood) was calculated as in Dharia, et al (2017)143:   
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  2 2 21.36 0.0031O Hg SaO PaO=   +   
Eq. 5.2 
where Hg  is the hemoglobin of the blood (mg/mL), 2SaO   is the percent of hemoglobin bound to 
oxygen, and 2PaO  is the partial pressure of oxygen in the blood (mm Hg). Similar to Eq. 5.1, the area-
normalized flux of O2 (
2O
J , mL O2/min/m2) is calculated by: 
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Eq. 5.3 
where Qblood is the flow rate of blood and Am is the porous area of the membrane. The calculation of CO2 
flux – described in Douglas et al. (1988) – accounts for CO2 stored as a dissolved gas (pCO2), as 
bicarbonate ion (HCO3-), and bound to hemoglobin 219. First, inlet and outlet CO2 concentration in plasma 
( 2 plasmaCO , mL O2/mL blood) is calculated using the logarithmic form of the Henderson-Hasselbalch 
equation for plasma CO2: 
   ( )
2
'
2 2
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Eq. 5.4 
where s (plasma CO2 solubility) and pK' (apparent pK) are known constants equal to 0.0307 mM 
CO2/mmHg CO2 and 6.0907, respectively. The inlet and outlet CO2 concentrations in blood ( 2 bloodCO , 
mL O2/mL blood) are then calculated using the McHardy-Visser equation: 
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Eq. 5.5 
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where SO2 is the oxygen saturation of blood. The values of  2 bloodCO are used for the inlet and outlet 
content of blood CO2. Finally, the area-normalized CO2 flux (
2CO
J , mL CO2/min/m2) is calculated as in 
Eq. 5.3: 
 
   ( )
2
2 2 bloodoutlet inlet
CO
m
CO CO Q
J
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− 
=  
Eq. 5.6 
 
Fig. 5.4: In vivo testing of SμM-PDMS devices with spacers. 
 
 Scanning Electron Microscopy (SEM) 
Two SµM were removed from each device, and each was broken into three representative pieces. 
These pieces were preserved for SEM through immersion in a fixative buffer for 48 hours. The buffer was 
composed of 3% glutaraldehyde (Sigma-Aldrich), 0.1 M sodium cacodylate (VWR), and 0.1 M sucrose in 
water. After 48 hours, the samples were washed twice with deionized water, and dehydrated through 10 
minute immersions in ethanol/water (v/v%) mixtures of 35%, 50%, 70%, 95%, and twice with 100% 
Peristaltic 
Pump 
Blood Flow 
From Pig 
Blood Flow 
To Pig 
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ethanol. The samples were dried overnight in air and then mounted on aluminum stubs for imaging using 
a Carl Zeiss Ultra 55 Field Emission Scanning Electron Microscope (Zeiss, Dublin, CA USA). Prior to 
imaging, the samples were sputter coated with gold. 
 RESULTS AND DISCUSSION 
 Oxygen Flux and Pressure Drop In Vitro 
Three oxygenator devices were assembled using four SµM each. The thickness of the center 
gasket was chosen to be 0.5 mm when uncompressed, making the channel height of the liquid flow path 
~0.45 mm when the devices were assembled. Each of the devices was tested with three conditions: 
without spacers, with fine spacers, and with coarse spacers. For each condition, two measurements were 
taken of the oxygen flux and hydraulic transoxygenator pressure drop at water flow rates of 10, 20, and 40 
mL/min. The measurements from all devices were averaged for each condition, and results are in Fig. 5.5. 
 
Fig. 5.5: (a) Transoxygenator pressure and (b) area-normalized flux of oxygenator with and without 
spacers. Bars indicate statistically significant difference in two-way ANOVA with Tukey post-hoc 
comparisons. 
 
Overall, the device without spacers demonstrated a pressure drop of 11-33 mmHg, while the fine 
spacers showed a range of 46-240 mmHg and the coarse spacers showed between 75-470 mmHg (Fig. 
5.5a). Compared to the no spacers condition, the presence of spacers strongly increased the hydraulic 
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pressure within the flow cells, mostly at higher water flow rates. For example, at 20 mL/min water flow, 
the pressure drops across the fine and coarse spacer conditions were 7.8 and 13 times greater, 
respectively, than without spacers. Given that the spacers present a physical obstruction to liquid flow in 
the channel, this elevated pressure drop would be expected by the Hagen-Poiseuille law. Additionally, the 
hydraulic pressure with coarse spacers was consistently higher than with fine spacers, though only 
statistically different at 40 mL/min. This result is consistent with the greater thickness of the coarse spacer 
mesh compared to the fine spacer mesh (Table 5.1).  
While the increased gas transfer is a clear benefit to using spacers, higher pressure drop has been 
thought to cause hemolysis throughout ECMO circuits. As such, most oxygenators are designed to 
minimize transoxygenator pressure. For example, the market-leading Maquet Quadrox Adult has a 
relatively low pressure drop of ~67 mmHg at a blood flow rate of 5 L/min – an adult’s typical cardiac 
output 27,220. However, some studies dispute that hemolysis is correlated with transoxygenator pressure 
drop, and other oxygenators show higher pressure drops of up to nearly 300 mmHg at adult cardiac output 
27. With the current SμM-PDMS oxygenator design, most test conditions showed less than 300 mmHg of 
pressure drop, although the water flow rates tested were only 10-40 mL/min. Should the SμM-PDMS 
oxygenator be expanded to a full-size device, multiple membrane channels would likely be arrayed in 
parallel to provide sufficient respiratory support. This would also reduce the pressure drop through each 
channel by distributing blood flow evenly. Until a full-size device is constructed, the pressure drop 
through each channel cannot be predicted. Still, testing spacer hemocompatibility in the current prototype 
SμM-PDMS oxygenator may indicate a full-size oxygenator with spacers would be a viable concept.  
In most cases, oxygen flux with either type of spacers was significantly increased compared to the 
no spacers condition, as assessed by two-way ANOVA with Tukey post-hoc analysis (Fig. 5.5b). 
Specifically, the fine spacers produced between 1.9-3.0 times greater oxygen flux, and the coarse spacers 
produced between 1.6-2.4 times greater flux. Though flux with the fine spacers was consistently higher 
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than with the coarse spacers, this difference was not statistically significant at any flow rate. Spacer 
meshes are known to create local vortices, which create convective “back mixing” and ultimately 
increased mass transfer 214. As such, both types of spacer meshes would be expected to increase mass 
transfer compared to the no spacers condition. The spacers are considerably different in all dimensions, so 
it is difficult to speculate which physical attributes led to both spacers yielding similar increases in mass 
transfer without computational modeling. Assuming these improvements, a SµM-PDMS oxygenator 
using spacers would need only half the surface area of a device without spacers. For example, a device 
with fine spacers would need only 0.57 m2 of surface area to completely support a 70 kg adult requiring 
~210 mL O2/min, while a no spacers device would need 1.3 m2 (Fig. 5.5) 157. Compared to the market-
leading Maquet Quadrox-i adult oxygenator with 1.8 m2 of surface area, a SµM-PDMS oxygenator using 
spacers would be less than one third of the size of the current standard of care.  
The spacers can be evaluated from a theoretical standpoint to understand any differences in 
spacer performance. Calculations below are based on methods from Schock and Miquel; all constants and 
variables can be found in. Essentially, using measurements of the spacer meshes’ overall thickness, mass, 
and volume, the effective Reynolds and Sherwood numbers through the channel can be calculated. 
Results from these calculations can be found in Table 5.3, using a water flow rate of 20 mL/min through 
one channel of the SµM-PDMS oxygenator (40 mL/min for the whole device). The Sherwood number of 
each spacer-filled channel represents the relative contributions of convection and diffusion to overall 
mass transfer, and may indicate which spacer type most strongly increases convective mass transfer in the 
oxygenator. Spacer thicknesses are already known from the manufacturer, and both the mass and volume 
of cut pieces of spacers were measured using a previously-described volume displacement method 164,218.  
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Table 5.2: Variables, geometric data of the SµM-PDMS oxygenator, and constants used in calculations. 
Geometric data applies to one channel of each device, and one membrane. 
Variable Units 
Flow Rate of Water (QH2O) m3 s-1 
Flow Rate of Gas (Qgas) m3 s-1 
Area-Normalized Flux (J) mL O2,STP min-1 m-2 
Oxygen Concentration ([O2]) mol L-1 
Pressure of CO2 (PCO2) mmHg 
Pressure of Sweep Gas at Outlet (Pgas,outlet) mmHg 
Volume Flow Rate of CO2 (
2CO
V ) m
3/s 
Volume Flow Rate of CO2 – Max (
2 ,maxCO
V ) m
3/s 
Data Units Value 
Channel Height (h) m 5 × 10-4 
Channel Length (l) m 8 × 10-3 
Channel Width (w) m 6.5 × 10-2 
Channel Volume (Vchannel) m3 2.60 × 10-7 
Membrane Area (Am) m2 7.53 × 10-4 
Constants Units Value 
Water Density (ρ) kg m-3 1000 
Water Dynamic Viscosity (µ) Pa s 8.90 × 10-4 
Water O2 Diffusivity at 20°C (DO2) m2 s-1 1.8 × 10--9 
   
Once the volume of each spacer ( spacerV ) is known, the porosity of the spacer in the channel ( ) 
can be calculated: 
 1
spacer
channel
V
V
 = −  
Eq. 5.7 
where channelV  is the volume of the overall channel. From calculations in Schock and Miquel, the porosity 
can be used to determine the effective area ( effA ), effective velocity ( effv ), and hydraulic diameter ( hd ) 
of the spacer-filled channel: 
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 effA w h =    
Eq. 5.8 
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Eq. 5.10 
where w is channel width [m], h is channel height [m], 
2H O
Q is volumetric flow rate [m3/s], and fd is the 
diameter of spacer filaments [m]. In this study, fd  is not known for either spacer. We have made an 
approximation of 2f spacerd h= , where spacerh  is the spacer height. Once the hydraulic diameter and 
effective velocity are known, the Reynolds number ( Re ) for the spacer-filled channel can be calculated: 
 Re
eff hv d

=  
Eq. 5.11 
By comparing Reynolds numbers of the spacer-filled channels, the relative amount of turbulence caused 
by the spacers can be assessed. Subsequently, through additional calculation of the Schmidt number, the 
Sherwood number can be determined to relate convective to diffusive mass transfer. The Sherwood 
number can be expressed as a correlation between Reynolds number and Schmidt number, depending on 
the particular geometry of the channel. Eq. 5.12 is the Leveque correlation for laminar flow in a 
rectangular channel without spacers, and Eq. 5.13 is a correlation from Schock and Miquel for a spacer-
filled channel. 
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Eq. 5.13 
   
 0.875 0.250.065ReSh Sc=  
Eq. 5.14 
Table 5.3: Results of theoretical calculations for Reynolds number and Sherwood number for spacer-
filled channels. Values for thickness, mass, and volume correspond to one cut spacer mesh. Values for 
effective area, effective velocity, and hydraulic diameter correspond to one channel of the SµM-PDMS 
oxygenator. 
Variable Units No Spacers Fine Spacers Coarse Spacers 
Spacer Thickness (hspacer) m --- 0.356 0.483 
Spacer Mass (mspacer) g --- 0.0504 0.0654 
Spacer Volume (Vspacer) m3 --- 1.06 × 10-7 1.14 × 10-7 
Porosity (ϕ) % 100 42.5 57.6 
Effective Area (Aeff) m2 4.00 × 10-6 1.21 × 10-6 2.22 × 10-6 
Effective Velocity (veff) m s-1 0.0833 0.276 0.150 
Hydraulic Diameter (dh) m 9.41 × 10-4 4.25 × 10-4 5.62 × 10-4 
Reynolds Number (Re) --- 78.4 58.6 42.1 
Schmidt Number (Sc) --- 557 557 557 
Sherwood Number (Sh) --- 13.6 20.4 15.3 
     
Based on the calculated values in Table 5.3, information about spacer performance can be 
gleaned. First, the low porosity of the spacers strongly reduces the effective cross-sectional area and 
hydraulic diameter of the channels. Notably, the fine spacer has a lower porosity than the coarse spacer 
despite its relative thinness, which further reduces these variables. Due to the reduced effective area, the 
effective velocities of the spacer-filled channels are higher than a channel without spacers, which leads 
directly to higher Reynolds numbers for the spacer-filled channels. The higher Reynolds numbers – 
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especially for the fine spacers – are consistent with the knowledge that spacers are known to create local 
zones of non-laminar flow. Finally, the theoretical Sherwood number for the fine spacer-filled channel is 
considerably higher than the no spacer and coarse spacer channels, which are somewhat close. Ultimately, 
these calculations indicate that the spacers increase the non-laminar flow within the channels, leading to 
increased convective mass transfer. While the fine spacer is thinner than the coarse spacer and does not 
completely fill the channel, its lower porosity results in even more non-laminar flow and higher 
convective mass transfer. This result may indicate that mesh density may play a larger role in mass 
transfer than mesh size, although more systematic study of many spacer mesh types would be needed to 
examine this question. Since the fine spacers also yielded a lower pressure drop than the coarse spacers, 
the fine spacers were expected to yield superior gas exchange and hemocompatibility results in vivo 
compared to the coarse spacers. 
 Hemocompatibility In Vivo 
The three devices with coarse, fine, and no spacers were connected to flowing, heparinized 
venous blood from the pig through a pump set to 20 mL/min. The 20 mL/min flow rate was chosen to 
maximize gas exchange, while preventing transoxygenator pressure in all devices from exceeding 300 
mmHg. After 40 minutes of blood exposure, blood was exiting one of the sweep gas channels in the 
coarse spacers device, indicating that one of the SμM-PDMS membranes may have broken. After 5 more 
minutes, the fine spacers device was leaking blood from the liquid channel gasket, likely due to occlusive 
clotting within the blood channel. Since both devices had shown blood leakage, they were removed from 
the circuit and saved for analysis. In this time, the device without spacers had not shown any signs of 
clotting, and flow was continued for a total of three hours. Blood gas readings were taken from only the 
device without spacers; raw data is in Table 5.4. Six total samples were taken: three at 20 mL/min, and 
three at 10 mL/min. After three hours, blood flow was discontinued, and the device was flushed with 
saline solution.  
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Table 5.4: Raw ABG data collected from no spacers device during in vivo experiment. Data is divided 
into pre- and post-device for the same time point. 
 Pre-Device Post-Device 
Flow Rate 
(mL/min) 
pH 
pCO2 
(mmHg) 
pO2 
(mmHg) 
HCO3- 
(mmol/L) 
SO2 pH 
pCO2 
(mmHg) 
pO2 
(mmHg) 
HCO3- 
(mmol/L) 
SO2 
20 7.37 51.8 52 29.9 0.85 7.373 45.3 52 26.3 0.85 
20 7.364 52.9 55 30.2 0.87 7.369 47 55 27.1 0.87 
20 7.363 53.3 60 30.3 0.89 7.365 48 59 27.4 0.89 
10 7.363 52.3 63 29.8 0.9 7.37 50.2 64 29 0.91 
10 7.362 54.6 66 31 0.91 7.372 48.1 74 27.9 0.94 
10 7.362 51 69 29 0.93 7.366 47.3 77 27.1 0.95 
           
 
 
Fig. 5.6: In vivo flux of O2 and CO2 in device without spacers. The bar indicates statistically significant 
difference in two-way ANOVA with Tukey post-hoc comparisons. 
 
 Measurements of O2 and CO2 flux taken from the device without spacers are in Fig. 5.6. 
Compared to the flux seen in vitro (Fig. 5.5), little to no O2 flux was seen with blood regardless of flow 
rate. Earlier data collected with a different SμM-PDMS oxygenator had demonstrated oxygen transport 
with blood, meaning that the low blood oxygenation may be exclusive to this experiment 143. In this 
experiment, the low O2 flux was likely due to the minimal sweep gas pressure that was used, since sweep 
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gas pressure is the primary driving force of oxygen into blood. Despite the low oxygenation, considerable 
CO2 removal was seen in the SμM-PDMS device, particularly at 20 mL/min. Given that CO2 removal is 
related to sweep gas flow rate, the high sweep gas flow rate relative to device size likely led to substantial 
CO2 transfer. In calculations by Federspiel and Hattler (1996), the sweep gas flow rate ( gasQ ) can be used 
to relate the measured CO2 gas exchange rate (
2CO
V ) and the theoretical maximum CO2 exchange rate (
2 ,maxCO
V ): 
 
 
2CO m
V J A=   
Eq. 5.15 
 
2 2
2 2
,
,max ,
1
2
CO COgas outlet
CO CO blood gas
V VP
V P Q
= −  
Eq. 5.16 
where ,gas outletP is the total pressure of gas at the sweep gas outlet of the device and 2 ,CO bloodP  is the 
measured partial pressure of carbon dioxide in the blood (Table 5.2) 221. Considering that the sweep gas 
was vented into the ambient air, ,gas outletP should be equal to atmospheric pressure. gasQ was set to 3 L/min. 
From Eq. 5.15 and Eq. 5.16, the calculated 
2 2 ,maxCO CO
V V  was 0.997 and 0.999 at blood flow rates of 20 
and 10 mL/min, respectively. These values indicate that CO2 removal was near the maximum possible 
with the oxygenator device, likely owing to the high gasQ flow rate. The SµM-PDMS membranes were 
able to sustain the high sweep gas flow rate without rupture, making the membranes suitable for use in a 
CO2 removal device. Based on the measured CO2 removal rate at 20 mL/min of blood flow, a total of 160 
mL CO2/min could be removed with only 0.12 m2 of membrane surface area representing 484 membranes 
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72. However, these calculations are only based on this current prototype device, and further design of a 
CO2 removal device using SµM-PDMS membranes would be required to optimize CO2 removal, blood 
flow rate, and surface area.  Ultimately, future experiments and iterations of the SµM-PDMS device 
would need to optimize O2 exchange in addition to ensuring high CO2 removal.  
 Examination of Devices 
Upon disassembly, the three devices were grossly inspected for evidence of thrombosis (Fig. 5.7). 
Both of the devices with spacers showed considerable clotting within and around the spacer meshes, 
particularly at the distal end of the spacers near the device outlet. One of the membranes in the coarse 
spacers device had broken, as was speculated during the experiment. It was possible that occlusive 
clotting in the channel could have led to a pressure buildup inside the flow cell, causing the membrane to 
break. As a comparison, the device without spacers showed no gross clots anywhere in the device, despite 
exposure to flowing blood for two additional hours. The membranes were removed from the flow cells 
and rinsed in PBS to dislodge any non-adherent blood cells prior to SEM preservation. No gross clots 
were visible on any of the membranes themselves.  
 
Fig. 5.7: Disassembled flow cells (a-c) and spacer meshes (d) after blood exposure 
 
a Inlet 
No Spacers 
b Inlet 
Coarse Spacers 
c Inlet 
Fine Spacers 
d 
Outlet Outlet Outlet 
Coarse Fine 
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Overall, the spacers are likely responsible for all gross clotting observed in each device, since the 
no spacers device showed no gross clots despite using the same flow path geometry and membranes. 
Furthermore, the variety of clot patterns in the spacer meshes indicates that multiple factors influenced the 
distributions of clots. Most obvious are the clots at the end of each spacer mesh, closest to the outlet. 
Clotting at this location could mean that thrombosis was likeliest at the interface between the spacer and 
the rest of the channel, or that clots formed upstream and collected at the end of the spacer. Smaller clots 
were indeed seen at the inlet interface of some of the spacer meshes. However, the larger size of the outlet 
clots indicates that the spacers likely collected clots that formed upstream. As seen in Fig. 5.4, the flow 
cells were arranged with the membranes perpendicular to the table surface, and one of the channels above 
the other. Due to this positioning, the spacers show evidence of gravitational clot settling. In Fig. 5.7d, the 
spacers show increased clot deposition on their left sides, which was the side closer to the table. 
Additionally, the spacer in the lower channel of each device – those on the left side of the two sets in Fig. 
5.7d – showed more clotting than the upper channel. Both patterns point to gravitational clot settling 
within the devices, and within the spacer meshes. 
In some of the spacer meshes, a banding pattern was observed going down the mesh from inlet to 
outlet. Particularly in the fine mesh on the furthest right of Fig. 5.7d, the clots appeared to be deposited in 
evenly spaced regions. One possibility is that these regions may have formed because of the pulsatile flow 
of the peristaltic pump. In unpublished experiments, we have observed similar bands of clotting in tubing 
exposed to pulsatile pump flow. We speculate that the pulsatile flow leads to waves of stagnancy, which 
leads to clot formation in periodic intervals. Likely, the same stagnation effect led to the similar banded 
clot pattern seen in some of the spacer meshes. However, the banded pattern was not significantly visible 
in the coarse spacer meshes. Given the larger mesh size, we speculate that any small clots in the coarse 
spacer mesh may have migrated away from where they formed, reducing the visibility of any clot 
 
 
106 
 
 
 
patterns. Comparatively, the banded pattern was not seen in the device without spacers, even though the 
device was exposed to the same pulsatile flow.  
 Scanning Electron Microscopy (SEM) 
 
Fig. 5.8: Example SEM micrographs of SµM post-blood exposure, taken at 500X magnification. Note 
that sample images from the coarse and fine spacers devices were selected to show regions where clots 
have formed, and are not necessarily representative of the overall surfaces. 
 
Under SEM, the SµM overall showed little deposition of clots, adhered cells, or adhered/activated 
platelets as seen in Fig. 5.8. Closer magnification showed that the surfaces all had an even layer of 
adsorbent proteins. In the no spacers device, the PDMS surface of the membranes showed only a few 
adherent non-erythrocyte cells. Considering the high hydrophobicity of PDMS, other studies have 
demonstrated considerable and platelet adhesion/activation on PDMS, even after similarly acute blood 
exposure. However, the incoming blood in this study was highly heparinized, likely preventing 
substantial platelet and cell adhesion. In both spacers devices, most SEM scans of the SµM showed little 
evidence of clotting on the surface, similar to the no spacers condition. Some scans showed clot formation 
on the surfaces, which were selected for Fig. 5.8. Although these scans are not representative of the 
overall surface, they do show some linear patterns of adhered cells, activated platelets, and fibrous protein 
deposition, likely where the spacer meshes were in contact with the surface. The image of the fine spacer 
membrane in particular shows a right angle intersection of multiple clots, indicating the shape of the 
mesh. In these regions on the membrane surface, the spacers may have perpetuated sufficient stagnation 
to form these clots. Considering that the vast majority of the SµM-PDMS surfaces showed little to no 
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clotting in any condition, it is likely that the membranes did not significantly contribute to the clot 
formation in the spacers devices. 
Although the spacers in this study may not be suitable for turbulence inducement in ECMO, other 
strategies that are less intrusive may be more successful. Imprinting a texture onto parallel plate PDMS 
membranes, such as in Femmer et al. 2015, has been shown to improve gas exchange in vitro without 
raising the pressure drop. As with other turbulence-inducing strategies, applying a texture to PDMS 
membranes may lead to localized blood stagnation and clotting. However, optimization of the texture 
geometry could mitigate these effects.  
 CONCLUSION 
In this work, two types of fluidic spacers were added to the SµM-PDMS oxygenator to evaluate 
impacts of the spacers on gas transfer efficiency and device hemocompatibility, with the overall goal of 
testing if turbulence inducement could benefit the SµM-PDMS oxygenator. Both types of spacers were 
shown to improve O2 exchange in water by at least 50%, and more than doubled oxygen flux under most 
test conditions. Though the spacers improved gas exchange, they also led to a significantly higher trans-
oxygenator pressure drop, which is often predicted to cause hemolysis and clotting in oxygenators. 
Theoretical analysis of the spacers showed that the spacers effectively increased the velocity of fluid 
through the oxygenator channels by decreasing hydraulic diameter, leading to more convective mass 
transfer with spacers.  
Once the spacers were put in contact with in vivo blood flow, the devices with spacers clotted 
within less than an hour of exposure, with some of the clot patterns indicating that stagnant zones may 
have formed due to pulsatile pump flow through the spacer meshes. Interestingly, no evidence of clotting 
was observed on the SµM-PDMS surfaces in any device, meaning that the spacers were likely responsible 
for the entirety of the clotting. Overall, the patterns of clots indicate that the spacers strongly reduced the 
hemocompatibility of the SµM-PDMS oxygenator, while the membranes and flow path design were 
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overall non-detrimental to hemocompatibility. ECMO systems are typically rated for a minimum of 6 
hours of use, and so the spacers as used in this study would be unsuitable for a full-scale device. 
In conclusion, the spacers are likely not a viable strategy for enhancing gas exchange efficiency 
in parallel plate microfluidic ECMO devices due to the high likelihood of thrombosis. However, 
turbulence generation can significantly increase gas exchange in vitro, and non-invasive methods of 
inducing convective flows may be valuable to PDMS oxygenators. Also, the SµM-PDMS membranes 
have shown considerable promise for a potential compact CO2 removal device. Future work will use the 
gas exchange measurements from the SµM-PDMS to continue developing a more advanced device for 
clinical gas exchange. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
 
 Current hollow fiber ECMO devices are unsuitable as a long-term lung replacement therapy due 
to a high risk of patient complications, restricting their use to only the most critically ill, bedbound 
patients with no other treatment options 9,150. The most common ECMO complications of thrombosis and 
bleeding stem from a lack of hemocompatibility throughout the large blood-contacting circuit. The 
complexity of pump-driven turbulent flow through the circuit – including the oxygenator – results in 
regions of stagnancy and uneven shear stresses, precipitating thrombosis. Additionally, to meet 
oxygenation and carbon dioxide removal needs, an adult-size oxygenator requires over 1 m2 of membrane 
surface. Beyond the high blood-contacting surface area, the membranes can become fouled over time due 
to protein and cell adhesion, leading to gradually reducing performance of the oxygenator over time 15. 
Ultimately, due to the cumbersome constraints on conventional ECMO, the therapy is unsuitable for most 
lung failure patients, especially in an ambulatory capacity. 
Since ECMO is not intended to be a destination therapy for lung failure, a clinical need exists to 
treat many chronically ill lung failure patients who require indefinite respiratory assistance. For these 
patients, an ambulatory lung supplementation device could be used as a long-term destination therapy or 
bridge to transplant, using a similar approach to ECMO oxygenation 6,14. Such a device would be ideally 
compact and pumpless to minimize thrombosis risk 52,222. Given the thrombosis risks with hollow fiber 
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oxygenators, another type of membrane oxygenator may be more suitable to create a long-term 
ambulatory device.  
This research work endeavors to implement a novel gas exchange technology – SµM-PDMS 
membranes – in the design of an ambulatory lung assistance device, optimized for gas exchange 
efficiency and hemocompatibility. In this pursuit, multiple approaches were used to improve the 
functionality of the SµM-PDMS oxygenator. First, different configurations of silicon membranes were 
characterized for mechanical strength and gas exchange capacity in order to determine the optimal 
platform for a robust, efficient oxygenator (Chapter 2). Following selection of SµM-PDMS membranes, 
oxygenator prototypes were developed to simulate and validate these membranes’ gas exchange 
performance, both in vitro and in vivo (Chapter 3). These in vivo experiments set an important 
performance benchmark for the SµM-PDMS oxygenator concept by characterizing blood-gas exchange 
through the membranes. Additionally, this data provided significant insight into the design elements that 
affected the implementation of SµM-PDMS membranes for gas exchange, and highlighted areas for 
future enhancement.  
Two optimization objectives were defined: hemocompatibility of the device flow path and the 
membrane surfaces, and gas exchange (both O2 and CO2) through the SµM-PDMS device. Since this 
work did not involve constructing a full-scale SµM-PDMS oxygenator, hemocompatibility refinement of 
the prototype device flow path was not significantly prioritized at this stage of development. To improve 
the hemocompatibility of the SµM-PDMS membrane surfaces, variations of a polyethylene glycol (PEG) 
coating was applied to silicon and PDMS surfaces using multiple liquid deposition protocols (Chapter 4). 
In vitro results indicated that, on silicon-PDMS composites specifically, no variation of the PEG coating 
yielded a stable antifouling coating. While thick multilayers of PEG (~15-20 nm) were highly effective at 
deterring protein fouling on cast PDMS, these benefits may have been observed due to instability of the 
coatings on cast PDMS specifically. In Chapter 5, convective mixing was introduced into the flow path of 
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a newer prototype SµM-PDMS device in order to increase oxygen and carbon dioxide exchange, thereby 
enabling the design of a more compact oxygenator. Placement of mesh spacers in the liquid flow channels 
increased oxygen flux up to threefold in vitro, but caused occlusive thrombosis within the devices upon 
acute exposure to flowing blood.  
Continuing from this early work with the functional coatings, further experiments are necessary to 
fully characterize and implement the coatings on SµM-PDMS membranes. Much effort is still required to 
establish the impacts of the coatings on gas exchange and hemocompatibility with more rigorous in vitro 
and in vivo testing, assuming that the difficulties with in vivo testing can be addressed. If a biomolecule 
coating is selected, such as hyaluronic acid, additional experiments will be required to evaluate the 
coatings’ stability and sterilizability prior to usage on a large-scale SµM-PDMS oxygenator. Any impact 
of the selected coating on O2 or CO2 exchange through the membranes should be factored into the scaling 
of the full-size SµM-PDMS oxygenator. Beyond using the functional coatings specifically on the SµM-
PDMS membranes, future work on the coatings could more deeply investigate the mechanisms by which 
the coatings impact gas exchange. Examining the interactions between the coatings and blood buffering 
systems could explain functional benefits of the coatings, and open up the possibilities for functional 
coatings on other medical devices.  
While the spacer meshes may not have been a viable option for a SµM-PDMS oxygenator, this 
study still justifies the need to improve gas exchange in an oxygenator through disruptive mixing. The 
addition of mixing in laminar flow blood channels could potentially reduce oxygenator size to a fraction 
of that of current hollow fiber devices, should thrombosis risk be mitigated. Through iterative 
optimization, future work can develop another type of thrombosis-minimizing mixer by reducing stagnant 
zones and controlling shear stress throughout the flow path. These structures can be simultaneously 
evaluated for improved gas exchange, ideally producing a mixing structure that meets both criteria. One 
potential solution could involve embossing mixing structures directly onto the membrane surfaces, 
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promoting mixing at the boundary layer region itself. Since the membrane surfaces are made of PDMS, 
soft lithography could be used to pattern a variety of structures onto the membrane surfaces, as described 
in other works 123,223. Usage of these structures throughout a SµM-PDMS oxygenator could significantly 
reduce the membrane area and overall device size required for scale up to a full-size oxygenator. 
Moving forward, development on the functional coatings and convective mixing can be leveraged 
to create a full-scale oxygenator capable of acting as a long-term lung assistance device. To prepare for 
scale up, mass transfer modeling and experimental validation can establish the ideal dimensions of a 
SµM-PDMS oxygenator. Using methods from Chapter 2 and Chapter 3, continuing experimental work 
can focus on arranging multiple membranes in various series and parallel configurations, with the goal of 
determining the effects of channel geometry on gas exchange and pressure drop. Any alterations to gas 
exchange from functional coatings or mixing structures can be factored into calculations of final device 
size. Once a final device geometry has been conceived, the SµM-PDMS can be stacked into an array of 
multiple membranes, achieving the required surface area for sufficient gas exchange. Using 
computational modeling, a manifold can be designed to house this membrane array and minimize 
thrombosis risk throughout the blood flow path. Finally, this full-scale oxygenator can be evaluated for 
gas exchange and hemocompatibility in a large-scale animal model, with the overarching goal of 
assessing its suitability as a long-term lung assistance therapy. 
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APPENDIX 
A.1. FUNCTIONAL OXYGENATOR COATINGS FOR IMPROVED GAS EXCHANGE AND 
HEMOCOMPATIBILITY 
Work in this chapter is ongoing and incomplete at the time of writing. This write up was included as an 
appendix for completeness. 
 
 INTRODUCTION 
ECMO oxygenators have been constructed out of a variety of materials throughout their history, 
with certain material properties being particularly desirable for this specific application. First, the material 
must be sufficiently permeable to both O2 and CO2 gases to ensure that the oxygenator membranes can 
perform with maximum efficiency and minimum surface area. Liquid tightness is highly important to the 
blood oxygenator to prevent both gas emboli from forming in the blood, and plasma leakage into the 
sweep gas compartment. In addition, hemocompatibility of the material is essential to both prevent 
thrombus formation through platelet activation, and performance-reducing fouling of the membranes 
through protein adsorption. Furthermore, mechanical robustness is a significant concern to prevent 
membrane rupture; however, multiple materials can be used in a composite to reinforce a material that has 
insufficient mechanical strength on its own. 
Some of the most common materials used in blood oxygenators are silicones because they feature 
high gas permeability to both O2 and CO2, biological inertness, and complete liquid tightness. 
Historically, silicone membranes were used as the basis for early parallel plate oxygenators 54,212,216,224, 
and subsequently silicones were used as coatings on porous hollow fiber oxygenators to prevent plasma 
leakage 26,217. More recently, research groups have constructed microfluidic capillary-like oxygenators 
using a silicone known as polydimethylsiloxane (PDMS), which has been extensively studied as a 
biomaterial in many applications 55,109,120,225. Similarly, our lab has developed novel membranes for blood-
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gas exchange, based on the MEMS manufacturing of silicon from the integrated circuits industry. We 
have designed a composite membrane consisting of a silicon membrane surmounted with a 5 µm thick 
layer of PDMS; this structure is completely liquid-tight, and mechanically highly robust despite the 
thinness of the PDMS layer 143,160.  
Still, while silicones such as PDMS can be desirable for blood oxygenators, they are also 
susceptible to significant blood reactivity. PDMS and other silicones are bioinert but naturally 
hydrophobic, meaning that they attract significant adhesion of proteins – including fibrinogen – to the 
surface. Over time, adhesion of proteins to membranes reduces performance through fouling, and may 
also trigger platelet activation and eventually thrombus formation 183,226,227. As such, surface modification 
of silicones is necessary for use in blood oxygenators. Through silane bonding chemistry, PDMS can be 
modified to have a variety of surface properties, especially hydrophilic or ionically charged groups, in 
order to reduce biofouling and thrombogenicity. Specifically for blood oxygenation, coatings that have 
been studied on PDMS include polyethylene glycol (PEG), zwitterionic polymers such as sulfobetaine, 
and endothelialization of the surface 124–127,180,227. These coatings are often successful at stably improving 
hydrophilicity of PDMS, and reducing protein fouling and platelet responsiveness. Still, on an 
oxygenator, these coatings must demonstrate that they do not impede the transport of O2 and/or CO2 
through the membranes, which most researchers on PDMS oxygenators have not addressed. 
Research on hollow fiber ECMO devices can inform future work on coatings for silicone-based 
oxygenators, though generally these studies are limited. In some cases, coatings on hollow fibers have 
significantly reduced the gas permeability through the membranes, especially for endothelialized hollow 
fibers 89. Other studies on polymeric coatings, such as zwitterionic coatings, have shown no change in 
permeability with the application of the coating 228. Interestingly, one particular coating on hollow fiber 
membranes was shown to significantly increase the removal of CO2 from blood. In work by Arazawa, et 
al., researchers covalently attached the enzyme carbonic anhydrase to the surfaces of hollow fibers 73; 
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physiologically, carbonic anhydrase maintains the buffering equilibrium between bicarbonate ion [HCO3]- 
and CO2 in blood. Along with the enzyme coating, a sweep gas containing sulfur dioxide (SO2) was 
introduced into the system, causing dissolved sulfites to enter the bloodstream. Through lowering the pH 
of the blood local to the membrane surface, the balance between [HCO3]- and CO2 shifted in favor of 
dissolved CO2, which was increasingly driven out of the blood. Ultimately, the acidic sweep gas and the 
enzyme coating worked synergistically to drive increased CO2 out of the bloodstream by interfering with 
the blood buffering system for CO2. This phenomenon, known as local acidification, demonstrates that 
the blood nearest to the membrane surface can strongly influence the gas permeability of the overall 
membrane. Interfering with the blood chemistry at this local level may provide options for improving gas 
flux through any type of oxygenator. 
The purpose of this work is to apply biomolecule-based coatings to the surfaces of PDMS 
membranes intended for use in a blood-gas exchange device. Through chemical interactions between the 
coatings and the blood, these coatings were intended to both improve the hemocompatibility of the 
hydrophobic PDMS, and enhance gas exchange of O2 and/or CO2 through the membranes. In this study, 
we applied an amine precursor coating, and subsequently attached a number of biomolecule coatings on 
PDMS. We then characterized their effects on hydrophilicity and in vitro oxygen permeability, over the 
course of two major experiments. The coated membranes were then exposed to an in vivo porcine blood 
oxygenation circuit to determine the effects of the coatings on O2 and CO2 gas exchange. Post-analysis of 
adhered proteins and activated platelets was conducted to determine if the coatings had a beneficial effect 
on membrane hemocompatibility. Results are documented by individual experiment. Using these 
findings, we determine which, if any, of the coatings would be desirable on a blood-gas exchange device 
using PDMS as a membrane material. 
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 MATERIALS AND METHODS 
 Substrates and Precursor Coatings 
A.1.2.1.1 Substrates 
Silicon micropore membranes, abbreviated as SµM, were prepared for use as gas exchange 
membranes following prior work in this lab 143,160. Briefly, SµM are created using silicon MEMS 
fabrication processes to yield flat-sheet membranes with highly organized, uniform pores. The membrane 
pores in this study were 1 µm in width. A 5 µm-thick layer of polydimethylsiloxane (PDMS) was formed 
from spin-coated Sylgard 184 PDMS (Dow Corning, Midland, MI, USA) mixed at a 10:1 elastomer-to-
crosslinker ratio, and then diluted 1:1 with hexanes (Millipore Sigma, Burlington, MA, USA) as 
described in prior work. Each SµM was bonded with PDMS through oxygen plasma treatment to yield the 
final membrane structure. These Si-PDMS membranes have been characterized in past work as both 
highly gas-permeable and structurally rigid – important qualities for designing a compact, efficient 
oxygenator. 
Two additional substrates were created as materials controls for the Si-PDMS membranes. The 
first substrate (“Si”) consisted of 1 cm2 pieces of silicon cut from 400 µm-thick double side polished, p-
type wafers. The second substrate (“PDMS”) consisted of undiluted Sylgard 184 PDMS mixed at a 10:1 
elastomer-to-crosslinker ratio, which was cast into a 3 mm-thick sheet and cut into 1 cm2 discs. Together, 
the Si-PDMS membranes and additional materials controls became the substrates for subsequent 
application of the biomolecule coatings. 
A.1.2.1.2 Aminosilane Precursor Application 
Prior to aminosilane application, all glassware was dried overnight in a 100°C oven. The 
aminosilane precursor was then applied to the surface of all substrates via silane bonding chemistry. The 
specific aminosilane chosen was N1-(3-Trimethoxysilylpropyl)diethylenetriamine, abbreviated as 
“DETA” (Millipore-Sigma). First, the substrates were treated with oxygen plasma (Harrick Plasma PDC-
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001, Harrick Plasma, Ithaca, NY, USA) for 1 minute at high power (~30 watts) to produce reactive silanol 
groups on the surfaces. A solution of 5% DETA in anhydrous N,N-Dimethylformamide (DMF) was 
prepared (Millipore-Sigma). After activation, each substrate was individually placed into a reaction 
vessel: Si-PDMS membranes into 15 mL polypropylene conical tubes, and Si and PDMS substrates into 
20 mL glass scintillation vials. 8 mL of DETA solution was added to the Si-PDMS membrane vessels, 
and 2 or 3 mL of the solution was added to the Si and PDMS vessels respectively. The reaction vessels 
were placed on a shaker and gently agitated for 3 hours at room temperature. Following the reaction, all 
substrates were washed 6 times: twice with DMF, twice with 1:1 DMF and methanol (VWR, Radnor, PA, 
USA), and twice with methanol. Substrates were dried in a desiccator overnight.  
A.1.2.1.3 Poly(acrylic acid) (PAA) Immobilization 
Prior to functionalization, poly(acrylic acid) (PAA) was modified to enable use in organic solvent 
systems. Poly(acrylic acid) sodium salt (3 g) was dissolved in 300 mL of deionized water. Following 
dissolution of polymer, HCl (3M) was added dropwise until pH of the solution reached 1, as monitored 
with litmus paper. This solution was stirred overnight at RT to allow the acidification of PAA (COO-Na 
to COO-H) to reach equilibrium. Following acidification of PAA, the reaction mixture was added 
dropwise to cold ethanol (500 ml) to precipitate the NaCl. Salt precipitate was filter by vacuum filtration, 
and the solvent was reduced by rotary evapoation until all ethanol was removed. Then water was removed 
by lyophilization and the product (white precipitate) was stored in a dry environment to prevent 
contamination of moisture.  
To tether PAA to the aminated surface, 2 g of PAA (0.27 mol) was dissolved in 100 mL of 
anhydrous DMF at 70 C, then once dissolved 5.7 g of O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium (HATU) (Thermo Fisher Scientific, Waltham, MA, USA) and 3 ml of DIPEA were 
added to the reaction solution and allowed to react for 30 minutes. HATU and DIPEA are amide coupling 
reagents which activate the carboxylate groups on PAA. After activation of PAA, the solution was added 
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to reaction vials containing the aminated substrates which reacted for at least 12 hours. Once finished the 
reaction solution was decanted and the substrates were thoroughly washed in excess solvent: twice with 
DMF, twice with 1:1 DMF:methanol, and twice with methanol. Thorough washing of the substrates with 
the reaction solvent is necessary to prevent deposition of reactants, which can be difficult to remove if 
formed. Substrates were then dried under vacuum and store in a desiccator until further reaction steps. 
 Secondary Reactions 
A.1.2.2.1 Hyaluronic Acid Application 
Hyaluronic acid (HA) was attached directly to the DETA-coated surfaces via EDC-NHS 
chemistry. 250 mg of HA (1.5-1.8 10E6 kDa, Millipore-Sigma) was dissolved in 50 mL MES buffer (50 
mM, pH 5.5) to reach a final concentration of 5 mg/mL. The pH was adjusted with 1 M HCl to keep the 
solution at pH 5.5. Next, while stirring, 95.0 mg N-(3-Dimethylaminopropyl)-N'-ethylcarbodi-imide 
Hydrochloride (EDC, 0.50 mmol) (Thermo Fisher Scientific) and 12.0 mg N-Hydroxysuccinimide (NHS, 
0.10 mmol)  were added to the HA solution to activate the carboxylate side chains, which can then react 
with the primary amines on the substrates. This solution was reacted for 30 minutes. In parallel, the 
freshly silanized substrates were incubated in PBS (pH 7.4) for 30 minutes to partially deprotonate the 
amine groups: 1 mL for Si substrates, 2 mL for PDMS substrates, and 12 mL for Si-PDMS membranes. 
After activation, the same amounts of the HA solution were added to the pretreated substrate reaction 
vials and allowed to react overnight while stirring. The samples were then washed in 6 cycles of excess 
solvent to remove the unreacted HA/EDC/NHS: twice with MES Buffer pH 5.5, twice with deionized 
water, and twice with methanol. Then were subsequently dried under vacuum overnight and stored in a 
desiccator prior to characterization. 
A.1.2.2.2 L-Histidine and Lysine Attachment to PAA 
Histidine and lysine were modified for use in organic solvents to facilitate attachment to PAA. L-
Histidine hydrochloride (Thermo Fisher Scientific) was purified using the same procedure as PAA. 
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To prepare the lysine for modification of PAA, the BOC protecting group of the lysine (Fmoc-
Lys(Boc)-OH) was deprotected to free up the epsilon amine for further reactions. 1 g/21 mmol of Fmoc-
Lys(Boc)-OH was dissolved in 25 mL of anhydrous DCM under stirring at 0°C. Second, 2.6 mL of 
trifluoroacetic acid (TFA) was added drop wise to the reaction mixture and allowed to react for 12 hours 
to remove the BOC protecting group. The reaction was then purified by rotary evaporation to remove the 
solvent and TFA salt byproducts. To achieve complete removal of TFA byproducts, the product was 
washed with dichloromethane and methanol two times. 
 Coating Characterization 
A.1.2.3.1 Contact Angle – Wettability 
Contact angle was used to assess successful application of the coatings at various stages of 
application (Fig. A. 1.1a). Changes to the contact angle after applying a coating would indicate if surface 
modification had occurred. Sessile drop measurements using deionized water were recorded for each 
sample using a Biolin Scientific Theta Lite optical tensiometer (Stockholm, Sweden) with OneAttension 
software 141. Additional characterization via colorimetric staining for amine content (Coomassie staining, 
Fig. A. 1.1b) and carboxyl content (Toluidine Blue), as well as x-ray photoelectron spectroscopy, was 
conducted. However, these datasets were incomplete and therefore not included in this analysis. 
 
Fig. A. 1.1: In vitro testing methods for biomolecule-coated membranes: (a) contact angle for wettability, 
(b) Coomassie staining and destaining for amine content analysis, and (c) in vitro oxygen flux testing. 
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 Gas Permeability and Hemocompatibility Evaluation 
A.1.2.4.1 Oxygen Flux In Vitro 
Following methods described in Abada, et al. (2018) 160, Si-PDMS membranes with each coating 
were evaluated for oxygen flux in an in vitro testing system (Fig. A. 1.1c). Briefly, deoxygenated water 
was pumped through a flow cell containing a single membrane, with oxygen sweep gas supplied to the 
opposite side of the membrane at a constant gauge pressure of 260 mmHg. Changes in oxygen 
concentration of the water as measured in µmol/L are detected by an optical oxygen probe (NeoFoxGT 
with FOSPOR probe, Ocean Optics, Dunedin, FL, USA) before and after the sweep gas is supplied ( 2 iO
and  2 fO , respectively). Three measurements were taken with each membrane at water flow rates 
varying from 5, 10, 20, 40, and 60 mL/min. Using measurements of  2 iO and  2 fO , the area-normalized 
flux (J, mL O2/min/m2) was determined with a conversion of 22.4 L O2/mol at STP: 
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Eq. A. 1.1 
where Q is the flow rate of water in mL/min and Am is the porous area of the membrane in m2. Through 
calculation of the area-normalized flux, the relative oxygen flux of each coating can be compared to 
determine if coating application compromises gas transport efficiency.  
Experiment 1 
The coatings tested in this experiment were unmodified PDMS, PAA-Lys, HA, and PAA-His. 
Membranes with these coatings were evaluated for O2 flux individually at water flow rates of 5 and 10 
mL/min. These flow rates were chosen to mimic previous studies on silicon membranes 143,160. Then, two 
membranes of a single coating were mounted into a parallel plate flow cell for in vivo use (Fig. A. 1.2). In 
this experiment, the membranes were mounted into a parallel plate flow cell as labeled in Fig. A. 1.2a, 
 
 
121 
 
 
 
with both membranes located on the same face of the device. Due to insufficient numbers of membranes, 
two materials controls without pores – unmodified silicon and unmodified Si-PDMS – were mounted on 
the opposing face of the device, with Si-PDMS at the inlet and Si at the outlet. This meant gas flow would 
only occur through the face of the device containing membranes. In this experiment, the coatings were 
only evaluated individually, and not in the assembled devices. 
Experiment 2 
The coatings tested in this experiment were unmodified PDMS, DETA, HA, Hemin, PAA alone, 
PAA-His, and PAA-Arg. Compared to Experiment 1, the inclusion of DETA and PAA alone ensured that 
the effects of these intermediates would be evaluated. Since sufficient membranes were available, four 
membranes with these coatings were tested individually at water flow rates of 10, 20, 40, and 60 mL/min. 
These flow rates were chosen to both encompass past in vitro data on silicon membranes at 10 mL/min, 
and also the possible flow rates that would be used in the in vivo experiment. Then, with the exception of 
PAA alone, the four membranes were assembled into the parallel plate flow cell seen in Fig. A. 1.2. When 
assembled with four membranes, the device effectively positions two Si-PDMS membranes in series, and 
two more membranes in opposition. The oxygen flux through this entire assembled devices were then 
evaluated at water flow rates of 20, 40, and 60 mL/min.  
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Fig. A. 1.2: Assembly of 4-membrane parallel plate flow cell used for in vitro and in vivo testing. (a) 
shows a diagram of the exploded flow cell, and (b) shows the assembled flow cell. 
 
A.1.2.4.2 In Vivo Gas Exchange and Hemocompatibility 
For both in vivo studies, devices with the coatings were were evaluated for O2 and CO2 flux and 
hemocompatibility using an in vivo porcine model (~40 kg Yucatan minipig). Circuit setups for both 
experiments are in Fig. A. 1.3. By exposing the coatings to flowing blood, the functional impact of the 
coatings on gas exchange could be determined, as well as the hemocompatibility of the modified surfaces. 
The general procedure for both of the in vivo studies was as follows. Under general endotracheal 
anesthesia, a 15-French dialysis catheter (Arrow Cannon II, Teleflex, Wayne, PA USA) was inserted into 
the left external jugular vein using Seldinger technique, with the tip positioned at the cavoatrial junction. 
Heparin (100 U/kg) was administered intravenously and serially re-dosed to achieve ACT>300. At the 
beginning of each experiment, the pig was ventilated through a mechanical ventilator, supplied with 
100% O2. Near the beginning of each experiment, ventilation was removed and paralytics were 
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administered to prevent natural breathing. The pig was then ventilated by hand with room air to lower the 
pig’s venous O2 saturation to achieve slight hypoxia (SO2 ~70%). The venous and arterial ports of the 
catheter were then attached to a closed flow circuit consisting of Tygon tubing (Masterflex L/S 25 Tygon 
E-LFL, Cole-Parmer, Vernon Hills, IL USA), divided into multiple channels (three for Experiment 1 and 
four for Experiment 2), and then passed through a peristaltic pump to control blood flow rate at 20 
mL/min. Downstream of the peristaltic pump, each oxygenator device was connected to one of the blood 
flow channels, and flow from each channel was rejoined to return blood flow to the catheter. The circuit 
was primed with isotonic crystalloid solution prior to establishing blood flow. Three-way stopcocks were 
inserted in the Tygon tubing at the inlet and outlet of each oxygenator device to allow blood sample 
collection before and after exposure to the oxygenator’s membranes.  
Heparinized blood was flowed through the devices over a period of 2-4 hours, during which 
samples were taken from the inlet and outlet of each device. Blood gas analysis was conducted on these 
samples to assess pO2, pCO2, pH, and HCO3- using either an arterial blood gas machine (GEM3000, 
Instrumentation Laboratory, Bedford, MA, USA) or an iSTAT handheld blood analyzer (Abbott Point of 
Care Inc., Princeton, NJ, USA). After sufficient samples were collected, the devices were flushed with 
saline and then disassembled. The devices were grossly inspected for clots, and the membranes were 
removed, broken into pieces, and added to fixation buffers for hemocompatibility analysis. The 
experiment was conducted at a contract resource organization (PMI Preclinical, San Carlos, CA).  
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Fig. A. 1.3: Set up of in vivo gas exchange circuits for experiments 1 and 2. Devices in (a) from top to 
bottom: Lys, HA, His. Devices in (b) from top to bottom: unmodified PDMS, HA, Hemin, and PAA-His. 
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The area-normalized flux of O2 and CO2 through the membranes was calculated from the ABG or 
iSTAT readings at the inlet and outlet of each device. Inlet and outlet O2 content ( 2O , mL O2/mL 
blood) was calculated as in Dharia, et al (2017)143:   
  2 2 21.36 0.0031O Hg SaO PaO=   +   
Eq. A. 1.2 
 where Hg  is the hemoglobin of the blood (mg/mL), 2SaO   is the percent of hemoglobin bound to 
oxygen, and 2PaO  is the partial pressure of oxygen in the blood (mm Hg). Similar to Eq. A. 1.1, the 
area-normalized flux of O2 (
2O
J , mL O2/min/m2) is calculated by: 
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Eq. A. 1.3 
where Qblood is the flow rate of blood and Am is the porous area of the membrane. The calculation of CO2 
flux – described in Douglas et al. (1988) – accounts for CO2 stored as a dissolved gas (pCO2), as 
bicarbonate ion (HCO3-), and bound to hemoglobin 219. First, inlet and outlet CO2 concentration in plasma 
( 2 plasmaCO , mL O2/mL blood) is calculated using the logarithmic form of the Henderson-Hasselbalch 
equation for plasma CO2: 
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Eq. A. 1.4 
where s (plasma CO2 solubility) and pK' (apparent pK) are known constants equal to 0.0307 mM 
CO2/mmHg CO2 and 6.0907, respectively. The inlet and outlet CO2 concentrations in blood ( 2 bloodCO , 
mL O2/mL blood) are then calculated using the McHardy-Visser equation: 
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Eq. A. 1.5 
where SO2 is the oxygen saturation of blood. The values of  2 bloodCO are used for the inlet and outlet 
content of blood CO2. Finally, the area-normalized CO2 flux (
2CO
J , mL CO2/min/m2) is calculated as in 
Eq. A. 1.3: 
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Eq. A. 1.6 
 
Experiment 1 
 Three of the coatings – HA, Lysine, and Histidine – were tested for O2 and CO2 flux, and 
hemocompatibility.  In this experiment, two membranes with the same coating were mounted on the same 
side of the parallel plate device, and two materials controls (Si and Si+PDMS) were mounted on the 
opposing side as described above. Set up of the circuit is shown in Fig. A. 1.3a. 
Blood was flowed through the circuit at a rate of 20 mL/min. Oxygen sweep gas was supplied to 
each device at a flow rate of 3 L/min between all devices and at a gauge pressure of 150 mmHg. Before 
taking measurements, blood was flowed through the circuit for one hour to stabilize the pig’s ventilation 
status. After the pig’s ventilation was stabilized, four samples were taken from the inlet and outlet of each 
device for blood gas analysis After two total hours of blood flow, the devices were flushed with saline 
and disassembled.  
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Experiment 2 
Four of the coatings – PDMS alone, HA, Hemin, and Histidine – were evaluated for O2 and CO2 
flux, and hemocompatibility using an in vivo porcine model (40 kg Yucatan minipig). In this experiment, 
four membranes of a single coating were mounted into a parallel plate flow cell (Fig. A. 1.2a). Set up of 
the circuit is shown in Fig. A. 1.3b.  
After one hour of extracorporeal blood circulation at 20 mL/min without oxygenation, flowing 
oxygen sweep gas was supplied at a flow rate of 3.5 L/min divided between all four devices, and gauge 
pressure of 220 mmHg. Five blood samples were taken from the inlet and outlet of each device for blood 
gas analysis to assess pO2, pCO2, pH, and HCO3- using either an arterial blood gas machine (GEM3000, 
Instrumentation Laboratory, Bedford, MA, USA) or an iSTAT handheld blood analyzer (Abbott Point of 
Care Inc., Princeton, NJ, USA). After nearly four hours of blood exposure, the devices were flushed with 
saline and disassembled. 
A.1.2.4.3 Scanning Electron Microscopy (SEM) 
After the porcine blood flow experiment, one fragment sample from each membrane was imaged 
for cell, platelet, and protein adhesion using scanning electron microscopy (SEM). Samples were placed 
in a solution of 3% glutaraldehyde (Millipore Sigma), 0.1 M sodium cacodylate (VWR), and 0.1 M 
sucrose (Millipore Sigma) at 4°C for 48 h. Then, the samples were washed twice with deionized water, 
and dehydrated by sequential 10 minute incubations with 35%, 50%, 70%, 90%, and two 100% 
ethanol/water (v/v%) solutions. The samples were dried in a desiccator overnight and mounted with 
conductive silver paint to aluminum SEM stubs. Finally, the samples were sputter coated with 4 nm of 
gold and imaged using a Carl Zeiss Ultra 55 Field Emission Scanning Electron Microscope (Zeiss, 
Dublin, CA, USA). 
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A.1.2.4.4 Platelet Immunohistochemistry (IHC) 
Fluorescent immunohistochemistry (IHC) staining was only performed on samples from 
Experiment 2. Two membrane fragments from each coating set were imaged for platelet adhesion and 
activation using fluorescent staining of CD-41 (platelet identification marker) and CD-62p (platelet 
activation marker). Samples were placed in a 4% paraformaldehyde (Thermo Fisher Scientific) solution at 
4°C until imaging (~2 weeks). The samples were washed and incubated with for an hour each with FITC-
labeled anti-CD41 (orb181793, Biorbyt, Cambridge, UK) and Cy3-labeled anti-CD62p (bs-0561R-Cy3, 
Bioss Inc., Woburn, MA, USA). Samples were rinsed and imaged using a Nikon TI-E microscope (Nikon 
Instruments, Melville, NY, USA).  
A.1.2.4.5 Statistical Analysis 
For the Si-PDMS membranes, contact angle measurements were taken of at least three 
membranes, and each membrane was measured in three locations. A minimum of three sample 
measurements was taken for the Si and PDMS substrates in the contact angle, Coomassie staining, and 
TBO staining experiments. In vitro area-normalized flux was measured for four membranes of each 
coating. Statistical significance was determined using Graphpad Prism 8.2.0 (San Diego, CA, USA). 
Contact angle measurements were analyzed through one-way ANOVA. Tukey post-hoc tests were used to 
determine statistical difference (p < 0.05) between different coating conditions on the same substrate. 
Area-normalized flux was analyzed through two-way ANOVA for all flow rates and coating groups. 
Tukey post hoc tests were used to evaluate significant difference (p < 0.05) for all coating groups at the 
same flow rate, and for the same coating at different flow rates.  
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 RESULTS 
 Coating Characterization 
A.1.3.1.1 Contact Angle 
Experiment 1 
 Measurements (average ± SD) of contact angle after coating application on each substrate from 
Experiment 1 can be found in Fig. A. 1.4. The unmodified substrates showed similar contact angles to 
prior work in this lab: Si at 30.6° 141, Si-PDMS at 93.0°, and PDMS at 105°. In examining Si-PDMS 
specifically, DETA application did not alter the hydrophobicity of the surface. Once the coatings were 
applied on top of DETA, the HA and PAA-His coatings did significantly decrease the contact angle of the 
surface, with no difference between the two groups. PAA-Lys, on the other hand, did not significantly 
alter the contact angle of Si-PDMS. Compared to Si-PDMS, the Si material control showed a significant 
increase in contact angle with DETA application, while the PDMS material control showed no change in 
contact angle with DETA. On both materials controls, HA and PAA-His application on top of DETA 
significantly decreased contact angle in a manner similar to the Si-PDMS group. Also, PAA-Lys 
application on DETA for both materials controls remained hydrophobic compared to the other two 
biomolecule coatings. 
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Fig. A. 1.4: Contact angle of biomolecule coatings on Si-PDMS membranes and Si and PDMS materials 
controls for Experiment 1. Significant difference (p < 0.05) is indicated above the columns: difference 
from the unmodified substrate is shown by (a), DETA shown by (b), HA shown by (c), and PAA-His 
shown by (d). 
 
Experiment 2 
Measurements (average ± SD) of contact angle after coating application on each substrate from 
Experiment 2 can be found in Fig. A. 1.5. As in Experiment 1, all unmodified substrates showed similar 
contact angles to prior work in this lab: Si at 30.6°, Si-PDMS at 92.8°, and PDMS at 105°. Focusing on 
the Si-PDMS membranes, data showed only a slight difference in wettability with DETA application on 
the unmodified material, with both substrates remaining strongly hydrophobic 229. However, the Si-PDMS 
showed significantly decreased contact angle with application of HA, PAA alone, and PAA bound to His 
(PAA-His). PAA bound to Arg (PAA-Arg) showed no difference from DETA alone, though more 
hydrophilic than the unmodified Si-PDMS. The Hemin coating did not significantly change wettability 
from the unmodified substrate, remaining strongly hydrophobic. The PDMS material control most of the 
same wettability trends as the Si-PDMS membranes, most notably significantly improved wettability with 
application of HA, PAA alone, PAA-His, and PAA-Arg. The Si material control exhibited different 
wettability changes than the Si-PDMS and PDMS substrates. DETA significantly increased contact angle 
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compared to unmodified Si, similar to values in prior literature 230. All coatings on Si except HA remained 
more hydrophobic than the unmodified material: PAA-based coatings significantly reduced 
hydrophobicity from DETA alone, while Hemin was as hydrophobic as DETA. 
 
Fig. A. 1.5: Contact angle of biomolecule coatings on Si-PDMS membranes and Si and PDMS materials 
controls for Experiment 2. Significant difference (p < 0.05) is indicated above the columns: difference 
from the unmodified substrate is shown by (a), DETA shown by (b), HA shown by (c), Hemin shown by 
(d), PAA shown by (e), and PAA-His shown by (f). 
 
Experiments 1 and 2 
Between both Experiments 1 and 2, results from all three substrates indicate that DETA 
application likely caused the wettability of all substrates to converge to a certain contact angle, with an 
increase in hydrophobicity of Si and slight decreases in Si-PDMS and PDMS. Of the biomolecule 
coatings, HA was consistently the most hydrophilic of the coatings, with PAA-His also significantly 
improving hydrophilicity compared to DETA application. PAA-Arg was more hydrophilic on all 
substrates than the unmodified materials, though on both Si-PDMS and PDMS the PAA-Arg was not 
different from DETA alone. PAA-Lys and Hemin were consistently the most hydrophobic biomolecule 
coating, showing wettability similar to DETA alone (on Si) or the unmodified Si-PDMS and PDMS. 
Considering these trends in wettability, the biomolecule coatings expected to show the lowest cell, 
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platelet, and protein adhesion on any substrate would be HA and then PAA-His, as the most hydrophilic 
coatings. In contrast, PAA-Lys and Hemin – the most hydrophobic coatings – would demonstrate the 
most clotting and fouling on all substrates. 
 Gas Permeability and Hemocompatibility Evaluation 
A.1.3.2.1 Oxygen Permeability In Vitro 
Experiment 1 
The area-normalized oxygen flux through the individual biomolecule-coated Si-PDMS 
membranes at water flow rates of 5 and 10 mL/min is shown in Fig. A. 1.6. At both of the tested flow 
rates, all of the substrates showed roughly equivalent O2 flux. The flux of the unmodified PDMS group 
ranged from 81.3±28.1 to 130±15.5 mL/min/m2. The flux ranges of the PAA-His (118±37.9 to 138±28.4 
mL/min/m2 ) and PAA-Lys (114±25.1 to 131±17.9 mL/min/m2 ) coatings were similar. Only the HA 
group (range of 143±12.9 to 134±15.7 mL/min/m2). at a flow rate of 5 mL/min showed a significant 
increase in flux compared to the unmodified group. There was no difference in the flux of any group 
between the 5 and 10 mL/min flow rates. Generally, these results indicate that the coatings do not alter the 
inherent O2 permeability of the Si-PDMS membranes. However, considerable variance in the flux 
measurements within each group may indicate that these results may not hold if more membranes were 
used. Furthermore, in this experiment, flux through the membranes was not measured at the in vivo flow 
rate of 20 mL/min, nor was flux measured through the assembled parallel plate devices. As such, for 
Experiment 2, the membranes were tested using a much wider range of flow rates, and were also tested in 
the parallel plate assembly that was used in vivo. 
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Fig. A. 1.6: In vitro oxygen flux of biomolecule coatings on individual Si-PDMS membranes from 
Experiment 1, normalized by membrane porous area. Significant difference (p < 0.05) between coating 
groups at the same flow rate is indicated by the letters above the columns: difference from the unmodified 
substrate is shown by (a). 
 
Experiment 2 
The area-normalized oxygen flux through the individual membranes at water flow rates of 10, 20, 
40, and 60 mL/min is shown in Fig. A. 1.7. At all four flow rates, the unmodified Si-PDMS membranes 
showed the highest oxygen flux, ranging from 185±24.7 to 361±18.8 mL/min/m2. Flux through these 
unmodified membranes significantly increased with each flow rate, consistent with boundary layer 
thinning and increased convective mass transfer at higher flow velocities. All the membranes with 
biomolecule coatings showed significantly lower oxygen flux than the unmodified substrate, with most 
coatings – DETA alone, HA, Hemin, and PAA-Arg – yielding around half the flux of the unmodified 
substrate. Membranes with DETA alone showed a range in flux of 108±12.9 to 155±32.5 mL/min/m2, and 
the HA, Hemin, and PAA-Arg coatings were insignificantly different from DETA at each flow rate. PAA-
His showed consistently lower flux than the other coatings, only around a quarter of the flux of the 
unmodified membranes (41.3±4.56 to 45.7±6.65 mL/min/m2). Interestingly, none of the biomolecule-
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coated Si-PDMS membranes showed statistically significant increases in flux with higher water flow 
rates. 
 
Fig. A. 1.7: In vitro oxygen flux of biomolecule coatings on individual Si-PDMS membranes from 
Experiment 2, normalized by membrane porous area. Significant difference (p < 0.05) between coating 
groups at the same flow rate is indicated by the letters above the columns: difference from the unmodified 
substrate is shown by (a), and PAA-His shown by (b). Significant difference of the same coating at 
different flow rates is indicated by (*). 
 
Once the membranes were mounted into the 4-membrane parallel plate flow cell (Fig. A. 1.2), the 
oxygen flux throughout the assmbled device was measured (Fig. A. 1.8). Compared to measuring the 
membranes individually, the flux measurements in the assembled device were much lower. For example, 
at 60 mL/min the individual unmodified membranes yielded 361±18.8 mL/min/m2 of O2 flux while the 
assembled device yielded 129±18.6 mL/min/m2. Most likely, this discrepancy is due to the different 
channel dimensions between the flow cells. The channel height of the flow cell used for individual testing 
was 200 µm, while the channel height of the flow cell in Fig. A. 1.2 was 3 mm, effectively 1.5 mm 
relative to each opposing chip. Considering that the flow rate through both devices was the same at 20, 
40, and 60 mL/min, the freestream velocity in the large channel parallel plate device would be 
significantly lower by around an order of magnitude. The reduced freestream velocity ( v , m/s) would 
0
100
200
300
400
In Vitro Oxygen Flux
Water Flow Rate (mL/min)
A
re
a
-N
o
rm
a
li
z
e
d
 F
lu
x
(m
L
/m
in
/m
2
)
Unmodified
DETA
HA
Hemin
PAA-His
PAA-Arg
10 20 40 60
ab
ab
ab ab
a
ab
ab
ab ab
a
ab
ab
ab
ab
a
ab
ab
ab ab
a
*
*
*
*
 
 
135 
 
 
 
directly impact the mass transfer boundary layer thickness ( , m) through the Reynolds number as 
follows: 
 
4.91
Rex
x


=  
Eq. A. 1.7 
  Rex
vx

=  
Eq. A. 1.8 
where x  is any position along the surface of the membrane,   is the density of the fluid (kg/m3), and   
is the dynamic viscosity of the fluid (kg/m·s). With a lower freestream velocity in the larger channel, the 
Reynolds number decreases and the mass transfer boundary layer becomes thicker, leading to reduced 
oxygen flux in the larger channel.  
 
Fig. A. 1.8: Experiment 2 – In vitro oxygen flux of assembled parallel plate devices containing coated 
membranes, normalized by membrane porous area. Significant difference (p < 0.05) between coating 
groups at the same flow rate is indicated by the letters above the columns: difference from the unmodified 
substrate is shown by (a), DETA by (b), HA by (c), and Hemin by (d). Significant difference of the same 
coating at different flow rates is indicated by (*). 
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Experiments 1 and 2 
Since the two experiments used a 10 mL/min flow rate, some comparisons between the two 
datasets can be made. Compared to Experiment 1, flux through the unmodified membranes at 10 mL/min 
was somewhat higher in Experiment 2, though not out of the range of error. Flux through the HA 
membranes was similar in both Experiments 1 and 2, but the flux through the PAA-His membranes was 
significantly lower in Experiment 2 compared to Experiment 1. The reason for this change may be due to 
variance in coating quality between the two datasets.  
The in vitro O2 flux results from Experiments 1 and 2 appear to contradict each other concerning 
whether the coatings impact the inherent O2 permeability of the Si-PDMS membranes. Experiment 1 
showed no significant difference in flux from the unmodified and coated membranes. However, from the 
in vitro results in Experiment 2, it is clear that application of any of the biomolecule coatings to Si-PDMS 
significantly reduces oxygen flux in water. Given that the dataset in Experiment 1 was more limited in 
scope, and did not test the membranes at higher flow rates, the dataset from Experiment 2 may be more 
reflective of the coatings’ reduction of O2 permeability. Most likely, the application of DETA to the 
surface is the primary driver of this reduction, since most of the biomolecule coatings added to DETA 
(HA, Hemin, and PAA-Arg) do not further reduce flux. Comparatively, PAA-His does seem to reduce 
flux beyond DETA alone. It is possible that the addition of PAA to DETA, which was not independently 
tested in this experiment, is responsible for this reduction in oxygen flux. However, since the PAA-Arg 
coating does not seem to impact oxygen flux through the membrane, it is unlikely that PAA addition 
alone reduces oxygen flux. Considering the in vitro data, it is possible that coated membranes will show a 
similar reduction when used in vivo with blood contact. Still, the coatings may provide some benefits over 
the unmodified PDMS substrate that will lead to better in vivo performance. The coatings may reduce 
biofouling on the surface – leading to higher gas transport with extended blood contact – or provide a 
functional benefit to gas exchange through ionic interference with blood buffering systems. 
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A.1.3.2.2 In Vivo Gas Permeability and Hemocompatibility 
Experiment 1 
All three of the coatings tested for contact angle and O2 flux were tested in the in vivo 
oxygenation circuit: HA, PAA-His, and PAA-Lys. Insufficient resources were available to add the 
unmodified PDMS group into the circuit. Although this important control group was lacking in the 
circuit, testing the coatings together would permit comparison of these coatings in vivo. 
After priming with saline, all three devices were connected to venous blood flow from the pig, 
circulating at 20 mL/min (Fig. A. 1.3). At the initial administration of blood flow, blood gas 
measurements indicated excessive oxygenation of the pig’s blood from the mechanical ventilation system, 
with venous O2 saturation of ~100%. Over the next hour, the pig’s ventilation was altered to reduce the 
venous O2 saturation to ~70%. During this time, the pig became significantly hypercarbic, with pH 
around 7.3 at the beginning of the measurement period, and 7.16 at the end of the period. With oxygen 
supplied through the sweep gas of each device, blood exiting the outlet of the devices became visibly 
brighter red in color, indicating some level of successful oxygenation and CO2 removal (Fig. A. 1.9). 
Once the pig’s ventilation had stabilized, a total of 4 measurement sets (inlet and outlet) were taken per 
device over an hour. In total, the membranes were exposed to flowing blood for 2 hours total during the 
experiment. 
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Fig. A. 1.9: Experiment 1 – Oxygenation of blood through assembled parallel plate devices in vivo. Inlets 
and outlets of each device are marked with blue and red arrows, respectively. Blood exiting the outlets 
was visibly brighter red in color compared to the inlets, indicating gas exchange of O2 and CO2. 
 
The ABG measurements (Table A. 1.1) were used to calculate the O2 and CO2 flux through each 
device using Eq. A. 1.2-Eq. A. 1.6, shown in Fig. A. 1.10. Due to the high variance in measurements, no 
significant difference was found between any of the coating groups for either O2 or CO2 flux. For all 
coatings, the O2 flux through the devices was negligible, with high variance in all measurements. The lack 
of blood oxygenation in this experiment may be attributable to the difficulty in controlling the ventilation 
to the pig throughout this experiment. However, the CO2 flux through the coated membranes was 
strikingly high at ~8 L/min/m2 for each of the devices. The CO2 removal rates through the HA, PAA-His, 
and PAA-Lys devices were respectively 7.68±4.92, 7.84±4.52, and 8.90±0.439 L/min/m2. Compared to 
other measurements of CO2 flux through unmodified Si-PDMS membranes, such as in Chapter 5 
(1.33±0.148 L/min/m2), the coatings’ alteration of CO2 flux is particularly dramatic. Given the severe 
hypercarbia of the pig in this experiment, it is possible that the CO2 flux through the coatings was merely 
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elevated due to the significant excess of CO2 in the blood. Without an unmodified PDMS control in this 
experiment, drawing conclusions from this data alone was unclear. 
Table A. 1.1: Raw ABG data collected from the three coated devices during Experiment 1. Data is 
divided into pre- and post-device for the same time point. 
 
 Pre-Device Post-Device 
 Flow 
Rate  
pH pCO2  pO2  HCO3-  SO2 pH pCO2  pO2 HCO3- SO2 
Units mL/min  mmHg mmHg mmol/L   mmHg mmHg mmol/L  
HA 
20 7.23 71 52 29.7 079 7.23 51 57 21.4 0.83 
20 7.314 54.2 63 27.6 0.89 7.316 51.2 59 26.2 0.88 
20 7.257 65 41 29 0.67 7.234 34 38 14.4 0.64 
20 7.248 64.6 35 28 0.56 7.192 48.5 41 18.6 0.64 
PAA-
His 
20 7.291 56.6 44 27.3 0.73 7.286 53.6 43 28.8 0.71 
20 7.32 56 56 28.9 0.86 7.32 31 60 16 0.88 
20 7.32 58 46 29.9 0.78 7.32 35 48 18 0.8 
20 7.23 72 44 30.2 0.7 7.24 51 39 21.9 0.63 
PAA-
Lys 
20 7.265 61.3 50 27.8 0.79 7.261 41.1 53 18.5 0.82 
20 7.31 58 47 29.2 0.78 7.31 37 49 18.6 0.8 
20 7.27 67 32 30.8 0.52 7.27 46 34 21.1 0.56 
20 7.16 88 53 31.4 0.76 7.17 60 46 21.9 0.68 
            
 
Fig. A. 1.10: Experiment 1 – Area-normalized O2 and CO2 flux in vivo of each parallel plate device, with 
a blood flow rate of 20 mL/min. 
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Experiment 2 
From the in vitro testing of oxygen flux and contact angle, four coatings were downselected for in 
vivo testing: PDMS alone, HA, Hemin, and PAA-His. PDMS alone showed the highest oxygen flux in 
vitro, and would also act as a control group for the other three coatings. Both HA and Hemin showed 
comparable in vitro oxygen flux, but were strongly different in wettability. HA was the most hydrophilic, 
while Hemin was strongly hydrophobic. Despite its lower oxygen flux in vitro, PAA-His was selected due 
to its superior wettability compared to PAA-Arg. All three of the coatings together would permit 
comparison the effects of both gas permeability and hydrophilicity in vivo. 
After priming with saline, all four devices were connected to venous blood flow from the pig, 
circulating at 20 mL/min (Fig. A. 1.3). During the first hour of blood flow, blood gas measurements 
indicated strong instability of the pig’s ventilation regimen. pH values ranged from 7.3-7.7 throughout 
this period, and SO2 ranged from 48-92%. Due to this instability, sweep gas oxygenation was not started 
until blood pH had stabilized to ~7.4 – around an hour after starting blood flow into the devices. Once the 
oxygen sweep gas was administered, blood exiting the outlet of the devices became visibly brighter red in 
color, again indicating some level of functional gas exchange (Fig. A. 1.11). Throughout the first hour of 
sweep gas administration, the incoming venous blood still showed significant instability in all ABG 
measurements – pH, pO2, and pCO2 – so only the measurements taken after 1 hour of oxygenation were 
used for subsequent calculations of O2 and CO2 flux. A total of 5 measurement sets (inlet and outlet) were 
taken per device over a period of an hour and 45 minutes. As such, the membranes were exposed to 
flowing blood for 3 hours and 45 minutes total during the experiment. 
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Fig. A. 1.11: Experiment 2 – Oxygenation of blood through assembled parallel plate devices in vivo. 
Inlets and outlets of each device are marked. Blood exiting the outlets of some devices was visibly 
brighter red in color compared to the blood at the inlets. 
The ABG measurements (Table A. 1.2) were used to calculate the O2 and CO2 flux through each 
device using Eq. A. 1.2-Eq. A. 1.6, shown in Fig. A. 1.12. Due to the high variance in measurements, no 
significant difference was found between any of the coating groups for either O2 or CO2 flux. In both flux 
calculations, the unmodified PDMS device showed less O2 and CO2 flux than most of the devices with 
coatings, though this difference was not significant due to the high measurement error. The unmodified 
PDMS device showed around half the O2 flux in vivo, at 36.2 ± 37.3 mL/min/m2, compared to in vitro at 
77.4 ± 9.37 mL/min/m2. Still, considering the measurement error of the in vivo data, it is likely these two 
values are not significantly different. The devices with coatings mostly showed much higher O2 flux in 
vivo than in vitro, though these values are also unlikely to be significantly different. 
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Fig. A. 1.12: Experiment 2 – Area-normalized O2 and CO2 flux in vivo of each parallel plate device, with 
a blood flow rate of 20 mL/min. 
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Table A. 1.2: Raw ABG data collected from the four devices during Experiment 2. Data is divided into 
pre- and post-device for the same time point. 
 
 Pre-Device Post-Device 
 Flow 
Rate  
pH pCO2  pO2  HCO3-  SO2 pH pCO2  pO2 HCO3- SO2 
Units mL/min  mmHg mmHg mmol/L   mmHg mmHg mmol/L  
Unmod. 
PDMS 
20 7.21 77 48 30.8 0.74 7.22 76 48 31.1 0.74 
20 7.22 74 54 30.3 0.8 7.22 74 54 30.3 0.8 
20 7.23 73 59 30.6 0.85 7.23 73 61 30.6 0.86 
20 7.24 69 59 29.6 0.84 7.24 69 60 29.6 0.86 
20 7.27 66 53 30.3 0.82 7.27 64 54 29.4 0.83 
HA 
20 7.2 77 53 30.1 0.78 7.22 75 53 30.7 0.79 
20 7.22 75 53 30.1 0.79 7.22 71 56 29.1 0.82 
20 7.22 74 56 30.3 0.82 7.23 73 58 30.6 0.84 
20 7.25 68 58 29.8 0.85 7.25 67 58 29.4 0.85 
20 7.27 65 48 29.8 0.77 7.24 64 52 29.4 0.81 
Hemin 
20 7.192 71.5 49 27.5 0.73 7.196 70.6 48 27.3 0.72 
20 7.191 72.4 49 27.7 0.73 7.148 71.8 54 27.9 0.78 
20 7.198 72.4 53 28.2 0.78 7.201 70.6 52 27.7 0.76 
20 7.219 67.6 55 27.6 0.8 7.239 63.8 51 27.2 0.78 
20 7.249 63.9 44 28 0.71 7.224 67.4 53 27 0.79 
PAA-
His 
20 7.186 75.3 42 28.5 0.63 7.191 72.8 47 27.8 0.7 
20 7.194 71 50 27.4 0.75 7.191 71.1 50 27.2 0.74 
20 7.205 69.8 52 27.6 0.77 7.203 71.8 54 28.3 0.79 
20 7.217 67 52 27.3 0.77 7.223 66.3 55 27.3 0.8 
20 7.223 69 40 28.4 0.63 7.238 66 42 28 0.67 
            
A.1.3.2.3 Scanning Electron Microscopy (SEM) 
Experiment 1 
Scanning electron micrographs of each coating after blood exposure from Experiment 1 are inFig. 
A. 1.13. The scans were taken at 200X magnification to view the overall distribution of adherent cells or 
platelets, while still being able to visualize small-scale adherence or activation. As seen in Fig. A. 1.13a-c, 
the coated surfaces did show some diffuse cell and platelet adhesion across the surfaces, with some 
activated and spread platelets and fibrin clot formation. Debris from the underlying silicon structure was 
also present on the surface. Relative to the other coatings, the HA surface (Fig. A. 1.13a) showed the least 
amount of adhered material, while the PAA-His surface (Fig. A. 1.13b) and PAA-Lys surface (Fig. A. 
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1.13c) showed similar adhesion. Compared to the coated membranes, the Si material control (Fig. A. 
1.13d) showed considerable platelet adhesion and activation, and the formation of larger fibrin networks. 
The unmodified PDMS surface in Fig. A. 1.13e showed considerable platelet and cell deposition across 
the entire surface. In general, the coated surfaces outperformed the material controls in terms of resisting 
cell and platelet adhesion, with the HA coating yielding the most resistance to adhesion.  
 
Fig. A. 1.13: Experiment 1 – 200X magnification SEM images of gross cell/platelet on membranes 
removed from the in vivo devices after 2 hours of blood contact. Coatings are: (a) HA, (b) PAA-His, (c) 
PAA-Lys, (d) unmodified Si, and (e) unmodified PDMS.  
 
Experiment 2 
Scanning electron micrographs of each coating after blood exposure are in Fig. A. 1.14. The 
scans were taken at 200X magnification. As seen in Fig. A. 1.14a, the unmodified PDMS surface had 
some adherence of biological material distributed across the surface, possibly with some activated and 
spread platelets. Debris from the underlying silicon structure was also present on the surface. The HA 
surface (Fig. A. 1.14b) showed much less adherence of biological material, and the PAA-His surface (Fig. 
A. 1.14d) showed similar adhesion to the unmodified PDMS. Comparatively, the Hemin surface (Fig. A. 
1.14c) showed substantially more adhesion of cells and platelets, with many nascent thrombi visible 
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across the surface. Given their size and rounded shape, the largest adherent objects are likely leukocytes, 
some with projections attached to the surface. Closer inspection of the lower right corner of the image 
reveals a fibrous clot likely containing activated platelets. Overall, the HA surface had the least adhesion 
of cells and platelets out of all coatings.  
 
Fig. A. 1.14: Experiment 2 – 200X magnification SEM images of gross cell/platelet on membranes 
removed from the in vivo devices after nearly 4 hours of blood contact. Coatings are: (a) unmodified 
PDMS, (b) HA, (c) Hemin, and (d) PAA-His. The arrow in (c) indicates the formation of a fibrous clot. 
 
A.1.3.2.4 Platelet Immunohistochemsitry (IHC) 
From Experiment 2, fluorescent images of platelet adhesion each coating after blood exposure are 
in Fig. A. 1.15, taken at 40X magnification to visualize a wide view of platelet distribution on the 
surfaces. On the unmodified PDMS surface (Fig. A. 1.15a), platelets can be seen distributed across the 
surface at a consistent, low density. Some platelets appear stained with only FITC, indicating adhesion 
but no activation, while some are also cross-stained with Cy-3, pointing to activation. Of the coatings, HA 
(Fig. A. 1.15b) shows the least platelet adhesion/activation, with only a few platelets present on the 
surface. The Hemin coated surface (Fig. A. 1.15c) shows a substantial increase in platelet adhesion and 
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activation compared to the unmodified PDMS surface, and the PAA-His surface (Fig. A. 1.15d) shows a 
modest increase. In particular, the Hemin surface is covered by a high density of cross-stained platelets, 
some of which have started to form larger aggregates. IHC imaging was not conducted on samples from 
Experiment 1. 
 
Fig. A. 1.15: Experiment 2 – 40X magnification IHC cross-stain of platelet adhesion (CD41, FITC green) 
and platelet activation (CD62p, Cy-3 red) on membranes removed from the in vivo devices after nearly 4 
hours of blood contact. Coatings are: (a) unmodified PDMS, (b) HA, (c) Hemin, and (d) PAA-His. 
 
 DISCUSSION 
Considering the data sets from all experiments, the biomolecule coatings strongly altered the 
hemocompatibility of the Si-PDMS membrane surfaces. Whether the benefit was positive or negative, the 
coatings generally showed consistent trends between in vitro wettability and in vivo hemocompatibility, 
and mostly differed from the unmodified PDMS surfaces. Between the two experiments, it is unclear if 
the coatings have a detrimental impact on the inherent gas permeability of the Si-PDMS membranes. 
Additional experiments would be necessary to increase sample numbers, and collect more conclusive 
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evidence. Although the coatings in Experiment 2 consistently decreased the in vitro O2 flux through the 
membranes, it is unclear if this trend was also observed in vivo due to the high measurement error. As 
such, the biomolecule coatings demonstrated a clear hemocompatibility benefit compared to unmodified 
PDMS, but were unable to show any blood-gas exchange improvements on gas exchange membranes. 
The presence of the biomolecule coatings on the surface was confirmed by contact angle changes. 
Characterization of the coatings was largely consistent with prior research on these coatings. To validate 
the presence of the coatings on the surface, two additional characterization techinques were employed in 
this study: colorimetric staining for amine and carboxyl groups and x-ray photoelectron spectroscopy. 
However, these datasets were not sufficiently complete to include in this analysis. As such, coating 
characterization in this study is currently limited to contact angle analysis. Still, other characterization 
techniques may have been useful to further define the functionality of the coatings. Data on thickness and 
conformity via ellipsometry could have identified possible links between coating thickness and 
thrombogenicity. Atomic force microscopy could have been used to image the topography of the coated 
surfaces, since surface roughness is also linked to thrombogenicity. Additionally, a technique to quantify 
the surface charge of the biomolecule coatings could have verified the charge state of the coatings under 
physiologic conditions.  
Comparison of the characterization and hemocompatibility data revealed some trends consistent 
with all data sets. Namely, the HA coating was the most hydrophilic, and also the most resistant to cell 
and platelet adhesion. This finding was consistent between Experiments 1 and 2. Conversely, the most 
hydrophobic coatings – PAA-Lys and Hemin – were more thrombogenic than HA, but to different 
extents. PAA-His was intermediate in both regards. These comparisons indicated a strong connection 
between hydrophilicity and hemocompatibility with the coatings. However, if hydrophobicity alone 
determined hemocompatibility, the unmodified PDMS and PAA-Lys surfaces should have been as 
thrombogenic as Hemin. In Experiment 1, the PAA-Lys surface was less thrombogenic than the 
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unmodified PDMS material control despite being equally hydrophobic. Also, in Experiment 2, the 
unmodified PDMS surface attracted relatively few cells and platelets, comparable to the PAA-His surface 
and far less than Hemin. As such, factors beyond wettability likely contributed towards 
hemocompatibility, although hydrophilicity was a clear factor in preventing thrombosis. 
Between all data sets, the influence of the coatings on gas permeability was unclear. The two in 
vitro data sets indicated opposite conclusions. Whereas Experiment 1 showed no significant difference 
with coating application, Experiment 2 showed a clear reduction in permeability with the application of 
any coating to the surface. Normalizing the flux measured through unmodified SµM-PDMS membranes 
from Chapter 2 (Fig. 2.7) to surface area, the O2 flux measured in prior studies at 10 mL/min flow rate 
was 306±35.2 mL/min/m2. Both datasets from Experiment 1 and 2 (Fig. A. 1.6 and Fig. A. 1.7) showed 
far less flux on the unmodified membranes than this study at the same flow rate, although the membranes 
used in these studies had different pore designs that may have influenced the normalization. Still, the flux 
measured in Experiment 2 was much closer to this previous measurement than Experiment 1, reaching 
close to the same flux at a higher water flow rate. Given the increased number of data points in 
Experiment 2, as well as the use of higher flow rates, the in vitro dataset in Experiment 2 is likely more 
reflective of the coatings’ effect on the inherent gas permeability of the membranes. As such, the coatings 
appear to strongly decrease gas permeability of SµM-PDMS membranes.  
The reduction seen with DETA application alone may be the most significant contributor to the 
overall lower permeability of the coatings, since most of the coatings did not decrease flux further than 
DETA alone. One possibility for this observation may be related to the effects of the plasma treatment 
required to apply the DETA coating. Plasma treatment of PDMS causes the formation of a stiff, glassy 
SiO2 layer on the PDMS surfaces, which has been shown to strongly reduce the gas permeability of 
PDMS 115,117. Usually, this SiO2 layer dissipates over time due to surface rearrangement of the PDMS 
within around a week. However, these studies were conducted on bulk PDMS that was hundreds of 
 
 
149 
 
 
 
microns thick, unlike the ultrathin spin-coated layer on the SµM-PDMS. It is possible that an SiO2 layer 
on SµM-PDMS membranes may not experience much surface rearrangement over time due to its 
thinness, and lack of sufficient PDMS required for rearrangement. Therefore, it is possible that the gas 
permeability reduction associated with plasma treatment may linger on SµM-PDMS membranes for an 
indefinite amount of time. Plasma-treated PDMS without DETA application was not independently 
evaluated in this experiment, so further studies would need to confirm this observation. 
The in vivo datasets from Experiments 1 and 2 were also unclear as to the impact of the coatings 
on gas exchange. Neither experiment was able to demonstrate oxygenation, unlike in Chapter 3. Lack of 
demonstrable oxygenation in both experiments is likely due to the instability of the ventilation regimen of 
the pigs. Unstable control over the incoming venous blood, and a limited collection of data points per 
device, resulted in high variance in O2 flux measurements. Similarly, CO2 flux measurements were 
affected by this instability in ventilation, particularly in Experiment 2 with the wide variation in blood pH 
(7.3-7.7 over the course of the experiment). Still, the extremely high CO2 removal seen in Experiment 1 
was striking, especially compared to past results from Chapter 5 under similar hypercarbic conditions. 
This CO2 removal vastly exceeds data from Arazawa, et al. (411 mL/min/m2), although – given the lack 
of a control uncoated device in this experiment – it is unclear if the coatings were the main driver of the 
high CO2 removal. When a control device was added in Experiment 2, no significant difference in CO2 
removal was seen between uncoated and coated devices, possibly attributable to the inconsistency in the 
pig’s ventilation. Considering all of the in vivo datasets, the impact of the coatings on in vivo gas 
exchange cannot be determined without additional experiments. 
Future in vivo experiments would need to significantly modify the animal handling procedures in 
order to maintain consistent O2 and CO2 control over the incoming venous blood from the pig. In 
Experiments 1 and 2, the pig was ventilated with only O2 because equipment to mix multiple gases for the 
ventilator, such as room air or N2, was not available. This led to the significant hyperoxia of the incoming 
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venous blood (SO2 ~100%), and the subsequent hand bag ventilation regimen to create a slightly hypoxic 
state. Titration of the inhaled ventilator gas with room air or N2 would prevent this venous hyperoxia, and 
allow for controllable hypoxia within the venous blood. If such a ventilation regimen is used, better 
quality in vivo data could be collected to demonstrate O2 and CO2 transport. 
 CONCLUSION 
Ultimately, the biomolecule coatings on SµM-PDMS membranes did significantly improve the 
hemocompatibility of the surfaces, but were unable to demonstrate consistent impacts on gas exchange 
through the membranes. Of the coatings, the HA coating proved to be the most hydrophilic and 
hemocompatible when exposed to flowing blood. Oxygen flux in vitro may have been significantly 
lessened by the application of the coatings, possibly due to the plasma treatment required for surface 
modification. However, in vivo no difference was observed in oxygenation with or without coatings. 
Strikingly high CO2 removal was seen in one of the experiments, signaling significant promise for the 
coatings in a CO2 removal device. However, this result was not validated by the second experiment. Both 
of the experiments were impacted by the instability of the in vivo setup, and so neither experiment can 
conclusively demonstrate the impact of the coatings on in vivo gas exchange. Nonetheless, this work 
raises significant interest in the use of these coatings for improving PDMS-based oxygenator 
hemocompatibility, and possibly the gas exchange efficiency through the membranes. Future work will 
focus on increasing sample numbers to improve overall data quality for characterization and membrane 
performance, and also altering the in vivo experiment procedure to improve the quality of in vivo datasets.  
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A.2. IN VIVO GAS EXCHANGE THROUGH OXYGENATOR PROTOTYPES 
 
 
 
 
 
 INTRODUCTION 
After completion of the in vivo experiment described in Chapter 5, further experiments with the 
prototype oxygenator were desired to better characterize transport through this particular device. As such, 
the purpose of this experiment was to collect additional in vivo data on the performance of the prototype 
oxygenator flow cell with greater sample numbers. In adding more replicates to the dataset, O2 and CO2 
transport through the prototype could be further characterized. 
 METHODS 
 Oxygen Flux and Pressure Drop In Vitro 
Four silicon micropores membranes (SµM) were created for each device, and plasma bonded to a 
polydimethylsiloxane (PDMS) layer as described in Chapter 2 143,160. Three of the parallel plate 
oxygenator devices described in Chapter 5 (Fig. 5.2) were assembled using four SµM-PDMS membranes 
each. No spacers were used in any of these devices, nor were the membranes coated with any surface 
modification. Essentially, all three devices were constructed in the same manner as the no spacers control 
device in Chapter 5. 
Each device was placed in an in vitro oxygen flux testing circuit as described in 5.2.4, and shown 
in Fig. 5.3. The devices were subjected to flowing degassed water at 10, 20, and 40 mL/min and supplied 
with a pure oxygen sweep gas at 260 mmHg gauge pressure. Transoxygenator pressure was measured at 
each flow rate using the pressure gauge in the water circuit upstream of the device. Area-normalized 
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oxygen flux (J, mL O2/min/m2) was determined using a downstream oxygen probe to measure 
concentration before and after supplying the sweep gas ( 2 iO and 2 fO , respectively), with a conversion 
of 22.4 L O2/mol at STP: 
   ( ) 62 2 10 22.4f i
m
mol L
O O Q
mol mol
J
A

−−   
=  
Eq. A. 2.1 
where Q is the flow rate of water in mL/min, and Am is the area of the membrane in m2. The 
measurements of transoxygenator pressure and flux at each flow rate were compared to results from 
Chapter 5 (Fig. 5.5a and b, respectively) to determine repeatability. 
 Gas Exchange and Hemocompatibility In Vivo 
All three devices were tested for gas exchange (O2 and CO2) and blood compatibility 
extracorporeally in a 40kg Yucatan minipig using the same circuit setup as in Chapter 5 (Fig. 5.4). The 
three devices were set up in parallel with each other. The pig used in this study was thought to have a 
naturally occurring respiratory deficiency, and so mechanical ventilation with inhaled pure O2 was 
sufficient to achieve venous blood O2 saturation of ~80%. Fully heparinized blood (ACT > 300 s) was 
flowed through the devices at a flow rate of 40 mL/min for 30 minutes, and flowing oxygen sweep gas 
was supplied to the devices at a pressure of 88 mmHg and a rate of 2 L/min (Fig. A. 2.1). Three blood 
samples from the inlet and outlet of each device were taken for blood gas analysis to assess pO2, pCO2, 
pH, and HCO3- using either an arterial blood gas machine (GEM3000, Instrumentation Laboratory, 
Bedford, MA, USA) or an iSTAT handheld blood analyzer (Abbott Point of Care Inc., Princeton, NJ, 
USA). After 30 minutes of blood flow at 40 mL/min, the blood flow rate was decreased to 20 mL/min for 
30 minutes to mimic the flow rate used in Chapter 5. Three sets of inlet/outlet samples were taken from 
each device at this flow rate for blood gas analysis. After a total of two hours of blood exposure, the 
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devices were flushed with saline and disassembled. The devices were grossly inspected for clots, and the 
membranes were removed and broken into pieces. The experiment was conducted at a contract resource 
organization (PMI Preclinical, San Carlos, CA). 
O2 and CO2 flux were calculated using equations Eq. 5.3 and Eq. 5.6, respectively. 
 
Fig. A. 2.1: Setup of in vivo testing circuit for replicates of the no spacers control device in Chapter 5. (a) 
shows a photograph of the setup, while (b) shows a simplified schematic. 
 
 Scanning Electron Microscopy (SEM) 
After the porcine blood flow experiment, one fragment sample from each membrane was imaged 
for cell, platelet, and protein adhesion using scanning electron microscopy (SEM) as described in Chapter 
5 and Appendix A.1. Samples were placed in a solution of 3% glutaraldehyde (Millipore Sigma), 0.1 M 
sodium cacodylate (VWR), and 0.1 M sucrose (Millipore Sigma) at 4°C for 48 h. Then, the samples were 
washed twice with deionized water, and dehydrated by sequential 10 minute incubations with 35%, 50%, 
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70%, 90%, and two 100% ethanol/water (v/v%) solutions. The samples were dried in a desiccator 
overnight and mounted with conductive silver paint to aluminum SEM stubs. Finally, the samples were 
sputter coated with 4 nm of gold and imaged using a Carl Zeiss Ultra 55 Field Emission Scanning 
Electron Microscope (Zeiss, Dublin, CA, USA). 
 Statistical Analysis 
Statistical significance was determined using Graphpad Prism 8.2.0 (San Diego, CA, USA). For 
each of the three devices in vitro, two measurements were taken of transmembrane pressure and O2 flux at 
each of the four flow rates tested. These measurements were averaged between all three devices at the 
same flow rate. Both the pressure and flux measurements from this experiment were compared to those 
from the no spacers control device in Chapter 5. The transmembrane pressure measurements were 
compared using two way ANOVA analysis with Tukey post-hoc tests for each experiment (Chapter 5 and 
Appendix A.2) and each flow rate (10, 20, and 40 mL/min). The area-normalized flux measurements were 
also compared using this method. 
Flux measurements of O2 and CO2 in vivo at 20 mL/min were averaged for all three devices from 
this experiment. These measurements were compared to those from the no spacers control device in 
Chapter 5 using standard t-tests. 
 RESULTS 
 Oxygen Flux and Pressure Drop In Vitro 
Measurements of transmembrane pressure drop and in vitro area-normalized oxygen flux are in 
Fig. A. 2.2, compared to the results from Chapter 5 (Fig. 5.5). Among the measurements of pressure, both 
experiments showed that there was significantly higher pressure in the circuit at 40 mL/min compared to 
10 mL/min and 20 mL/min, which were not different. Also, there was no significant difference between 
the two experiments at 10 mL/min, but the original spacers study showed significantly higher pressure at 
20 and 40 mL/min compared to the replicate study. It is possible that some variation in the in vitro testing 
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setup was behind this slight increase in pressure through the circuit in the original experiment. As such, 
the pressure data only shows some replicability between the experiments at the lower flow rates. 
Between both experiments, area-normalized flux was not significantly different at any of the three 
flow rates tested, indicating strong replicability. In both experiments, the flux at 40 mL/min was 
significantly greater than at 10 mL/min, but only the original experiment showed a significant difference 
between flux at 40 and 20 mL/min. Still, the flux data shows significant replicability between trials. 
 
Fig. A. 2.2: In vitro testing comparison of replicate devices to the original data from Chapter 5 (Fig. 5.5). 
(a) shows transoxygenator pressure while (b) shows the area-normalized oxygen flux. Bars above the 
chart indicate significant difference between groups in the same experiment (spacers study or replicates) 
at different flow rates. The * symbol indicates significant difference between experiments at the same 
flow rate. Significant difference was determined using two-way ANOVA with Tukey post-hoc tests. 
 
 Gas Exchange and Hemocompatibility In Vivo 
In vivo measurements of area-normalized O2 and CO2 flux can be found in Fig. A. 2.3, compared 
to results from Chapter 5 (Fig. 5.6). Raw ABG data used to calculate flux for all three devices can be 
found in Table A. 2.1. O2 flux at blood flow rates of 20 and 40 mL/min was 63.7 ± 53.7 mL/min/m2 and 
111 ± 56.9 mL/min/m2, respectively. CO2 flux was 297 ± 366 mL/min/m2 and 515 ± 668 mL/min/m2, 
respectively. In this experiment, there was no significant difference between O2 or CO2 flux at 20 and 40 
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mL/min. This was likely related to the high variance within the blood gas samples. The data from the 
replicate experiment shows that O2 flux was higher than in the original spacers study, though this 
difference at 20 mL/min was not significant. Likely, this lack of significant difference was due to the low 
sample size of the original study, and high variance within the datasets. Interestingly, CO2 flux in the 
replicate experiment was significantly lower than in the original study, and also much more variable.  
 
Fig. A. 2.3: In vivo O2 and CO2 area-normalized flux comparison of replicate devices to the original data 
from Chapter 5 (Fig. 5.5). (a) shows O2 flux while (b) shows CO2 flux. Bars above the chart indicate 
significant difference between groups at the same 20 mL/min flow rate as assessed by t-test. 
  
 
 
157 
 
 
 
Table A. 2.1: Raw ABG data collected from all three replicate devices during in vivo experiment. Data is 
divided into pre- and post-device for the same time point. 
 
 Pre-Device Post-Device 
 Flow 
Rate  
pH pCO2  pO2  HCO3-  SO2 pH pCO2  pO2 HCO3- SO2 
Units mL/min  mmHg mmHg mmol/L   mmHg mmHg mmol/L  
Device 
1 
40 7.33 61 51 32.2 0.83 7.33 59 53 31.1 0.84 
40 7.327 52 52 27.3 0.84 7.326 51.6 53 27 0.84 
40 7.362 49.4 58 28 0.88 7.364 47.2 60 26.9 0.9 
20 7.359 49.1 59 27.7 0.89 7.363 49.2 64 28 0.91 
20 7.36 49.3 55 27.8 0.87 7.355 47.1 58 26.3 0.88 
20 7.39 50 61 30.3 0.91 7.4 48 65 29.7 0.92 
Device 
2 
40 7.34 56 52 30.2 0.84 7.35 55 54 30.4 0.86 
40 7.38 52 62 30.8 0.91 7.39 50 66 30.3 0.93 
40 7.39 51 59 30.9 0.9 7.39 49 64 29.7 0.92 
20 7.39 51 63 30.9 0.92 7.38 51 67 30.2 0.93 
20 7.361 48.1 56 27.2 0.87 7.357 46 69 25.8 0.93 
20 7.367 47.8 58 27.4 0.89 7.369 45.9 62 26.5 0.9 
Device 
3 
40 7.309 53.9 49 27.1 0.8 7.312 54.9 51 27.8 0.81 
40 7.36 54 55 30.5 0.87 7.37 53 60 30.6 0.9 
40 7.39 51 58 30.9 0.89 7.39 49 62 29.7 0.91 
20 7.38 52 62 30.8 0.91 7.4 50 67 31 0.93 
20 7.38 51 58 30.2 0.89 7.38 49 62 29 0.91 
20 7.38 49 63 29 0.91 7.38 50 65 29.6 0.92 
            
The disassembled devices after 2 hours of exposure to fully-heparinized blood can be seen in Fig. 
A. 2.4. Within each device, there was one gross clot visible at the same location within all three of the 
flow paths. This location was within the stainless steel header region leading into the silicon membranes, 
just prior to the parallel split over the two membranes. These clots were only observed at the inlet, and 
were largely “white” (fibrinous) in composition rather than “red” (hemolytic). Other than these inlet clots, 
no other gross thrombi were observed in the channels, including over the membranes themselves. 
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Fig. A. 2.4: Disassembly of oxygenator devices after 2 hours of exposure to heparinized blood. Each 
device is oriented with the blood flow inlet at the bottom of the image. Blue arrows indicate clot 
formation. 
 
 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy images at 200X and 1000X can be found in Fig. A. 2.5. From the 
micrographs, the surfaces are largely free of significant platelet and cell adhesion. Still, some adhesion of 
cells and thrombi can be seen on the surfaces. In some of the closer magnification images, some fibrous 
protein adhesion was observed, possibly indicating the potential for thrombus formation. 
Compared to the SEM images in Chapter 5, the surfaces in the replicate study showed slightly 
less adhesion than the control sample in the original experiment. Little adhesion of cells and proteins was 
seen overall in both experiments, though. Given that the replicate devices were exposed to only 2 hours of 
blood flow instead of 3, there may have been less adhesion on these samples due to the reduced contact 
time with blood. All samples in the original and replicate experiments were the same unmodified PDMS. 
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Fig. A. 2.5: SEM micrographs of replicate devices at 200X and 1000X magnification. (a) and (b) show 
the same sample at both magnifications, as do (c) and (d). Blue arrows indicate notable adhesion of cells 
or proteins. 
 
 DISCUSSION 
This study was an attempt to replicate data from the control device in Chapter 5, with moderate 
success. Overall, the in vitro data was reasonably replicable between experiments, especially the area-
normalized oxygen flux. Both experiments saw pressure drop and oxygen flux significantly increase with 
higher water flow rates. Although transoxygenator pressure differed between experiments at 20 and 40 
mL/min, increased sample numbers could potentially reduce this difference.  
However, the in vivo data was not consistent between experiments. O2 flux may not have shown a 
significant difference between experiments, but flux in the replicate experiment was generally higher than 
in the original study. The reason for this difference is likely the higher sweep gas pressure used in the 
replicate experiment compared to the original (88 mmHg vs minimal pressure, respectively). Oxygen flux 
into the blood is driven by pressure gradients between the sweep gas and the venous blood. Most likely, 
little oxygenation was seen in the original experiment since no sweep gas pressure was applied beyond 
atmospheric pressure. In contrast, the replicate experiment increased the O2 driving pressure into blood by 
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elevating the sweep gas pressure. Comparatively, CO2 removal in the original experiment was 
significantly higher than the replicate study. Since CO2 removal is driven by sweep gas flow rate, the 
higher O2 sweep flow rate used in the original study for the control device (3 L/min) is likely responsible 
for the increased CO2 removal. The replicate study used only 2 L/min of O2 sweep gas flow, which was 
further split amongst three devices to yield ~0.67 L/min of sweep gas flow per device. This difference in 
CO2 flow rate between experiments was likely the reason for the discrepancy in flux. 
In all in vivo experiments described, especially in Chapter 5 and Appendix A.1, considerable 
variance in the measured O2 and CO2 flux limited the significance of the datasets. Much of the variance is 
attributable to the instability of the ventilation regimen of the pig and resulting effects on venous O2 blood 
saturation. Ultimately, the testing protocol used for future in vivo oxygenator experiments must establish a 
stable ventilation regimen to ensure consistent, slight hypoxia of the venous blood. However, the 
ventilation of the pig was not an issue in this experiment due to the compromised respiratory physiology 
of the pig. Essentially, beyond the instability of the pig, other factors may be contributing to the high 
variance in gas flux. Given the small membrane area in these prototypes, the surface area of these devices 
may be low to allow for a significant, repeatable signal to be observable by the ABG data. For example, 
the observable differences in pO2 pre- and post-device are often less than 10% of the total pO2 readings. 
This means that any variability within sample sets of the same device (i.e. differences in pO2 of 2 vs. 4 
mmHg) become amplified in the flux calculations to yield an overall high variance in gas flux. Future 
scaled up devices with higher area would yield a larger difference in O2 and CO2 flux, and would likely 
produce more consistent ABG data. 
In summary, all three devices in this study showed replicability to the control device of Chapter 5 
in vitro, but did not replicate in vivo gas flux results for O2 or CO2 due to the differences in testing 
protocol and high variance. Future work should emphasize the establishment of a stable in vivo testing 
protocol, and the use of larger silicon membrane oxygenators to improve measurement quality.  
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